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Functionalizing arenes and heteroarenes has been an active area of 
research since the 19th century, due to the presence of  these molecular 
structures in many industrially important sectors. A tremendous amount of 
research has been published in achieving these chemical transformations using 
stoichiometric reagents and transition metal -catalyzed reactions. However, 
challenges still remain. An alternative and comparable methodology to metal -
catalyzed reactions to overcome the drawbacks will advance this particular area 
of research is desirable.  
Hypervalent iodine compounds offer a promising approach to metal -free 
arylation reactions. These mild, air and moisture stable compounds have 
showed significant success as non-toxic and metal-free reagents for the 
arylation reactions. In particular, unsymmetrical diaryliodonium salts offer 
functionalization of complex arene structure in an efficient and sustainable 
pathway.  
A base-mediated coupling reaction for the metal -free synthesis of alkyl-
aryl ethers by using unsymmetrical diaryliodonium salts and aliphatic alcohols 
is described.  This method shows broad substrate scope with respec t to both of 
the coupling partners to produce industrially useful alkyl -aryl ethers in 
moderate to excellent yields.  The reaction is operationally simple, proceeds at 
mild temperature, and is atom-economical. Sustainability and synthetic utility 
of this reaction is demonstrated by the use of unsymmetrical 
aryl(mesityl)iodonium salts as the arylating agents. A limitation of poor 
reactivity of electron rich unsymmetrical diaryliodonium salts was overcome 
by designing 2nd generation conditions and using trime thoxy benzene (TMP) 
as the auxiliary group. 
Additionally discovery and development of an efficient method to access 
highly functionalized arynes from unsymmetrical aryl(mesityl)iodonium 
tosylate salts is presented. The aryne intermediates are generated by ortho C-H 
deprotonation of aryl(mesityl)iodonium salt with an amide base and 
subsequently trapped in a cycloaddition reaction with furan in moderate to good 
yields. Selective iodonium moiety elimination is discussed and the effect of 
auxiliary and temperature to reduce the regioisomeric ratio is demonstrated. 
Finally, additional coupling partner including benzyl azide and aliphatic amines 
are presented to show further utility of this methodology.  Also, mechanistic 
investigations leading to the moderate reactivity of some electron rich 
unsymmetrical diaryliodonium salts is discussed.  
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iii 
Dedicated to my little brother 
Vinod Sundalam (1992 - 2012) 
We wish you were still among us 
Acknowledgements 
Dave – I don’t have enough words to express my gratitude for your constant 
guidance and support over these past 5 years. I am forever indebted to you for 
the knowledge you have bestowed upon me. Thank you. I could not have asked 
for a better mentor. Thank you for making me a better chemist. Th ank you for 
being available whenever you were needed. Thank you for being patient and 
answering my questions and not making me feel dumb even when my questions 
were actually dumb. I am very proud to be graduating under your supervision 
and I wish our group will achieve great heights and publish a lot of papers in 
the years to come.  
I am very fortunate to meet so many awesome people in the journey I 
have commenced here in States. Lily Jayatissa, my friend and colleague whom 
I have started Stuart group together, I missed you so much after you have 
graduated from the group. I wish you were still here and pursued Ph.D. so that 
we could have graduated together. Thomas Seidl, Man, I am very thankful to 
have worked with such an intelligent and competitive personal ity, I have 
learned a lot from you. Thank you for the discovery of simple and efficient 
synthesis of aryl(TMP)iodonium salt. I think I am probably the person who used 
your method and having you around for the tech-support was very helpful. 
Thank you for letting me borrow your iodonium salts when I needed them.  
iv 
I would like to extend my gratitude to Thomas Siedl, Alexandra Nilova 
and Cassandra Ballou for your contributions to my work. I am very thankful to 
Rory Gallagher for his contributions to my work and continuing my research.  
I would like thank all the members of Stuart Research group for their 
valuable feedback and maintaining a work space.  
I am delighted to have worked with so many undergraduate volunteer 
students Olga Britantchouck, Chandler Barton, Nicole Vollum, Phoung Phan, 
Tricia Clemens, and Ezra Young.  
I am extremely thankful to Dr. Andrea DeBarber for giving me the job 
as lab tech for a very powerful instrument - Mass Spectrometer. I have gained 
a lot of knowledge about the instrument and it’s  utility. She has been a great 
boss and person to work for.  
 I don’t think my thesis would have looked coherent and cohesive if it 
wasn’t for the people who have taken some time out of their busy life to review 
it. David Stuart, Sarah Park, Astrid Woodall,  and Amber Vogel. I owe you guys 
big time.  
I am so thankful for the Department of Chemistry at Portland State 
University for giving me an opportunity to pursue my doctorate and funding me 
to survive.  
Although, my family doesn’t have any idea about what the hell I do here, 
they were always very proud of me and shared my success with all the people 
v 
vi 
they know. I am extremely lucky to have such supporting parents and a 
wonderful brother Sudheer Sundalam. 
Finally, I would like to show my deepest regards to my committee 
members Dr. Robert Strongin, Dr. Andrea Goforth and Dr. Jonathan Abramson 
for accepting my humble request on being on my committee.  
vii 




List of Tables………………………………………………………………………….xiii 
List of Figures…………………………………………………………………………xiv 
List of Schemes……………………………………………………………………..xxviii 
List of Abbreviations……………………………………………………………………xxxi  
CHAPTER 1: Importance of Arylation and its Real World Applications…………..1 
1.1 Introduction and Background 
1.1.1  Aromatic rings are important structural motifs for synthetic studies……..1 
1.2 Strategies to Functionalize Arenes 
1.2.1  Non-Metal catalyzed reactions……………………………………………3 
A) Electrophilic Aromatic Substitution; SEAr Reaction (EAS)………………………......3 
B) Nucleophilic Aromatic Substitution: SNAr Reaction………………………………….4 
C) Aryne Reaction…………………………………………………………………….......4 
1.2.2  Metal catalyzed reactions………………………………………………..5 
1.3 Alternatives for Metal-Catalyzed Reactions are needed………………………….6 
1.4 Hypervalent Iodine Compounds……………………………………………………7 
1.4.1 Hypervalent iodine offers a promising metal-free approach…………….7 
1.4.2 Diaryliodonium Salts: Significance and structure……………………….8
1.4.3 Types of diaryliodonium salts……………………………………………10 
viii 
1.4.4 Synthetic methodologies to access diaryliodonium salts………………..11 
A) From aryl iodides……………………………………………………………………..12 
B) From arylboronic acids…………………………………………………….................12 
C) From simple arenes…………………………………………………………………...13 
1.4.5  General reactions of diaryliodonium salts……………………………...14 
1.4.6 Unsymmetrical salts are advantageous over symmetrical salts…………15 
1.4.7 Reactivity of diaryliodonium salts via nucleophilic addition……………17 
CHAPTER 2  PART I 
Base Mediated Synthesis of Alkyl-aryl Ethers from the Reaction of Aliphatic Alcohols 
and Unsymmetrical Diaryliodonium Salts……………………………………………….19 
2.1 Significance of Alky-Aryl ethers…………………………………………………...20 
2.2 Literature Precedent for the Synthesis of Alkyl-Aryl ethers…………………….21 
2.2.1 Type I: Formation of Calkyl-Oaryl ether bond……………………………….21 
2.2.2 Type II: Formation of Caryl -Oalkyl ether bond……………………………...22 
2.3 Literature Precedent from Diaryliodonium Salts…..……………………………24 
2.4 Reaction Discovery...……………………………………………………………….27 
2.5 Reaction Development…...………………………………………………………...27 
2.6 Scope of the Reaction………………………………………………………………30 
2.6.1 Aryl group substrate scope ………………………………………………………..30 
2.6.2 Alcohol group substrate scope …………………………………………………….31 
2.7 Sustainability of the Reaction……………………………………………………...33 
ix 
2.8 Formal Synthesis of Pioglitazone………………………………………………….34 
CHAPTER 2  PART II 
Base-Mediated O-Arylation of Electron Rich Unsymmetrical Diaryliodonium Salts with 
Aliphatic Alcohols……………………………………………………………………….35 
2.9 Proposed Reaction Mechanisms Occurring in the Presence of a Strong Base with 
Unsymmetrical Diaryliodonium salts………………………………………………….36 
2.10 Reaction Development…………………………………………………………….36 
2.11 Auxiliary Screen...…………………………………………………………………37 
2.12 Parameters Affecting the Reaction Yield.……………………………………….38 
2.14 Scope of Electron Rich Unsymmetrical Diaryliodonium Salts…………………40 
2.15 Scope of Alcohols………………………………………………………………......41 
2.16 Conclusion…………………………………………………………………………43 
CHAPTER 3 
Discovery and Development of Arylation Reactions Through “Arynes” Generated from 
Unsymmetrical aryl(mesityl)iodonium salts……………………………………………..44 
3.1 Importance of Arynes as the Intermediates in Organic Synthesis………………44 
3.2 Structure and Regio-Relectivity of Arynes…….………………………………….45 
3.3 Initial Discovery of Arynes…………………………………………………………46 
3.4 Types of Methods to Generate Arynes..………………………………………… ..49 
3.5 Representative Reactions of Arynes……………………………………………….53 
3.5.1 Pericyclic reactions………………………………………………………………..54 
3.5.2 σ-bond insertion reaction…………………………………………………………..55 
x 
3.5.3 Transition Metal-catalyzed annulations…………………………………………...55 
3.5.4 Nucleophilic addition reactions…………………………………………………....56 
3.5.5 Multicomponent reactions (MCRs)………………………………………………...56 
3.6 Limitations to Kobayashi’s method need to be addressed……………………….57 
3.7 Diaryliodonium salts as Aryne Precursors………………………………………..58 
3.8 Literature Precedent for the Generation of Arynes via C-H Deprotonation of 
Aryl halides……………………………………………………………………………..59 
3.9 Generation of Arynes using Unsymmetrical Aryl(mesityl)iodonium Salts via C-H 
Deprotonation…………………………………………………………………………..62 
3.10 Reaction Discovery……..…………………………………………………………63 
3.10.1 Preliminary experiments showing benzyne type reactivity……………….63 
3.10.2 Trapping experiments of aryne with furan………………………………..65 
3.11 Reaction Development…………………………………………………………….66 
3.12 Scope of the Reaction……………………………………………………………...69 
3.12.1 From aryl iodides…………………………………………………………69 
3.12.2 From arylboronic acids…………………………………………………..71 
3.13 Aryne Formation with Selective Iodonium elimination………………………...72 
3.14 Auxiliary and Temperature Controlled Selectivity of C-H Deprotonation……74 





Mechanistic Investigations on Different Modes of Reactivity of Unsymmetrical 
Diaryliodonium Salts…………………………………………………………………….78 
4.1 Investigation of Product Distribution for some Electron Unsymmetrical 
Diaryliodonium 
Salts……………………………………………………………………………………..78 
4.2 Addition of Aryne Trap……………………………………………………………79 
4.3 Influence of the “Position and Electronics” of the Functional Group on the 
Iodonium salt……………………………………………………………………………81 
4.3.1 Effect arising due to ortho groups………………………………………………....81 
4.3.2 Effect arising due to meta groups……………………………………………….....82 
4.3.3 Effect arising due to para groups………………………………………………….82 
4.4 Computational Studies are needed………………………………………………...83 
4.5 Nature of the Nucleophile and its pKa Effects on the Aryne Formation………...84 
CHAPTER 5 
EXPERIMENTAL SECTION………………………………………………………..86 
5.1: General Considerations…………………………………………………………….86 
5.2: Synthesis of aryl(mesityl)iodonium bromide salts.……… …………………….88 
5.2.1: Representative procedure A………………………………………………………88 
5.2.2: Representative procedure B………………………………………………………89 
5.2.3: Representative procedure C………………………………………………………90 
5.2.4: Representative procedure D………………………………………………………90 
5.3: Synthesis of Alkyl-Aryl ethers…………………………………………….............99 
5.3.1: General procedure for the synthesis of alkyl-aryl ethers E……………………….99 
5.4: Synthesis and Characterization of aryl(TMP)iodonium salts………………....111 
xii 
5.4.1: General procedure to synthesize diaryliodonium tosylates A…………………...111 
5.4.2: General procedure to synthesize diaryliodonium trifluoroacetates B……………111 
5.4.3: General procedure C; Synthesis of alkyl-aryl ethers……………………………118 
5.5: Synthesis and Characterization of aryl(mesityl)iodonium tosylate salts……..127 
5.5.1: General procedure from aryl iodides……………………………………………127 
5.5.2: General procedure from arylboronic acids……………………………………..127 
5.6: General procedure for the coupling reaction with furan………………………141 
5.7: General procedure for coupling of arynes with nitrogen arynophiles………..150 
5.8: 1H, 13C, 19F NMR spectra of new compounds…………………………….153 - 435 
References…………………………………………………………………………............431 
xiii 
List of Tables 
Table 2.1: Optimization …………………………………………………………………28 
Table 2.2: Aryl scope for the synthesis of alkyl-aryl ethers……………………………..31 
Table 2.3: Alcohol scope for the synthesis of alkyl-aryl ethers…………………………32 
Table 2.4: Reaction development………………………………………………………..39 
Table 2.5: Aryl scope for the synthesis of alkyl-aryl ethers using electron rich 
unsymmetrical    diaryliodonium salts…………………………………………………..41 
Table 2.6: Alcohol scope for the synthesis of alkyl-aryl ethers using electron rich 
unsymmetrical diaryliodonium salts…………………………………………………….42 
Table 3.1: Optimization of aryne chemistry…………………………………………….68 
Table 3.2: Scope of aryl groups generated from aryl iodides……………………………70 
Table 3.3: Scope of aryl groups generated from arylboronic acids……………………...72 
Table 3.4: Aryne formation with selective iodonium elimination………………………73 
Table 3.5: Auxiliary and temperature controlled selectivity of C-H deprotonation…….74 
xiv 
List of Figures 
Figure 1.1 Industrial important molecules containing aromatic rings……………………2 
Figure 1.2: Metal like alternative…………………………………………………………6 
Figure 1.3: Types of Hypervalent Iodine compounds…………………………………….8 
Figure 1.4: Structure of diaryliodonium salt………………………………………………9 
Figure 1.5: Types of diaryliodonium salts……………………………………………….11 
Figure 2.1: Industrially important compounds with alkyl-aryl ether linkages…………...20 
Figure 3.1: Structure and regio-selectivity in arynes…………………………………….45 
Figure 3.2: Alternative aryne intermediates proposed by J. Roberts…………………….48 
Figure 3.3: Types of methods to generate "arynes"……………………………………...50 
Figure 3.4: Representative reactions of "arynes"………………………………………...53 
Figure 5.1: 1H NMR of 1.1 at 400 MHz in DMSO-d6 at 298K………………………...153 
Figure 5.2: 13C NMR of 1.1 at 100 MHz in DMSO-d6 at 298K………………………..154 
Figure 5.3: 19F NMR of 1.1 at 377 MHz in DMSO-d6 at 298K…………………….....155 
Figure 5.4: 1H NMR of 1.2 at 400 MHz in DMSO-d6 at 298K
 ………………………..156 
Figure 5.5: 13C NMR of 1.2 at 100 MHz in DMSO-d6 at 298K ……………………….157 
Figure 5.6: 1H NMR of 1.3 at 400 MHz in DMSO-d6 at 298K ………………………..158 
Figure 5.7: 13C NMR of 1.3 at 100 MHz in DMSO-d6 at 298K …………………….....159 
Figure 5.8: 1H NMR of 1.4 - Mes at 400 MHz in DMSO-d6 at 298K
 …………………160 
Figure 5.9: 13C NMR of 1.4 – Mes at 100 MHz in DMSO-d6 at 298K ………………..161 
Figure 5.10: 1H NMR of 1.4 - Ph at 400 MHz in DMSO-d6 at 298K
 …………………162 
Figure 5.11: 13C NMR of 1.4 - Ph at 100 MHz in DMSO-d6 at 298K ………………...163 
xv 
Figure 5.12: 1H NMR of 1.4 - TMB at 400 MHz in DMSO-d6 at 298K………………164 
Figure 5.13: 13C NMR of 1.4 - TMB at 100 MHz in DMSO-d6 at 298K ……………..165 
Figure 5.14: 1H NMR of 1.4 - Th at 400 MHz in DMSO-d6 at 298K…………………166 
Figure 5.15: 13C NMR of 1.4 - Th at 100 MHz in DMSO-d6 at 298K…………………167 
Figure 5.16: 1H NMR of 1.5 at 400 MHz in DMSO-d6 at 298K………………………168 
Figure 5.17: 13C NMR of 1.5 at 400 MHz in DMSO-d6 at 298K………………………169 
Figure 5.18: 1H NMR of 1.6 at 400 MHz in DMSO-d6 at 298K ………………………170 
Figure 5.19: 13C NMR of 1.6 at 100 MHz in DMSO-d6 at 298K ……………………...171 
Figure 5.20: 19F NMR of 1.6 at 377 MHz in DMSO-d6 at 298K………………………172 
Figure 5.21: 1H NMR of 1.7 at 400 MHz in DMSO-d6 at 298K……………………….173 
Figure 5.22: 13C NMR of 1.7 at 100 MHz in DMSO-d6 at 298K………………………174 
Figure 5.23: 1H NMR of 1.8 at 400 MHz in DMSO-d6 at 298K……………………….175 
Figure 5.24: 13C NMR of 1.8 at 100 MHz in DMSO-d6 at 298K………………………176 
Figure 5.25: 19 F NMR of 1.8 at 377 MHz in DMSO-d6 at 298K………………………177 
Figure 5.26: 1H NMR of 1.9 at 400 MHz in DMSO-d6 at 298K……………………….178 
Figure 5.27: 13 C NMR of 1.9 at 100 MHz in DMSO-d6 at 298K……………………...179 
Figure 5.28: 1H NMR of 1.10 at 100 MHz in DMSO-d6 at 298K……………………...180 
Figure 5.29: 13C NMR of 1.10 at 100 MHz in DMSO-d6 at 298K……………………..181 
Figure 5.30: 1H NMR of 1.11 at 400 MHz in DMSO-d6 at 298K……………………...182 
Figure 5.31: 13C NMR of 1.11 at 100 MHz in DMSO-d6 at 298K……………………..183 
Figure 5.32: 19F NMR of 1.11 at 377 MHz in DMSO-d6 at 298K……………………..184 
Figure 5.33: 1H NMR of 1.12 at 400 MHz in DMSO-d6 at 298K……………………...185 
xvi 
Figure 5.34: 13C NMR of 1.12 at 100 MHz in DMSO-d6 at 298K……………………..186 
Figure 5.35: 1H NMR of 1.13 at 400 MHz in DMSO-d6 at 298K……………………...187 
Figure 5.36: 13C NMR of 1.13 at 100 MHz in DMSO-d6 at 298K……………………..188 
Figure 5.37: 1H NMR of 1.14 at 400 MHz in DMSO-d6 at 298K……………………...189 
Figure 5.38: 13C NMR of 1.15 at 100 MHz in DMSO-d6 at 298K……………………..190 
Figure 5.39: 1H NMR of 1.16 at 400 MHz in CDCl3 at 298K…………………….........191 
Figure 5.40: 13C NMR of 1.16 at 100 MHz in CDCl3 at 298K…………………………192 
Figure 5.41: 1H NMR of 1.17 at 400 MHz in CDCl3 at 298K………………………….193 
Figure 5.42: 13C NMR of 1.17 at 100 MHz in CDCl3 at 298K…………………………194 
Figure 5.43: 1H NMR of 1.18 at 400 MHz in CDCl3 at 298K………………………….195 
Figure 5.44: 13C NMR of 1.18 at 100 MHz in CDCl3 at 298K…………………………196 
Figure 5.45: 19F NMR of 1.18 at 377 MHz in CDCl3 at 298K…………………………197 
Figure 5.46: 1H NMR of 1.19 at 400 MHz in CDCl3 at 298K………………………….198 
Figure 5.47: 13C NMR of 1.19 at 100 MHz in CDCl3 at 298K…………………………199 
Figure 5.48: 1H NMR of 1.20 at 400 MHz in CDCl3 at 298K………………………….200 
Figure 5.49: 1H NMR of 1.21 at 400 MHz in CDCl3 at 298K …………………………201 
Figure 5.50: 1H NMR of 1.22 at 400 MHz in CDCl3 at 298K………………………….202 
Figure 5.51: 13C NMR of 1.22 at 100 MHz in CDCl3 at 298K…………………………203 
Figure 5.52: 1H NMR of 1.23 at 400 MHz in CDCl3 at 298K………………………….204 
Figure 5.53: 13C NMR of 1.23 at 100 MHz in CDCl3 at 298K…………………………205 
Figure 5.54: 1H NMR of 1.24 at 400 MHz in CDCl3 at 298K………………………….206 
Figure 5.55: 13C NMR of 1.24 at 100 MHz in CDCl3 at 298K…………………………207 
xvii 
Figure 5.56: 19F NMR of 1.24 at 377 MHz in CDCl3 at 298K…………………………208 
Figure 5.57: 1H NMR of 1.25 at 400 MHz in CDCl3 at 298K………………………….209 
Figure 5.58: 13C NMR of 1.25 at 100 MHz in CDCl3 at 298K…………………………210 
Figure 5.59: 1H NMR of 1.26 at 400 MHz in CDCl3 at 298K………………………….211 
Figure 5.60: 13C NMR of 1.26 at 100 MHz in CDCl3 at 298K…………………………212 
Figure 5.61: 1H NMR of 1.27 at 400 MHz in CDCl3 at 298K………………………….213 
Figure 5.62: 13C NMR of 1.27 at 100 MHz in CDCl3 at 298K…………………………214 
Figure 5.63: 1H NMR of 1.28 at 400 MHz in CDCl3 at 298K………………………….215 
Figure 5.64: 1H NMR of 1.29 at 400 MHz in CDCl3 at 298K………………………….216 
Figure 5.65: 1H NMR of 1.30 at 400 MHz in CDCl3 at 298K………………………….217 
Figure 5.66: 13C NMR of 1.30 at 100 MHz in CDCl3 at 298K…………………………218 
Figure 5.67: 1H NMR of 1.31 at 400 MHz in CDCl3 at 298K………………….………219 
Figure 5.68: 1H NMR of 1.32 at 400 MHz in CDCl3 at 298K…………………….........220 
Figure 5.69: 13C NMR of 1.32 at 100 MHz in CDCl3 at 298K…………………………221 
Figure 5.70: 19F NMR of 1.32 at 377 MHz in CDCl3 at 298K…………………………222 
Figure 5.71: 1H NMR of 1.33 at 400 MHz in CDCl3 at 298K…………………….........223 
Figure 5.72: 13C NMR of 1.33 at 100 MHz in CDCl3 at 298K……………………........224 
Figure 5.73: 1H NMR of 1.34 at 400 MHz in CDCl3 at 298K…………………….........225 
Figure 5.74: 13C NMR of 1.34 at 100 MHz in CDCl3 at 298K…………………………226 
Figure 5.75: 19F NMR of 1.34 at 377 MHz in CDCl3 at 298K…………………………227 
Figure 5.76: 1H NMR of 1.35 at 400 MHz in CDCl3 at 298K…………………….........228 
Figure 5.77: 13C NMR of 1.35 at 100 MHz in CDCl3 at 298K…………………………229 
xviii 
Figure 5.78: 19F NMR of 1.35 at 377 MHz in CDCl3 at 298K…………………………230 
Figure 5.79: 1H NMR of 1.36 at 400 MHz in CDCl3 at 298K…………………….........231 
Figure 5.80: 13C NMR of 1.36 at 100 MHz in CDCl3 at 298K………………………....232 
Figure 5.81: 19F NMR of 1.36 at 377 MHz in CDCl3 at 298K………………………....233 
Figure 5.82: 1H NMR of 1.37 at 400 MHz in CDCl3 at 298K………………………….234 
Figure 5.83: 1H NMR of 1.38 at 400 MHz in CDCl3 at 298K………………………….235 
Figure 5.84: 13C NMR of 1.38 at 100 MHz in CDCl3 at 298K…………………………236 
Figure 5.85: 19F NMR of 1.38 at 377 MHz in CDCl3at 298K………………………….237 
Figure 5.86: 1H NMR of 1.39 at 400 MHz in DMSO-d6 at 298K……………………...238 
Figure 5.87: 1H NMR of 1.39 at 400 MHz in DMSO-d6 at 373K……………………...239 
Figure 5.88: 1H NMR of 1.39 at 400 MHz in CDCl3 at 298K………………………….240 
Figure 5.89: 13C NMR of 1.39 at 100 MHz in CDCl3 at 298K…………………………241 
Figure 5.90: 1H NMR of 1.40 at 400 MHz in CDCl3 at 298K………………………….242 
Figure 5.91: 1H NMR of 1.41 at 400 MHz in CDCl3 at 298K………………………….243 
Figure 5.92: 13C NMR of 1.41 at 100 MHz in CDCl3 at 298K…………………………244 
Figure 5.93: 19F NMR of 1.41 at 377 MHz in CDCl3 at 298K…………………………245 
Figure 5.94: 1H NMR of 1.42 at 400 MHz in CDCl3 at 298K………………………….246 
Figure 5.95: 13C NMR of 1.42 at 100 MHz in CDCl3 at 298K…………………………247 
Figure 5.96: 1H NMR of 1.43 - anisole at 400 MHz in DMSO-d6 at 298K…………....248 
Figure 5.97: 13C NMR of 1.43 - anisole at 100 MHz in DMSO-d6 at 298K …………..249 
Figure 5.98: 1H NMR of 1.43 - Th at 400 MHz in DMSO-d6 at 298K………………...250 
Figure 5.99: 13C NMR of 1. 43 - Th at 100 MHz in DMSO-d6 at 298K……………….251 
xix 
Figure 5.100: 1H NMR of 1.44 at 400 MHz in DMSO-d6 at 298K……………………252 
Figure 5.101: 13C NMR of 1.44 at 400 MHz in DMSO-d6 at 298K…………………...253 
Figure 5.102: 19F NMR of 1.44 at 377 MHz in DMSO-d6 at 298K……………………254 
Figure 5.103: 1H NMR of 1.45 at 400 MHz in DMSO-d6 at 298K……………………255 
Figure 5.104: 13C NMR of 1.45 at 100 MHz in DMSO-d6 at 298K……………………256 
Figure 5.105: 1H NMR of 1.46 at 400 MHz in DMSO-d6 at 298K……………………257 
Figure 5.106: 13C NMR of 1.46 at 100 MHz in DMSO-d6 at 298K……………………258 
Figure 5.107: 1H NMR of 1.47 at 400 MHz in DMSO-d6 at 298K…………………….259 
Figure 5.108: 13C NMR of 1.47 at 100 MHz in DMSO-d6 at 298K……………………260 
Figure 5.109: 1H NMR of 1.48 at 400 MHz in DMSO-d6 at 298K……………………261 
Figure 5.110: 13C NMR of 1.48 at 100 MHz in DMSO-d6 at 298K……………………262 
Figure 5.111: 1H NMR of 1.49 at 400 MHz in DMSO-d6 at 298K……………………263 
Figure 5.112: 13C NMR of 1.49 at 100 MHz in DMSO-d6 at 298K……………………264 
Figure 5.113: 1H NMR of 1.50 at 400 MHz in DMSO-d6 at 298K……………………265 
Figure 5.114: 1C NMR of 1.50 at 100 MHz in DMSO-d6 at 298K……………………266 
Figure 5.115: 1H NMR of 1.51 at 400 MHz in DMSO-d6 at 298K……………………267 
Figure 5.116: 13C NMR of 1.51 at 100 MHz in DMSO-d6 at 298K……………………268 
Figure 5.117: 1H NMR of 1.52 at 400 MHz in DMSO-d6 at 298K……………………269 
Figure 5.118: 13C NMR of 1.52 at 100 MHz in DMSO-d6 at 298K……………………270 
Figure 5.119: 19F NMR of 1.52 at 377 MHz in DMSO-d6 at 298K……………………271 
Figure 5.120: 1H NMR of 1.53 at 400 MHz in CDCl3 at 298K………………………..272 
Figure 5.121: 13C NMR of 1.53 at 100 MHz in CDCl3 at 298K………………………273 
xx 
Figure 5.122: 1H NMR of 1.54 at 400 MHz in CDCl3 at 298K………………………274 
Figure 5.123: 13C NMR of 1.54 at 100 MHz in CDCl3 at 298K………………………275 
Figure 5.124: 1H NMR of 1.55 at 400 MHz in CDCl3 at 298K………………………276 
Figure 5.125: 13C NMR of 1.55 at 100 MHz in CDCl3 at 298K………………………277 
Figure 5.126: 1H NMR of 1.56 at 400 MHz in CDCl3 at 298K………………………278 
Figure 5.127: 13C NMR of 1.56 at 100 MHz in CDCl3 at 298K………………………279 
Figure 5.128: 1H NMR of 1.57 at 400 MHz in CDCl3 at 298K………………………280 
Figure 5.129: 13C NMR of 1.57 at 100 MHz in CDCl3 at 298K………………………281 
Figure 5.130: 1H NMR of 1.58 at 400 MHz in CDCl3 at 298K………………………282 
Figure 5.131: 13C NMR of 1.58 at 100 MHz in CDCl3 at 298K………………………283 
Figure 5.132: 1H NMR of 1.59 at 400 MHz in CDCl3 at 298K………………………284 
Figure 5.133: 13C NMR of 1.59 at 100 MHz in CDCl3 at 298K………………………285 
Figure 5.134: 1H NMR of 1.61 at 400 MHz in CDCl3 at 298K………………………286 
Figure 5.135: 13C NMR of 1.61 at 100 MHz in CDCl3 at 298K………………………287 
Figure 5.136: 1H NMR of 1.62 at 400 MHz in CDCl3 at 298K………………………288 
Figure 5.137: 13C NMR of 1.62 at 100 MHz in CDCl3 at 298K………………………289 
Figure 5.138: 1H NMR of 1.63 at 400 MHz in CDCl3 at 298K………………………290 
Figure 5.139: 13C NMR of 1.63 at 100 MHz in CDCl3 at 298K………………………291 
Figure 5.140: 1H NMR of 1.64 at 400 MHz in CDCl3 at 298K………………………292 
Figure 5.141: 13C NMR of 1.64 at 100 MHz in CDCl3 at 298K………………………293 
Figure 5.142: 1H NMR of 1.65 at 400 MHz in CDCl3 at 298K………………………294 
Figure 5.143: 13C NMR of 1.65 at 100 MHz in CDCl3 at 298K………………………295 
xxi 
Figure 5.144: 1H NMR of 1.66 at 400 MHz in CDCl3 at 298K………………………296 
Figure 5.145: 13C NMR of 1.66 at 100 MHz in CDCl3 at 298K………………………297 
Figure 5.146: 1H NMR of 1.67 at 400 MHz in CDCl3 at 298K………………………298 
Figure 5.147: 13C NMR of 1.67 at 100 MHz in CDCl3 at 298K………………………299 
Figure 5.148: 1H NMR of 1.68 at 400 MHz in CDCl3 at 298K………………………300 
Figure 5.149: 13C NMR of 1.68 at 100 MHz in CDCl3 at 298K………………………301 
Figure 5.150: 1H NMR of 1.69 at 400 MHz in CDCl3 at 298K………………………302 
Figure 5.151: 13C NMR of 1.69 at 100 MHz in CDCl3 at 298K………………………303 
Figure 5.152: 1H NMR of 1.70 at 400 MHz in CDCl3 at 298K………………………304 
Figure 5.153: 13C NMR of 1.70 at 100 MHz in CDCl3 at 298K………………………305 
Figure 5.154: 19F NMR of 1.70 at 377 MHz in CDCl3 at 298K………………………306 
Figure 5.155: 1H NMR of 1.71 at 400 MHz in CDCl3 at 298K………………………307 
Figure 5.156: 13C NMR of 1.71 at 100 MHz in CDCl3 at 298K………………………308 
Figure 5.157: 1H NMR of 2.1 at 400 MHz in DMSO-d6 at 298K……………………309 
Figure 5.158: 13C NMR of 2.1 at 100 MHz in DMSO-d6 at 298K……………………310 
Figure 5.159: 1H NMR of 2.2 at 400 MHz in DMSO-d6 at 298K……………………311 
Figure 5.160: 13C NMR of 2.2 at 100 MHz in DMSO-d6 at 298K……………………312 
Figure 5.161: 19F NMR of 2.2 at 377 MHz in DMSO-d6 at 298K……………………313 
Figure 5.162: 1H NMR of 2.3 at 400 MHz in DMSO-d6 at 298K……………………314 
Figure 5.163: 13C NMR of 2.3 at 100 MHz in DMSO-d6 at 298K……………………315 
Figure 5.164: 1H NMR of 2.4 at 400 MHz in DMSO-d6 at 298K……………………316 
Figure 5.165: 13C NMR of 2.4 at 100 MHz in DMSO-d6 at 298K……………………317 
xxii 
Figure 5.166: 19F NMR of 2.4 at 377 MHz in DMSO-d6 at 298K……………………318 
Figure 5.167: 1H NMR of 2.5 at 400 MHz in DMSO-d6 at 298K……………………319 
Figure 5.168: 13C NMR of 2.5 at 100 MHz in DMSO-d6 at 298K……………………320 
Figure 5.169: 1H NMR of 2.6 at 400 MHz in DMSO-d6 at 298K……………………321 
Figure 5.170: 13C NMR of 2.6 at 100 MHz in DMSO-d6 at 298K……………………322 
Figure 5.171: 1H NMR of 2.7 at 400 MHz in DMSO-d6 at 298K……………………323 
Figure 5.172: 13C NMR of 2.7 at 100 MHz in DMSO-d6 at 298K……………………324 
Figure 5.173: 1H NMR of 2.8 at 400 MHz in DMSO-d6 at 298K……………………325 
Figure 5.174: 13C NMR of 2.8 at 400 MHz in DMSO-d6 at 298K……………………326 
Figure 5.175: 19F NMR of 2.8 at 377 MHz in DMSO-d6 at 298K……………………327 
Figure 5.176: 1H NMR of 2.9 at 400 MHz in DMSO-d6 at 298K……………………328 
Figure 5.177: 13C NMR of 2.9 at 400 MHz in DMSO-d6 at 298K……………………329 
Figure 5.178: 19F NMR of 2.9 at 377 MHz in DMSO-d6 at 298K……………………330 
Figure 5.179: 1H NMR of 2.10 at 400 MHz in DMSO-d6 at 298K……………………331 
Figure 5.180: 13C NMR of 2.10 at 400 MHz in DMSO-d6 at 298K……………………332 
Figure 5.181: 19F NMR of 2.10 at 377 MHz in DMSO-d6 at 298K……………………333 
Figure 5.182: 1H NMR of 2.11 at 400 MHz in DMSO-d6 at 298K……………………334 
Figure 5.183: 13C NMR of 2.11 at 100 MHz in DMSO-d6 at 298K……………………335 
Figure 5.184: 1H NMR of 2.12 at 400 MHz in DMSO-d6 at 298K……………………336 
Figure 5.185: 13C NMR of 2.12 at 100 MHz in DMSO-d6 at 298K……………………337 
Figure 5.186: 1H NMR of 2.13 at 400 MHz in DMSO-d6 at 298K……………………338 
Figure 5.187: 13C NMR of 2.13 at 100 MHz in DMSO-d6 at 298K……………………339 
xxiii 
Figure 5.188: 1H NMR of 2.14 at 400 MHz in DMSO-d6 at 298K……………………340 
Figure 5.189: 13C NMR of 2.14 at 100 MHz in DMSO-d6 at 298K……………………341 
Figure 5.190: 19F NMR of 2.14 at 377 MHz in DMSO-d6 at 298K……………………342 
Figure 5.191: 1H NMR of 2.15 at 400 MHz in DMSO-d6 at 298K……………………343 
Figure 5.192: 13C NMR of 2.15 at 100 MHz in DMSO-d6 at 298K……………………344 
Figure 5.193: 1H NMR of 2.16 at 400 MHz in DMSO-d6 at 298K……………………345 
Figure 5.194: 13C NMR of 2.16 at 100 MHz in DMSO-d6 at 298K……………………346 
Figure 5.195: 1H NMR of 2.17 at 400 MHz in DMSO-d6 at 298K……………………347 
Figure 5.196: 13C NMR of 2.17 at 100 MHz in DMSO-d6 at 298K……………………348 
Figure 5.197: 1H NMR of 2.18 at 400 MHz in DMSO-d6 at 298K……………………349 
Figure 5.198: 13C NMR of 2.18 at 100 MHz in DMSO-d6 at 298K……………………350 
Figure 5.199: 1H NMR of 2.19 at 400 MHz in DMSO-d6 at 298K……………………351 
Figure 5.200: 13C NMR of 2.19 at 100 MHz in DMSO-d6 at 298K……………………352 
Figure 5.201: 1H NMR of 2.20 at 400 MHz in DMSO-d6 at 298K……………………353 
Figure 5.202: 13C NMR of 2.20 at 100 MHz in DMSO-d6 at 298K……………………354 
Figure 5.203: 1H NMR of 2.21 at 400 MHz in DMSO-d6 at 298K……………………355 
Figure 5.204: 13C NMR of 2.21 at 100 MHz in DMSO-d6 at 298K……………………356 
Figure 5.205: 1H NMR of 2.22 at 400 MHz in DMSO-d6 at 298K……………………357 
Figure 5.206: 13C NMR of 2.22 at 100 MHz in DMSO-d6 at 298K……………………358 
Figure 5.207: 1H NMR of 2.23 at 400 MHz in DMSO-d6 at 298K……………………359 
Figure 5.208: 13C NMR of 2.23 at 100 MHz in DMSO-d6 at 298K……………………360 
Figure 5.209: 1H NMR of 2.24 at 400 MHz in DMSO-d6 at 298K……………………361 
xxiv 
Figure 5.210: 13C NMR of 2.24 at 100 MHz in DMSO-d6 at 298K……………………362 
Figure 5.211: 1H NMR of 2.25 at 400 MHz in DMSO-d6 at 298K……………………363 
Figure 5.212: 13C NMR of 2.25 at 100 MHz in DMSO-d6 at 298K……………………364 
Figure 5.213: 1H NMR of 2.26 at 400 MHz in DMSO-d6 at 298K……………………365 
Figure 5.214: 13C NMR of 2.26 at 100 MHz in DMSO-d6 at 298K……………………366 
Figure 5.215: 1H NMR of 2.27 at 400 MHz in CDCl3 at 298K………………………..367 
Figure 5.216: 13C NMR of 2.27 at 100 MHz in CDCl3 at 298K………………………368 
Figure 5.217: 1H NMR of 2.28 at 400 MHz in CDCl3 at 298K……………………….369 
Figure 5.218: 13C NMR of 2.28 at 100 MHz in CDCl3 at 298K………………………370 
Figure 5.219: 19 F NMR of 2.28 at 377 MHz in CDCl3 at 298K………………………371 
Figure 5.220: 1H NMR of 2.29 at 400 MHz in CDCl3 at 298K……………………….372 
Figure 5.221: 13C NMR of 2.29 at 100 MHz in CDCl3 at 298K………………………373 
Figure 5.222: 1H NMR of 2.30 at 400 MHz in CDCl3 at 298K……………………….374 
Figure 5.223: 13C NMR of 2.30 at 100 MHz in CDCl3 at 298K………………………375 
Figure 5.224: 19 F NMR of 2.31 at 377 MHz in CDCl3 at 298K………………………376 
Figure 5.225: 13C NMR of 2.31 at 100 MHz in CDCl3 at 298K………………………377 
Figure 5.226: 19 F NMR of 2.31 at 377 MHz in CDCl3 at 298K………………………378 
Figure 5.227: 1H NMR of 2.32 at 400 MHz in CDCl3 at 298K……………………….379 
Figure 5.228: 13C NMR of 2.32 at 100 MHz in CDCl3 at 298K………………………380 
Figure 5.229: 1H NMR of 2.33 at 400 MHz in CDCl3 at 298K……………………….381 
Figure 5.230: 13C NMR of 2.33 at 100 MHz in CDCl3 at 298K………………………382 
Figure 5.231: 1H NMR of 2.34 at 400 MHz in CDCl3 at 298K……………………….383 
xxv 
Figure 5.232: 13C NMR of 2.34 at 100 MHz in CDCl3 at 298K………………………384 
Figure 5.233: 19 F NMR of 2.34 at 377 MHz in CDCl3 at 298K………………………385 
Figure 5.234: 1H NMR of 2.35 at 400 MHz in CDCl3 at 298K……………………….386 
Figure 5.235: 13C NMR of 2.35 at 100 MHz in CDCl3 at 298K………………………387 
Figure 5.236: 19 F NMR of 2.35 at 377 MHz in CDCl3 at 298K………………………388 
Figure 5.237: 1H NMR of 2.36 at 400 MHz in CDCl3 at 298K……………………….389 
Figure 5.238: 13C NMR of 2.36 at 100 MHz in CDCl3 at 298K………………………390 
Figure 5.239: 19 F NMR of 2.36 at 377 MHz in CDCl3 at 298K………………………391 
Figure 5.240: 1H NMR of 2.37 at 400 MHz in CDCl3 at 298K……………………….392 
Figure 5.241: 13C NMR of 2.37 at 100 MHz in CDCl3 at 298K………………………393 
Figure 5.242: 1H NMR of 2.38 at 400 MHz in CDCl3 at 298K……………………….394 
Figure 5.243: 13C NMR of 2.38 at 100 MHz in CDCl3 at 298K………………………395 
Figure 5.244: 1H NMR of 2.3 9at 400 MHz in CDCl3 at 298K……………………….396 
Figure 5.245: 13C NMR of 2.39 at 100 MHz in CDCl3 at 298K………………………397 
Figure 5.246: 1H NMR of 2.40 at 400 MHz in CDCl3 at 298K……………………….398 
Figure 5.247: 13C NMR of 2.40 at 100 MHz in CDCl3 at 298K………………………399 
Figure 5.248: 19F NMR of 2.40 at 377 MHz in CDCl3 at 298K………………………400 
Figure 5.249: 1H NMR of 2.41 at 400 MHz in CDCl3 at 298K……………………….401 
Figure 5.250: 13C NMR of 2.41 at 100 MHz in CDCl3 at 298K………………………402 
Figure 5.251: 1H NMR of 2.42 at 400 MHz in CDCl3 at 298K……………………….403 
Figure 5.252: 13C NMR of 2.42 at 100 MHz in CDCl3 at 298K………………………404 
Figure 5.253: 1H NMR of 2.43 at 400 MHz in CDCl3 at 298K……………………….405 
xxvi 
Figure 5.254: 13C NMR of 2.43 at 100 MHz in CDCl3 at 298K………………………406 
Figure 5.255: 1H NMR of 2.44 at 400 MHz in CDCl3 at 298K……………………….407 
Figure 5.256: 13C NMR of 2.44 at 100 MHz in CDCl3 at 298K………………………408 
Figure 5.257: 1H NMR of 2.45 at 400 MHz in CDCl3 at 298K……………………….409 
Figure 5.258: 13C NMR of 2.45 at 100 MHz in CDCl3 at 298K………………………410 
Figure 5.259: 1H NMR of 2.46 at 400 MHz in CDCl3 at 298K……………………….411 
Figure 5.260: 13C NMR of 2.46 at 100 MHz in CDCl3 at 298K………………………412 
Figure 5.261: 1H NMR of 2.47 at 400 MHz in CDCl3 at 298K……………………….413 
Figure 5.262: 13C NMR of 2.47 at 100 MHz in CDCl3 at 298K………………………414 
Figure 5.263: 1H NMR of 2.48 at 400 MHz in CDCl3 at 298K……………………….415 
Figure 5.264: 13C NMR of 2.48 at 100 MHz in CDCl3 at 298K………………………416 
Figure 5.265: 1H NMR of 2.49 at 400 MHz in CDCl3 at 298K……………………….417 
Figure 5.266: 13C NMR of 2.49 at 100 MHz in CDCl3 at 298K………………………418 
Figure 5.267: 1H NMR of 2.50 at 400 MHz in CDCl3 at 298K……………………….419 
Figure 5.268: 13C NMR of 2.50 at 100 MHz in CDCl3 at 298K………………………420 
Figure 5.269: 1H NMR of 2.51 at 400 MHz in CDCl3 at 298K……………………….421 
Figure 5.270: 13C NMR of 2.51 at 100 MHz in CDCl3 at 298K………………………422 
Figure 5.271: 1H NMR of 2.52 at 400 MHz in CDCl3 at 298K……………………….423 
Figure 5.272: 13C NMR of 2.52 at 100 MHz in CDCl3 at 298K………………………424 
Figure 5.273: 1H NMR of 2.53 at 400 MHz in CDCl3 at 298K……………………….425 
Figure 5.274: 13C NMR of 2.53 at 100 MHz in CDCl3 at 298K………………………426 
Figure 5.275: 1H NMR of 2.54 at 400 MHz in CDCl3 at 298K……………………….427 
xxvii 
Figure 5.276: 13C NMR of 2.54 at 100 MHz in CDCl3 at 298K………………………428 
Figure 5.277: 1H NMR of 2.55 at 400 MHz in CDCl3 at 298K……………………….429 
Figure 5.278: 13C NMR of 2.55 at 100 MHz in CDCl3 at 298K………………………430 
xxviii 
List of Schemes 
Scheme 1.1: Electrophilic aromatic substitution reaction…………………………………3 
Scheme 1.2: Nucleophilic aromatic substitution reaction…………………………………4 
Scheme 1.3: Aryne reaction……………………………………………………………….5 
Scheme 1.4: Catalytic pathway using transition metals…………………………………...5 
Scheme 1.5: Preparation of diaryliodonium salts from aryl iodides……………………..12 
Scheme 1.6: Preparation of diaryliodonium salts from arylboronic acids……………….13 
Scheme 1.7: Preparation of diaryliodonium salts from simple arenes…………………...14 
Scheme 1.8: General reaction an diaryliodonium salt…………………………………...16 
Scheme 1.8.1: Using symmetrical diaryliodonium salts…………………………16 
Scheme 1.8.2: Using unsymmetrical diaryliodonium salts………………………16 
Scheme 1.9: Proposed mechanism of nucleophilic addition on diaryliodonium salts…...18 
Scheme 2.1: Base mediated synthesis of alky-aryl ethers……………………………….19 
Scheme 2.2: Retro synthetic disconnections towards alky-aryl ether synthesis…………21 
Scheme 2.3: Protocols towards the synthesis of Caryl-Oalkyl ethers………………………23 
Scheme 2.4: Literature precedent for the syntheis alkyl-aryl ether from diaryliodonium 
salt………………………………………………………………………………………..26 
Scheme 2.5: Sustainability of the reaction; recovery and reuse of the auxiliary group…33 
Scheme 2.6: Formal synthesis of Pioglitazone………………………………………….34 
Scheme 2.7: Alkoxide nucleophiles trigger two different pathways with diaryliodonium 
salts………………………………………………………………………………………36 
Scheme 3.1: Reaction developed by Stoermer and Kahlert in 1902……………………..46 
xxix 
Scheme 3.2: Reaction scheme proposed by Georg Wittig and Coworkers in 1940-42….47 
Scheme 3.3: Reaction scheme proposed by John D. Roberts in 1953……………..…….48 
Scheme 3.4:  Reaction pathway proposed by Witting and Pohmer in 1955……………..49 
Scheme 3.5: Most recent efficient method to syntheisize 2-(trimethylsilyl)aryl 
triflate…….........................................................................................................................58 
Scheme 3.6: Literature precedent for the generation of arynes via C-H deprotonation of 
aryl halides……………………………………………………………………………….60 
Scheme 3.7: Trapping of benzyne formed from sodium acetate and diphenyliodonium 
chloride…………………………………………………………………………………..61 
Scheme 3.8: Our work…………………………………………………………………...62 
Scheme 3.9: Proposed reaction mechanism of C-H deprotonation on unsymmetrical 
diaryliodonium salts …………………………………………………………………….62 
Scheme 3.10: Preliminary reactions towards the discovery of arynes generated via C-H 
deprotonation of unsymmetrical diaryliodonium salts…………………………………..64 
Scheme 3.11: Product distribution of previously reported aryne mechanism…………...65 
Scheme 3.12: Trapping of aryne formation with Furan…………………………………66 
Scheme 3.13: Model reactions using electron rich unsymmetrical diaryliodonium 
salt………………………………………………………………………………………..67 
Scheme 3.14: Representative examples of cycloaddition and nucleophilic addition 
reactions.............................................................................................................................76 
Scheme 4.1: Analysis of products and side product distribution of electron rich 
unsymmetrical diaryliodonium salt in C-O coupling reaction…………………………...79 
Scheme 4.2: Analysis of products distribution of electron rich unsymmetrical 
diaryliodonium salt when aryne trap was added…………………………………………80 
xxx 
Scheme 4.3: Plausible mechanism when milder base is employed……………………...80 
Scheme 4.4: Product distribution when ortho substituted salts are employed…………..81 
Scheme 4.5: Product distribution when meta substituted salts are employed…………...82 
Scheme 4.6: Product distribution when para substituted salts are employed……………83 
Scheme 4.7: Nature and pKa of nucleophiles triggering aryne pathway………………...85 
Scheme 5.1: Representative procedure A………………………………………………..88 
Scheme 5.2: Representative procedure B………………………………………………..89 
Scheme 5.3: Representative procedure C………………………………………………..90 
Scheme 5.4: Representative procedure D………………………………………………..90 
Scheme 5.5: General procedure for the synthesis of alkyl-aryl ethers E………………...99 
xxxi 
List of Abbreviations 
Ar – Aryl 
BF4 – Tetrafluroborate 
Br – Bromide 
Cl – Chloride 
DBU - 1,8-Diazabicyclo(5.4.0)undec-7-
ene 
DEAD - Diethyl azodicarboxylate 
DPE - 1,1-diphenylethyl- ene 
Et – Ethyl 
EDG – Electron donating group 
EWG – Electron withdrawing group 
GC-MS – Gas Chromatography Mass 
Spectrometry 
KBr – Potassium bromide 
LG – Leaving group 
Me – Methyl 
Mes – 1,3,5 –Trimethylphenyl 
NMR - Nuclear Magnetic Resonance 
spectroscopy 
Nu – Nucleophile 
OTs – Tosylate 
OTf – Triflate 
Ph – Phenyl 
PF6 – Hexaflurophosphate 
TFA – Trifluroacetate 
THC – Tetrahydrocannabinol 
TMS - Tetramethylsilane 
TMB – 1,3,5-Trimethoxybenzene 
TMP – 2,4,6 -Trimethoxyphenyl 
TBAF – Tetrabutylammonium fluoride 





Importance of Arylation and its Real World Applications 
1.1 Introduction and Background 
1.1.1 Aromatic rings are important structural motifs for synthetic studies 
Arenes and heteroarenes are ubiquitous groups in active pharmaceutical ingredients (API),1 
agrochemicals,2 natural products,3 liquid crystal displays,4 and conducting polymers5 
(Figure 1.1, red).  Of the top 200 pharmaceuticals prescribed in the United States in 2012, 
157 possessed one or more aromatic rings.6  Hence, functionalizing aromatic compounds 
1 For reviews, see: (a) Yeh, V. S. C. Tetrahedron 2004, 60, 11905–12042; (b) Bagley, M. C.; Dale, J. W.; 
Meritt, E. A.; Xiong, X. Chem. Rev. 2005, 105, 685–714; (c) Riego, E.; Hernandez, D.; Alberico, F.; 
Alvarez, M. Synthesis 2005, 1907–1922; (d) Hughes, R. A.; Moody, C. Angew. Chem., Int. Ed. 2007, 46, 
7930–7954. 
2 (a) Leroux, P.; Lanen, C.; Fritz, R. Pestic. Sci. 2006, 36, 255–261; (b) The Agrochemical Handbook; 
Hartley, D., Kidd, H., Eds.; Royal Society of Chemistry, University of Nottingham: England, 1991; (c) 
Baker, D.R.; Basarab, G.S.; Fenyes, J.G. Eds., Synthesis and Chemistry of Agrochemicals IV, Oxford 
University Press; ACS Symposium Series No 584, Washington, D.C., 1995; (d) Modern Crop Protection 
Compounds; Kra¨mer, W., Schirmer, U., Eds.; Wiley-VCH: Weinheim, 2007. 
3 For representative recent examples, see: (a) Higuchi, K.; Kawasaki, T. Nat. Prod. Rep. 2007, 24, 843–
868; (b) Mason, J. J.; Bergman, J.; Janosik, T. J. Nat. Prod. 2008, 71, 1447–1450; (c) Chen, Y.; Wei, X.; 
Xie, H.; Deng, H. J. Nat. Prod. 2008, 71, 929–932; (d) Fehe´ r, D.; Barlow, R. S.; Lorenzo, P. S.; 
Hemscheidt, T. K. J. Nat. Prod. 2008, 71, 1970–1972; (e) Wang, Y.; Shang, X.-Y.; Wang, S.-J.; Mo, S.-Y.; 
Li, S.; Yang, Y.-C.; Ye, F.; Shi, J.-G.; He, L. J. Nat. Prod. 2007, 70, 296–299 
4  Hiroaki Iino, Takayuki Usui & Jun-ichi Hanna, Nature Communications, 6, 2015, 6828 
5 For representative recent examples, see: (a) Zhong, C.; He, A.; Guo, R.; Huang, H. Synth. Met. 2008, 158, 
33–37; (b) Atwani, O.; Baristiran, C.; Erden, A.; Sonmez, G. Synth. Met. 2008, 158, 83–89; (c) Ha, Y.; Seo, 
J.-H.; Kim, Y. K. Synth. Met. 2008, 158, 548–552; (d) Blouin, N.; Michaud, A.; Gendron, D.; Wakim, S.; 
Blair, E.; Neagu-Plesu, R.; Belleteˆte, M.; Durocher, G.; Tao, Y.; Leclerc, M. J. Am. Chem. Soc.  2008, 
130, 732–742; (e) Xin, H.; Lim, F. S.; Jenekhe, S. A. J. Am. Chem. Soc.  2008, 130, 5424–5425
6 http://www.pharmacytimes.com/publications/issue/2013/july2013/top-200-drugs-of-2012 
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forming new carbon-carbon and carbon-heteroatom bonds constitute a significant portion 
of organic synthesis.7  For over a century, the synthesis and functionalization of aromatic 






                                                          
7 Steven V. Ley and Andrew W. Thomas, Angew. Chem. Int. Ed. 2003, 42, 5400 – 5449; b) F. Bellina, R. 
Rossi / Tetrahedron 65 2009, 10269–10310. 
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1.2 Strategies to Functionalize Arenes 
1.2.1 Non-metal catalyzed reactions 
A) Electrophilic Aromatic Substitution; SEAr Reaction (EAS) 
Electrophilic aromatic substitution reactions are one of the most extensively studied 
reactions in organic synthesis. Since its discovery in the 19th century, the utilization of this 
chemistry at an industrial level has been ongoing. The two stages of reactions involving π 
and σ complexes are very well-studied8 and contribute to a significant portion of arylation 
reactions (Scheme 1.1). In this reaction, an incoming group is added to the arene ring as 
the electrophile. Depending on the type of group present on the arene ring, the incoming 
electrophile is directed onto different positions of the arene ring. Electron donating groups 
(R, OR, N(H2)/(R2), NHR, OH, etc.) and weak electron withdrawing groups (halogens) 
direct the incoming electrophiles to ortho and para positions; whereas, strong electron 
                                                          
8 a)Arene Chemistry: Reaction Mechanisms and Methods for Aromatic Compounds; Mortier, J., 
Ed.; Wiley: Hoboken, NJ, 2016. b) Ingold, C. K.Structure and Mechanism in Organic Chemistry; Cornell 
University Press: Ithaca, NY, 1969; Chapter 6. c) Carey, F. A.; Sundberg, R. J.Advanced Organic 
Chemistry, Part A: Structure and Mechanisms, 5th ed.; Springer: New York,2007; Chapter 9. d) Olah, G. 
A.Mechanism of Electrophilic Aromatic SubstitutionsAcc. Chem. Res. 1971, 4, 240–248 e) Taylor, 
R.Electrophilic Aromatic Substitution; Wiley: New York, 1990. 
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withdrawing groups ( -C=O, NO2, CN, NR3
+, etc.) direct to meta positions. Several classic 
reactions including nitration, halogenation, sulfonation, and Friedel-Crafts alkylation and 
acylation reactions follow the SEAr mechanism.
1 
 B) Nucleophilic Aromatic Substitution: SNAr Reaction (NAS) 
A complementary approach to EAS towards the arylation of aromatic compounds is the 
SNAr reaction — a well-established and versatile method both for industrial and academic 
processes.9 In this process, an incoming nucleophile replaces a halide from an aromatic 
ring which undergoes through a resonance-stabilized Meisenheimer complex (Scheme 
1.2). Strong electron withdrawing groups (NO2, CN, etc.) are required to stabilize this 
complex, which limits the reactivity only to aromatic moieties containing these groups. 
Additionally, electron withdrawing groups must be located on either ortho or para position 




C) Aryne Reaction 
Contrary to the above mentioned strategies, functionalizing arenes is also accomplished by 
                                                          
9 1. Schlosser, M.; Ruzziconi, R.Synthesis 2010, 2010, 2111–2123 B) Miller, J. Aromatic Nucleophilic 
Substitution; Elsevier: Amsterdam, 1968. C) March, J.; Smith, M. B.March’s Advanced Organic 
Chemistry, Reactions, Mechanism and Structure, 6th ed.; John Wiley & Sons: New York, 2007. D) 
Mąkosza, M. Chem. Soc. Rev. 2010, 39, 2855–2868 e) Terrier, F.Modern Nucleophilic Aromatic 
Substitution; Wiley-VCH: Weinheim, Germany, 2013 
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the generation of aryne intermediates using strong base on a mono or 
dihalogenated/pseudo-halogenated arenes (Scheme 1.3). Thus, the highly reactive aryne 
intermediates generated are used in several different transformations to functionalize 






1.2.2 Metal catalyzed reactions 
Transition metal catalyzed reactions are currently state-of-the-art in the formation of 
aromatic carbon-carbon or carbon-heteroatom bonds.10  These reactions have received 
enormous attention as they have significantly increased the breadth of the scope of 
substrates that participate in arylation reactions.11 This is due to the new mode of reactivity 
                                                          
10 D. Alberico, M. E. Scott, M. Lautens, Chem. Rev. 2007, 107, 174–238; b) I. V. Seregin, V. Gevorgyan, 
Chem. Soc. Rev. 2007, 36, 1173–1193; c) T. Satoh, M. Miura, Chem. Lett. 2007, 36, 200–205; d) R. G. 
Bergman, Nature 2007, 446, 391–393; 
11 Kumada, M. Pure Appl. Chem. 1980, 52, 669–679 b) Stille, J. K. Angew. Chem. Int. Ed. 1986, 
25, 508–523. C) Negishi, E., Baba, S. J. Chem. Soc., Chem. Commun. 1976, 596–597; d) Baba, S., Negishi, 
E. J. Am. Chem. Soc. 1976, 98, 6729–6731. E) Sonogashira, K., Tohda, Y., Hagihara, N. Tetrahedron Lett. 
1975, 4467–4470. F) Miyaura, N., Suzuki, A. Chem. Rev. 1995, 95, 2457–2483. G) Suzuki, A. Pure Appl. 
Chem. 1991, 63, 419–422. 
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of transition metals, which follow a completely different mechanism compared to 
previously described methods (Scheme 1.4). As the reductive elimination step completely 
avoids the formation and stabilization of charged intermediates, such as the Meisenheimer 
complex, limitations to substrate scope are greatly reduced.12  These reactions allowed the 
researcher to attain transformations which were not possible with classic reaction pathways 
and have greatly advanced the field of organic synthesis.  
 






Although transition metal-catalyzed reactions are synthetically useful, challenges still 
remain. For example, residual metal removal from the end product is difficult and 
cumbersome, and the cost of transition metals (especially Pd, Pt) and some additional 
reactions require expensive or proprietary designer ligands.  Metal-free arylation methods 
are emerging to address these issues.13  Medicinal and process chemists are primarily 
                                                          
12 For reviews, see: (a) Hartwig, J. F. in Handbook of Organopalladium Chemistry for Organic Synthesis, 
b) Negishi, E., Ed., Wiley-Interscience, New York, 2002, 1051–1096; (c) Muci, A. R., Buchwald, S. L. 
Top. Curr. Chem. 2002, 219, 131–209. 
13 Anup Bhunia , Santhivardhana Reddy Yetra and Akkattu T. Biju Chem. Soc. Rev., 2012, 41, 3140-3152 
b) Lutz Ackermann, Monica Dell’Acqua, Sabine Fenner, Rubén Vicente, and René Sandmann Org. 
Lett., 2011, 13, 2358–2360 c) Jalalian, N., Petersen, T. B. and Olofsson, B., Chem. Eur. J., 2012, 18, 
14140–14149. 
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interested in mild and economically feasible synthetic methods that ensure 
functionalization of aromatic rings that will tolerate a wide range of functional groups.  
New reaction modules, which enable a metal-free reaction scheme which address these 
challenges and advance organic synthesis, are cost-effective, do not need further 
purification of the end product, and are atomically economical (Figure 1.2). 
 
1.4 Hypervalent Iodine Compounds 
1.4.1 Hypervalent iodine offers a promising metal-free approach 
 Hypervalent iodine compounds (Figure 1.3) have recently attracted significant attention 
as non-toxic, mild, and selective reagents in organic synthesis and as oxidants and 
electrophilic reagents.14  Trivalent hypervalent iodine (III) compounds are named λ3- 
iodanes according to IUPAC nomenclature.15 These salts with an aryl group are more stable 
than the other types of hypervalent iodine compounds and are mostly used in chemical 
transformations; however, pentavalent iodine (V) reagents, specifically Dess-Martin 
periodinane (DMP) and 2-iodoxybenzoic acid (IBX), are often used as oxidizing 
reagents.16 
                                                          
14 a) T. Wirth, Angew. Chem. 2005, 117, 3722; Angew. Chem. Int.Ed. 2005, 44, 3656; b) R. D. Richardson, 
T. Wirth, Angew. Chem. 2006, 118, 4510; Angew. Chem. Int. Ed. 2006, 45, 4402. 
15 Wirth, T., Ed. Hypervalent Iodine Chemistry: Modern Developments in Organic Synthesis. Top. Curr. 
Chem. 2003, 224, 1−248. 
16 Zhdankin, V. V. Organoiodine(V) Reagents in Organic Synthesis. J. Org. Chem. 2011, 76, 1185−1197. 




1.4.2 Diaryliodonium salts: significance and structure15 
Diaryliodonium salts were discovered in 1894 by Hartmann and Meyer and have received 
significant attention in comparison to other hypervalent iodine compounds.17 Despite the 
discovery of these reagents over a century ago, their use as metal-free reagents for various 
reaction platforms continues to evolve.  Diaryliodonium salts are air and moisture stable, 
offer mild reaction conditions, and are synthetically accessible.  Analogous to transition 
                                                          
17 a)Zhdankin, V. V.; Stang, P. J. Chem. Rev. 2008, 108, 5299−5358. b) Merritt, E. A.; Olofsson, B. Angew. 
Chem., Int. Ed. 2009, 48, 9052−9070. c) Yusubov, M. S.; Maskaev, A. V.; Zhdankin, V. V. ARKIVOK, 
2011, 370−409. Ochiai, M. Wirth, T., Ed.; Springer-Verlag: Berlin, 2003; Vol. 224, pp 5−68. d) Zhdankin, 
V. V., John Wiley & Sons: West Sussex, 2014, 145−336. e) Hartmann, C.; Meyer, V. Chem. Ber. 1894, 27, 
426. 
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metals, hypervalent iodine compounds oxidatively facilitate the formation of aryl-






Diaryliodonium salts consist of hypervalent iodine (III) bonded to two aryl groups (ligands) 
occupying the equatorial position and a counter-anion X located in axial positions, giving 
the molecules pseudo-trigonal bipyramidal, or T-shape, geometry (Figure 1.4, left). The 
high electrophilic reactivity of hypervalent iodine compounds arises due to the bonding 
orbitals in λ3- iodanes. These bonding orbitals are engaged by two electrons from the non-
hybridized 5p orbital of iodine and one electron of each ligand L resulting in long, weak, 
and highly polarized hypervalent bond (Figure 1.4, right).12 The counter-anion X plays a 
crucial role in the solubility and reactivity of these salts. The common counter-anions 
employed are OTf, OTs, BF4, Br, Cl, PF6, etc., Salts containing halides as the counter-
anions are usually less soluble in organic solvents compared to other counter-anions. 
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1.4.3 Types of diaryliodonium salts 
Diaryliodonium salts can be categorized into two types, based on the different aryl groups 
present. If the two aryl groups are the same (Ar = Ar), they are referred as symmetrical 
diaryliodonium salts (Figure 1.5, left). If they are different (Ar ≠ Ar), they are called 
unsymmetrical diaryliodonium salts (Figure 1.5, right).  Symmetrical salts compared to 
unsymmetrical salts avoid chemo-selectivity issues that may arise due to sterics and 
electronics;18 however, symmetrical diaryliodonium salts present challenges in the 
synthesis of elaborated/complex symmetrical salts, thus, limiting their utility to only simple 
diaryliodonium salts. Unsymmetrical salts, on the contrary, can offer advantage over 
symmetrical salts where one of the aryl groups (auxiliary) is electronically rich and acts as 
the spectator group. There are several different auxiliary groups synthesized, including 
mesityl (Mes), trimethoxyphenyl (TMP), thienyl etc. These unsymmetrical diaryliodonium 
salts overall transfer the most electron-deficient aryl groups to the nucleophile.  
                                                          
18 N. R. Deprez, M. S. Sanford, Inorg. Chem. 2007, 46, 1924-1935; b) D. Kalyani, N. R. Deprez, L. V. 
Desai, M. S. Sanford, J. Am. Chem. Soc. 2005, 127, 7330-7331; c) R. J. Phipps, M. J. Gaunt, Science 2009, 
323, 1593-1597. d) Lancer, K.M. , Wiegand, G.H, J. Org. Chem. 1976, 41, 3360. 




1.4.4 Synthetic methodologies to access diaryliodonium salts 
Diaryliodonium salts can be conveniently prepared via one pot synthetic route each 
typically with an initial oxidation of aryl iodide and ligand exchange with an arene to yield 







A) From Aryl iodides19
The most common route to synthesize diaryliodonium salts is by initial oxidation of aryl 
iodide to an iodine (III) species followed by subsequent ligand exchange with simple arenes 
or organometallic reagents in acidic or neutral conditions; and the anion is usually 
generated from acid used (Scheme 1.5). The commonly employed acids are 
trifluoromethane sulfonic acid (TfOH) and p-toluenesulfonic acid (TsOH). Many inorganic 
acids are also employed, but the use of organic acids is advantageous due to their solubility 
in organic solvents and their easy isolation as triflate or tosylate salts without an anion 
exchange step. Both symmetrical and unsymmetrical diaryliodonium salts can prepared 
conveniently with this route.  
B) From Arylboronic acids
This method was first developed by Ochiai et al.20 In this method, high yielding 
diaryliodonium salts were synthesized using hypervalent diacetoxyiodoarenes and alkali 
metal tetraarylborates. Later, the use of arylboronic acids was developed in the presence of 
19 a) Kryska, A.; Skulski, L. Molecules 2001, 6, 875−880. b) Bielawski, M.; Olofsson, B. Chem. Commun. 
2007, 2521−2523. c) Bielawski, M.; Zhu, M.; Olofsson, B. Adv. Synth. Catal. 2007, 349, 2610−2618. d) 
Zhu, M.; Jalalian, N.; Olofsson, B. Synlett 2008, 2008, 592−596. e) Bielawski, M.; Aili, D.; Olofsson, B. J. 
Org. Chem. 2008, 73, 4602−4607. Dohi, T.; Yamaoka, N.; Itani, I.; Kita, Y. Aust. J. Chem. 2013, 64, 
529−535. f) Qin, L.; Hu, B.; Neumann, K. D.; Linstad, E. J.; McCauley, K.; Veness, J.; Kempinger, J. J.; 
DiMagno, S. G. Eur. J. Org. Chem. 2015, 2015, 5919−5924. 
20 M. Ochiai, M. Toyonari, T. Sueda, Y. Kitagawa, Tetrahedron Lett. 1996, 37, 8421. 
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a Lewis acid e.g., boron trifluoride (Scheme 1.6).21 The tetrafluoroborate salts are easily 
isolated after the anion exchange step. Our group has isolated bromide salts using saturated 
KBr in the anion exchange reaction instead of tetrafluroborates, which were more bench 





C) From Simple Arenes 
Synthesis of diaryliodonium salts can also be accomplished using only simple arenes and 
molecular iodine or hypervalent diacetoxyiodoarenes. Using molecular iodine follows a 
similar oxidation approach as used in method A but instead, utilized simple arene and I2; 
however, this method can only be applied to make symmetrical salts and is limited to a few 
groups, such as benzene, tert-butylbenzene and halobenzene (Scheme 1.7).23    
Another method, which involves the modification of Ochiai’s, is the use of 
diacetoxyiodoarene with simple arene instead of a boronic acid, and subsequent addition 
of saturated KBr to yield unsymmetrical diaryliodonium bromide salts.23 
 
                                                          
21 M. Ochiai, M. Toyonari, T. Nagaoka, D.-W. Chen, M. Kida, Tetrahedron Lett. 1997, 38, 6709. 
22 Sundalam, S. K.; Stuart, D. R. J. Org. Chem. 2015, 80, 6456−6466. 
23 M. D. Hossain,Y. Ikegami, T. Kitamura, J. Org. Chem. 2006, 71, 9903.b) M. D. Hossain, T. Kitamura, 
Bull. Chem. Soc. Jpn. 2007, 80, 2213. 




1.4.5 General reactions of diaryliodonium salts 
Diaryliodonium salts have shown several applications in organic synthesis.12 In 1953, 
Beringer established the reactivity of diaryliodonium salts primarily with 
diphenyliodonium bromide.24  This reagent has been employed in arylation of carbon 
nucleophiles such as enolates,25 alkyl Grignard reagents26 and a wide range of heteroatom 
nucleophiles such as nitrogen,27 oxygen,28 and fluorine,29 under metal-free conditions. 
However, these reactions are mostly explored using symmetrical diaryliodonium salts; 
additionally to diphenyliodonium salts, show poor atom economy. Hence, unsymmetrical 
diaryliodonium salts can be more efficient in accessing complex aryl groups and also avoid 
                                                          
24 Beringer, F. M.; Brierley, A.; Drexler, M.; Gindler, E. M.; Lumpkin, C. C. J. Am. Chem. Soc.  1953, 75, 
2708−2712. 
25 J. H. Ryan, P. J. Stang, Tetrahedron Lett. 1997, 38, 5061. 
26 C. H. Oh, J. S. Kim, H. H. Jung, J. Org. Chem. 1999, 64, 1338. 
27 M. A. Carroll, R. A. Wood, Tetrahedron 2007, 63, 11349. 
28 J. R. Crowder, E. E. Glover, M. F. Grundon, H. X. Kaempfen, J. Chem. Soc. 1963, 4578. b) Lindstedt, 
E.; Ghosh, R.; Olofsson, B. Org. Lett. 2013, 15, 6070−6073. c) Ghosh, R.; Lindstedt, E.; Jalalian, N.; 
Olofsson, B. ChemistryOpen, 2014, 3, 54−57. 
29 a) M. A. Carroll, J. Nairne, J. L.Woodcraft, J. Labelled Compd.Radiopharm. 2007, 50, 452; b) S. Martin-
Santamaria, M. A.Carroll, C. M. Carroll, C. D. Carter, H. S. Rzepa, D. A. Widdowson, V.W. Pike, Chem. 
Commun. 2000, 649; c) M. A.Carroll, J. Nairne, G. Smith, D. A. Widdowson, J. Fluorine Chem. 2007, 128, 
127. 
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waste of aryl iodide byproduct as they bear a cheap (reusable) auxiliary group. 
 
1.4.6 Unsymmetrical salts are advantageous over symmetrical salts 
General reactions of diaryliodonium salts with a nucleophile provide the desired coupling 
product and aryl iodide side product (Scheme 1.8).  In symmetrical diaryliodonium salts, 
an equal ratio of aryl iodide side product is generated along with the desired ligand coupling 
product. In simple symmetrical diaryliodonium salts, this may not be an issue, but in 
complex symmetrical diaryliodonium salts, a significant portion of the starting material is 
wasted (Scheme 1.8.1).  Unsymmetrical diaryliodonium salts contain an auxiliary (or 
spectator group) as the other aryl group.  The stoichiometric quantity of this generated 
auxiliary iodide is inexpensive and can be reused to synthesize diaryliodonium salts 
(Scheme 1.8.2). 21 These salts are more atom economical compared to symmetrical 
diaryliodonium salts.  A current challenge is identifying competent auxiliary groups and 
controlling aryl transfer selectivity. 
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We have focused our attention on using unsymmetrical diaryliodonium salts as they are a 
critical area of future study in metal-free arene functionalization reactions. These salts offer 
more atom economic strategies to arylation compared to symmetrical salts, which is 
important for the transfer of more elaborate “real-world” aryl groups. Additionally, the 
synthesis of complex and highly functionalized symmetrical diaryliodonium salts can be 
very challenging as opposed to the synthesis of unsymmetrical diaryliodonium salts. Even 
if one succeeds to make elaborate symmetrical diaryliodonium salts, the loss of an 
equivalent group as an iodide is not very practical compared to losing an inexpensive 
dummy/auxiliary group (such as Mes, TMP etc.) in the case of unsymmetrical 
diaryliodonium salts. 
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1.4.7 Reactivity of diaryliodonium salts via nucleophilic addition 
The general mechanism of the nucleophilic addition reaction of unsymmetrical 
diaryliodonium salts is shown in Scheme 1.9.  In this, upon the addition of the nucleophile, 
the electrophilic hypervalent iodine center is attacked by the nucleophile replacing the 
counter-anion X, and forming a 3-centered complex. This complex is in equilibrium with 
its geometric isomer formed via Berry pseudorotation-like process, the top structure being 
the major lower energy species. This is due to the presence of the electron withdrawing 
group present on the aryl group, which is axial to the nucleophile making the aryl group 
more electron deficient. The interaction of the nucleophile with the ipso-carbon of the 
electron withdrawing aryl group causes the formation of the transition state which will 
ultimately undergo ligand coupling to yield the desired nucleophile coupling product and 

























         Chapter 2: Part I 
Base Mediated Synthesis of Alkyl-Aryl Ethers from the Reaction of Aliphatic 




This work demonstrates metal-free synthesis of alkyl-aryl ethers by using unsymmetrical 
diaryliodonium salts and aliphatic alcohols through a base-mediated coupling reaction 
(Scheme 2.1).  This method shows broad substrate scope with respect to both of the 
coupling partners to produce industrially useful alkyl-aryl ethers in moderate to excellent 
yields.  The reaction is operationally simple, proceeds at low temperature, and is atom-
economical. Sustainability and synthetic utility of this reaction is demonstrated by the use 
of unsymmetrical aryl(mesityl)iodonium salts as the arylating agents. 
 
 
                                                          
30 S. K. Sundalam, D. R. Stuart, J. Org. Chem. 2015, 80, 6456 – 6466. 
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2.1 Significance of Alky-Aryl Ethers 
Alkyl-aryl ethers are important building blocks in pharmaceuticals, agrochemicals, and 
high-tech devices such as liquid crystal displays (Figure 2.1).31 Three of the five top-selling 
drugs in 2012 contained alkyl-aryl ether linkages in their structures.32 Among all of the 
heteroatoms, nitrogen constitutes the most abundant heteroatom, present in more than half 
of the drugs known so far.  Oxygen, although not as abundant as nitrogen, is the next most 
abundant heteroatom in industrially important molecules.33 Aside from pharmaceuticals, a 
myriad of naturally occurring compounds contain alkyl-aryl ether linkages, for example, 
alkaloids and lignins.31 Many of these natural compounds have a vital role in biological 
processes.  
 
                                                          
31 a) J. J. Li, D. S. Johnson, D. R. Sliskovic, B. D. Roth, Contemporary Drug Synthesis, Wiley, 2004; (b) J. 
J. Li and D. S. Johnson, Modern Drug Synthesis, Wiley, 2010; (c) H.-G. Elias, An Introduction to Polymer 
Science, Wiley-VCH, 1997; (d) F.Muller, Agrochemicals, Wiley-VCH, 1999. e) Puterova, Zita et al, 
Tetrahedron, 2012, 68, 8172-8180  
32 http://www.pharmacytimes.com/publications/issue/2013/July2013/Top-200-Drugs-of-2012 
33 Carey, J.S., Laffan, D., Thomson, C., Williams, M.T. Org. Biomol. Chem. 2006, 4, 2337 – 2347. 
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Given the abundance of the alkyl-aryl ether motif in man-made and naturally 
occurring molecules, the development of synthetic methods to form these bonds is of 
crucial importance.  Despite their prevalence, the direct synthesis of these linkages by Caryl-
O bond formation remains relatively underdeveloped.  Although, various methodologies 
have recently emerged, novel synthetic protocols are still of interest for this particular 
transformation. 
 
2.2 Literature Precedent for the Synthesis of Alkyl-Aryl Ethers 
The retro synthesis shown in Scheme 2.2 describes two conceptual paths that may be taken 
towards the formation of the alkyl-aryl ether linkage. The two paths differ by the nature of 
the nucleophiles and electrophiles used in the forward synthesis. I have specifically focused 




2.2.1 Type I: Formation of Calkyl-Oaryl ether bond 
In this type of bond formation reaction, phenolic nucleophiles and alkyl electrophiles react 
to form alkyl-aryl ether bonds.  Traditional syntheses of alkyl-aryl ethers using this 
approach are the classic Williamson ether synthesis,34 the Mitsunobu reaction,35 and the 
                                                          
34 Juršić, B. Tetrahedron 1988, 44, 6677−6680. 
35 Gentles, R. G.; Wodka, D.; Park, D. C.; Vasudevan, A. J. Comb. Chem. 2002, 4, 442−456. 
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condensation of phenols and alcohols using Bronsted or Lewis acids.36 In the case of the 
Williamson ether synthesis, an example of phenol alkylation proceeds by the formation of 
a phenolic nucleophile in the presence of base, followed by SN2 attack on the electrophilic 
alkylating agents, such as alkyl halides. This reaction suffers from the drawbacks of using 
toxic alkylating agents and the substrate scope is limited.  The other reaction of this type is 
the Mitsunobu reaction, which replaces the use of toxic alkylation agents by alcohols. In 
this reaction, a phenolic nucleophile is formed, followed by nucleophilic substitution on 
the alcohol. However, this reaction suffers from the drawbacks of using toxic phosphine 
reagents and explosive reagents such as DEAD. The substrate scope of these reactions is 
limited due to all the aforementioned drawbacks. 
 
2.2.2 Type II: Formation of Caryl -Oalkyl ether bond 
In the second scenario, the aromatic group is the electrophile and is attacked by an alkoxide 
nucleophile. A good example of this type of reaction is the traditional nucleophilic aromatic 
substitution (SNAr) of aryl halide with metal alkoxide,
37 (Scheme 2.3, top) which is a direct 
method for the formation of alkyl-aryl ethers. However, the aryl substrate scope is limited 
due to the formation of an anionic intermediate Meisenheimer complex, which is only 
stabilized by strong electron withdrawing substituents (NO2, CN, etc.).   
                                                          
36 Simons, J. H.; Passino, H. J. J. Am. Chem. Soc. 1940, 62, 1624 
37 March, J. Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed.; John Wiley & 
Sons: New York, 1992; 501−569, 641−676. 




Another method to form this type of alkyl-aryl ether bond is via transition metal-catalysis 
(Scheme 2.3, bottom). Transition metal-catalyzed coupling chemistry is currently the 
“state-of-the-art” and a very powerful protocol for the carbon-carbon and carbon-
heteroatom bond formation.  Despite the success that has been achieved with this type of 
reaction, there is still further improvement needed considering sustainability and 
environmental issues. One of the drawbacks of the metal-catalyzed reaction is the use of 
expensive and designer catalyst-ligand combinations and heavy metal toxicity.  The 
common aryl substrates used for this chemistry are aryl halides or pseudo-halides, which 
are replaced by an oxygen nucleophile during the reaction. Palladium, copper, and nickel 
are the most commonly used metals in these metal-catalyzed coupling reactions. A 
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common challenge for metal-catalyzed reactions is the competing β-hydride elimination 
from the palladium alkoxide intermediate and reductive elimination of the C-H bond, 
which results in an oxidized alcohol and a reduced arene, ultimately lowering the yield of 
the desired product.  
Consequently, there is a need for a new approach that is operationally simple and 
avoids the limitations of the traditional approaches and eliminates the use of transition 
metals to avoid further purification of the end product. A method which will provide a 
broad substrate scope both with reference to the aryl group and alcohols group would 
advance this particular field of forming alkyl-aryl ether bonds.  
 
2.3 Literature Precedent from Diaryliodonium Salts 
Using unsymmetrical diaryliodonium salts for the synthesis of alkyl-aryl ethers was first 
discovered by Beringer in 1953 by refluxing diaryliodonium salt and sodium methoxide in 
methanol (Scheme 2.4, 1st reaction). In this work, two diaryliodonium salts were presented, 
and it was demonstrated that the nucleophile favored the attack on the electron deficient 
aryl group when unsymmetrical diaryliodonium salts were used.38 After 20 years, McEwen 
and co-workers applied this approach to ethoxide and 2-propoxide, which were generated 
from their respective alcohols.  They also identified a radical pathway that formed alcohol 
oxidation products, which they mitigated by adding a radical trap (DPE) and using non 
                                                          
38 Beringer, F. M.; Brierley, A.; Drexler, M.; Gindler, E. M.; Lumpkin, C. C. J. Am. Chem. Soc.  1953, 75, 
2708−2712. 
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polar solvents (Scheme 2.4, second reaction).39 In 2006, Fujita and Okuyama demonstrated 
that solvolysis of diaryliodonium salts takes place in alcohols at higher temperatures 
(130oC) even in the absence of a base to generate alkyl-aryl ethers (Scheme 2.4, third 
reaction).40 Olofsson’s group, in 2013, provided a milder and synthetically useful reaction 
to form alkyl-aryl ethers.  Alcohols, including allylic, benzylic, and also phenolic groups 
were coupled to diaryliodonium salts in aqueous medium using hydroxide base.41  In 2014, 
a modified method was developed from the same group with aliphatic alcohol coupling 
partners as they were not tolerated in the previous work (Scheme 2.4, fourth reaction).42  In 
the latter work, sodium t-butoxide was used to deprotonate the aliphatic alcohol to form an 
alkoxide in presence of toluene as the solvent. At last in 2016 (Scheme 2.4, 5th reaction), 
after our work was published, Oloffsson’s group showed a similar reaction using tertiary 
alcohols on sterically hindered diaryliodonium salts where the ortho positions were 
blocked or replaced by other groups instead of hydrogens.  In all cases, addition of the 
nucleophile to the most electron-deficient aryl group is observed, which is consistent with 
other reactions of unsymmetrical diaryliodonium salts. 
 
 
                                                          
39 McEwen, W. E.; Lubinkowski, J. J.; Knapczyk, J. W. Tetrahedron Lett. 1972, 32, 3301−3304. b) 
Lubinkowski, J. J.; Knapczyk, J. W.; Calderon, J. L.; Petit, L. R.; McEwen, W. E. J. Org. Chem. 1975, 40, 
3010−3015. 
40 Fujita, M.; Mishima, E.; Okuyama, T. J. Phys. Org. Chem. 2007, 20, 241−244. 
41 Lindstedt, E.; Ghosh, R.; Olofsson, B. Org. Lett. 2013, 15, 6070−6073. 
42 Ghosh, R.; Lindstedt, E.; Jalalian, N.; Olofsson, B ChemistryOpen, 2014, 3, 54−57. 
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2.4 Reaction Discovery 
The initial discovery of alkyl-aryl ether bond formation in our lab was observed when an 
unsymmetrical diaryliodonium salt was reacted with CF3B(OMe)3 in an attempt to arylate 
the trifluoromethyl group in the presence of copper iodide and bipyridyl ligand. To our 
surprise, instead of a Caryl-CF3 bond, we witnessed the formation of a Caryl-O ether bond. 
Although it was not the product we desired to form, we were intrigued by this 
transformation. We sought to develop this transformation because of the prevalence of 
alkyl-aryl ether linkages mentioned in the introduction section of this chapter.  
With a few modifications to the reaction conditions, the preliminary results were 
determined to be profitable using with both symmetrical and unsymmetrical 
diaryliodonium salts to form alkyl-aryl ethers; in these conditionsan alkoxide which was 
generated insitu using a strong base.  On the basis of these promising preliminary results, 
we sought to further develop the base-mediated O-arylation chemistry to be extensible 
towards a range of aryl electrophiles and also to enable a broad scope with respect to the 
choice of alcohols.  
 
2.5 Reaction Development 
To optimize the reaction, 3-bromophenyl derived iodonium salt was selected since the 3-
bromo group is only mildly electron withdrawing.  2-butanol was chosen as the alcohol 
group, since the secondary alcohol is challenging in the metal-catalyzed reactions due to 
 28   
 
 
the formation of alcohol oxidation 
product. This combination successfully 
established an overall advance in this 
transformation.  After running a series of 
reactions, optimized conditions provided a 
yield of 81% and complete consumption 
of starting material was observed in the 
crude 1H NMR spectrum vs 1,3,5-
trimethoxybenze as internal standard 
(Table 2.1, entry 1). While optimizing the 
reaction parameters, interesting 
observations were made that merit 
discussion.  First, to eliminate the 
possibility of SNAr reaction, the precursor 
iodide, 3-bromoiodobenze, was used 
instead of diaryliodonium salt (Table 2.1, 
entry 2).  Unsurprisingly, there was no 
reaction, suggesting that the reaction is not 
going through SNAr.  A series of auxiliary 
groups were tested including phenyl (1-
Ph), 2-thienyl (1-Th), trimethoxybenzene 
(1-TMB), and mesityl (Mes) auxiliary, which provided the highest yield (see entry 3-5). 
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This auxiliary not only gave the highest yields but also enabled easy separation of the 
product by column chromatography.  
Additionally, installing mesityl auxiliary presented an advantage over the other 
auxiliary groups due to its commercial availability as simple arene mesitylene, 
iodomesitylene, and iodomesitylene diacetate. This mes auxiliary group enabled the 
corresponding unsymmetrical diaryliodonium salts synthesis with the use of simple aryl 
iodides, simple arenes, and arylboronic acids (Section 1.4). Counter-anions tetrafluroborate 
(BF4) and triflate (OTf) had little to no effect on the yield (Table 2.1, entries 6 and 7). 
Therefore, bromide (Br) was chosen as the counter ion because it is relatively cheaper than 
the other two and are easy to triturate, and we observed that they are more bench stable 
compared to OTf and BF4.  Other inorganic bases were tested but sodium hydride provided 
the highest yields (Table 2.1, see entries 8-10).  Interestingly, amine bases showed little to 
no reactivity.  Two equivalents of alcohol and 1.5 equivalents of sodium hydride, with 
respect to iodonium salt, provided the best yield (see entry 1 vs 11 and 12 respecively).  
The solvent had a significant effect on the yield of the reaction.  Toluene was the next best 
solvent (72%) to TBME, 1,2-dichloroethane gave low yield (29%), and a polar protic 
solvent (DMF) provided no detectible product in the crude 1H NMR spectrum (Table 2.1, 
see entries 13-15). Lower and higher temperatures yielded less product vs 50 oC (Table 
2.1, see entries 16 and 17).  Finally, the concentration of the reaction was tested, and 0.2 
M using tert-butyl methyl ether (TBME) solvent gave the best yield; the reaction was 
complete in one hour. 
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2.6 Scope of the Reaction 
To demonstrate the breadth of scope of this transformation, several different 
unsymmetrical diaryliodonium salts and various alcohols were employed, which showed 
varying impacts of steric and electronics in this reaction. 
2.6.1 Aryl group substrate scope  
The reaction scope with respect to the selection of aryl group showed that all possible 
substitutions (i.e., ortho, meta, and para) are tolerated.  A broad range of functional groups 
are acceptable, such as halides, nitrile, carbonyl, trifluoromethoxy, nitro, trifluoromethyl, 
methoxy, and methyl on the aryl electrophile. In SNAr chemistry, only ortho and para 
substituted aryl groups that are highly electron deficient are tolerated, which distinguishes 
our work since various more substitution patterns are tolerated as are less electron deficient 
aryl groups showed reactivity.  To the best of our knowledge, no prior diaryliodonium salt 
chemistry had shown that poly-substituted aryl groups react with aliphatic alcohol to 
provide good yields. These multi-substituted aryl groups will facilitate further 
functionalization of the product. Electron rich diaryliodonium salts suffered in this 
reaction. However, in these cases, where electron rich groups were involved, the presence 
of an additional electron deficient functional group on the ring was shown to overcome the 
challenge to produce good reactivity.  In total, 13 different aryl groups were shown to be 
reactive to provide moderate to excellent yields (Table 2.2).  
 
 





2.6.2 Alcohol group substrate scope 
Primary, secondary, and tertiary aliphatic alcohols were reacted with unsymmetrical 
diaryliodonium salts to form alkyl-aryl ethers in moderate to good yields (Table 2.3).  In 
addition, benzylic, allylic, and phenolic alcohols were well tolerated in the reaction.  In the 
case of the benzyl alcohol derived product, only 3% oxidation product (benzaldehyde) was 
observed in the crude 1H NMR spectrum. In comparison to the metal-catalyzed and other 
reactions, oxidation product formation is significantly suppressed representing an 
advantage of this reaction. Thus, a variety of complex aromatic groups bearing alcohols 
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proceeded in this reaction with ease. This scope also shows the compatibility of various 
fluorinated reagents which are desirable in pharmaceuticals and agrochemicals. Fluoride is 
usually a leaving group in SNAr reaction. Heteroatom containing alcohols such as 
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2.7 Sustainability of the Reaction 
To demonstrate the sustainability of this reaction using unsymmetrical diaryliodonium 
salts, 3-nitrophenyl(mesityl)bromide was prepared by a one-pot method using 3-
iodonitrobenzene and mesitylene (Scheme 2.5, top).  Further reaction of the unsymmetrical 
diaryliodonium salt under our standard conditions yielded alkyl-aryl ether product and 
mesityl iodide as the byproduct in high yield.  The formed mesityl iodide gains a 100 fold 
increase in value ($1.07/mmol) vs. its precursor, mesitylene ($0.01/mmol).  Mesityl iodide 
can be readily converted to hypervalent diacetoxymesityliodide, which can be used as the 
starting material in a complementary synthesis to form unsymmetrical diaryliodonium salt 
using arylboronic acids. (Scheme 2.5, bottom).  Recovery and reuse of the mesityl group 
highlights that the reaction is not only metal-free but also shows that the byproduct can be 
used for further transformations in a sustainable manner.  
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2.8 Formal synthesis of Pioglitazone  
To further emphasize the efficacy of this protocol, the active pharmaceutical ingredient 
(API) of the antidiabetic drug Actos was synthesized. The formal synthesis of pioglitazone 
was achieved in two steps from commercial materials (Scheme 2.6). Step one was the 
synthesis of diaryliodonium salt from the 4-iodobenzaldehyde and followed by the 
coupling reaction with the alcohol. Further, the isolated aldehyde product is converted to 
Actos in two steps.43  This synthesis demonstrates that an aldehyde and pyridine functional 





                                                          
43 Bhanja, C.; Jena, S. J. Chem. Pharm. Res. 2012, 9, 4323−4333.   





         
             Chapter 2: Part II 
Base-Mediated O-Arylation of Electron Rich Unsymmetrical Diaryliodonium Salts 
with Aliphatic Alcohols 
A limitation of the previous work was that it does not proceed with unsymmetrical 
diaryliodonium salts containing electron rich aryl groups, leading to poor yields. We have 
observed decomposition of the electron rich diaryliodonium salts under these conditions. 
After discovering that the unsymmetrical diaryliodonium salts could potentially proceeds 
through the aryne pathway in the presence of strong bases, we suspected that the poor 
reactivity could be due to the competing C-H deprotonation of the salts. Overcoming this 
limitation would result in a method that works with all types of unsymmetrical 
diaryliodonium salts and alcohols and will represent an advancement in the overall utility 
of this transformation.  
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2.9 Proposed Reaction Mechanisms Occurring in Presence of a Strong Base with 
Unsymmetrical Diaryliodonium Salts 
 
2.10 Reaction Development 
Preliminary experiments to suppress the formation of arynes and to favor the ipso 
substitution was very challenging using electron rich unsymmetrical diaryliodonium salts. 
We have witnessed that in electron poor unsymmetrical diaryliodonium salts ipso 
substitution overrides C-H deprotonation. So we suspected that this inherent reactivity 
could be related to the electronics of the aryl group which could be indirectly affecting the 
acidity of the ortho proton and thus resulting in competing pathways for electron rich salts.  
In our aryne methodology, we have demonstrated that using sterically bulky bases selective 
C-H deprotonation can be achieved even with electron rich unsymmetrical diaryliodonium 
salts (Chapter 3). After a series of preliminary experiments with the electron rich 
unsymmetrical salt 4-tolyl(TMP)bromide and n-butanol, it was determined that the 
auxiliary group has the most significant effect in determining the mechanism of the 
reaction. 
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2.11 Auxiliary Screen 
The mesityl group which was the best auxiliary group in both of the previous projects was 
selected to learn about this reaction. An electron rich unsymmetrical diaryliodonium salt 
4-biphenyl(mesityl)iodonium salt was chosen as the optimal substrate and n-butanol as the 
alcohol.  First, to assess and quantify the generation of aryne, furan was added to the 
reaction an aryne trap after the deprotonation step.  The reaction resulted in a low yield of 
23% ipso substituted product (25% without adding aryne trap) and 5% of aryne cyclo 
adduct (Table 2.4, entry 1). It was unclear if the reaction was undergoing decomposition 
or if there is a selectivity issue due to the similarity in the electronics of both the aryl groups 
of the salt.  
 So, more electron rich auxiliaries, such as anisole and thienyl, were synthesized and 
subjected to the reaction conditions. The thienyl group resulted in 33% yield, whereas the 
anisole auxiliary resulted in 52% yield (Table 2.4, entries 2 and 3). It was indicated at this 
point that increasing the electronics of the auxiliary has a positive effect on the percent 
yield. Therefore, a much more electronically rich trimethoxyphenyl group (TMP) was 
installed as the auxiliary group and was tested in the reaction. There was a significant 
increase in the percent yield of the ipso substituted product (~80%). After a little further 
optimization, we attained a yield of 92% (82% isolated) (Table 2.4).   
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Our groups have published an efficient one-pot method to synthesize 
aryl(TMP)iodonium salts using aryl iodides44 which were cumbersome to prepare using 
previously developed methods.   
 
2.12 Parameters Affecting the Reaction Yield 
This reaction is very robust. Synthetically useful yields were obtained after varying 
multiple parameters. There was no parameters except the auxiliary that resulting in 
complete decomposition or low yield of the product. 
 To start off, counter-anions Br, OTf, BF4 and TFA in place of OTs had little to no 
effect on the percent yield (Table 2.4, entries 4-7). OTs was the best yielding counter-anion, 
thus the synthesis route developed by our group yields iodonium tosylate and does not 
require further steps to convert the counter anions. TFA was the next best counter-anion 
(88%). It is important to note that some electron rich diaryliodonium salts were made by a 
modified method where TFA was used as the acid instead of TsOH.45    
Bulky bases such as NaOt-Bu and LiHMDS (Table 2.4, entries 8-9) provided synthetically 
useful yields. However it was interesting to see that weak inorganic base Cs2CO3 performed 
exceptionally well in this setup to furnish a yield of 82% (Table 2.4, entry 10).  Solvent 
screening revealed that several types of solvents could be employed in this reaction and 
achieve synthetically useful yields; however, toluene gave the best yield (Table 2.4, entries 
                                                          
44 T. L. Seidl, S. K. Sundalam, B. McCullough, D. R. Stuart, J. Org. Chem. 2016, 81, 1998 – 2009 
45 V. Carreras, A. H. Sandtorv, and D. R. Stuart J. Org. Chem., 2017, 82 1279–1284 
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11-14). Temperature (Table 2.4, entries 
15-16) had an insignificant effect towards 
the reaction, room temperature furnished a 
lower yield than the optimal and high 
temperature was very close to the standard 
yield. Lastly, furan was added as an aryne 
trap to infer how much aryne was forming 
in the reaction. Surprisingly, the yield of 
the reaction was substantially lower 
compared to without addition of aryne trap 
and there was only 4% of the aryne adduct 
formed. This could be due to the 
competition of two pathways occurring at 
the same time leading to a lower yield of 
the products. With optimal conditions at 
our disposal, we continued to the next step 
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2.14 Scope of Electron Rich Unsymmetrical Diaryliodonium Salts 
Several different electron rich unsymmetrical diaryliodonium salts were tested and have 
been successfully shown to be reactive in the coupling reaction with n-butanol to give 
alkyl-aryl ethers in moderate to good yields (Table 2.5). 4-biphenyl as well as 2-
biphenyl(TMP) iodonium salts furnished good yields of 81% and 71%, respectively.  2-
napthyl and 3-napthyl groups both gave 70% yields; however, very minute amounts of 
regioisomers were observed in the latter (20:1:1). Bulky electron rich substrates, such as 
9,9-dimethyl-9H-fluoren-2-yl and diphenyl ether, provided synthetically useful yields of 
85% and 55% respectively. In both cases, regioisomer mixtures of 6:1 and 10:1 were 
observed.  Other electron rich aryl groups including ortho, meta and, para tolyl and meta 
anisyl iodonium salts were shown to be reactive with moderate to good yields alkyl-aryl 












2.15 Scope of Alcohols 
Alcohol scope was investigated, using the unsymmetrical diaryliodonium 4-
biphenyl(TMP)iodonium tosylate, to show compatibility with a wide variety of alcohols 
(Table 2.6). Primary and secondary aliphatic alcohols were well-tolerated producing good 
yields ranging 61% to 89%.  Interestingly, sterically hindered menthol produced similar 
yield (61%) compared to non-hindered cyclohexanol (61%). The fluorinated alcohol, 2,2,2-
trifluroethanol also furnished excellent yield (86%). Additionally, alcohols bearing 
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aromatic groups, such as thiophene and pyridine, were well-received. Finally halogenated 









In conclusion, a mild and convenient method to synthesize industrially crucial molecules 
containing alkyl-aryl ether bonds was developed. A broad range of unsymmetrical 
diaryliodonium salts were coupled with a range of aliphatic alcohols including primary, 
secondary, and tertiary; moderate to excellent yields were achieved in all cases.  
Additionally, allylic, phenolic, and aromatic alcohols were also shown to provide good 
yields under this protocol.  To highlight this method, sustainability of the reaction was 
demonstrated using unsymmetrical aryl(mesityl)iodonium salt by recovery and reuse of the 
auxiliary group. Finally, formal synthesis of Pioglitazone (API of Actos) was shown, which 
demonstrates that this chemistry can be applied to pharmaceuticals industries with ease. A 
limitation of poor reactivity of electron rich unsymmetrical diaryliodonium salts was 
overcome by modifying the reaction and using 2,4,6-trimethoxyphenyl (TMP) as the 
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   Chapter 3 
Discovery and Development of Arylation Reactions Through “Arynes” Generated 
from Unsymmetrical Aryl(mesityl)iodonium Salts46 
3.1 Importance of Arynes as the Intermediates in Organic Synthesis. 
Arynes are highly reactive intermediates, which offer rapid functionalization of aromatic 
rings by forming multiple carbon-carbon and carbon-heteroatom bonds.  The high 
reactivity of arynes is due to the presence of a strained triple bond within a 6-membered 
ring system, resulting in distorted bond angles of the alkyne.  Classically, arynes are 
generated by ortho deprotonation of an aromatic ring with a halide leaving group.  In the 
early stages after the discovery of arynes, their synthetic utility was limited due to the harsh 
conditions required to generate these intermediates. However, milder reaction conditions 
have been developed over time and have led to their use in diverse reaction schemes, 




                                                          
46 Sundalam, S. K.; Nilova, A.; Seidl, T. L.; Stuart, D. R. Angew. Chem. Int. Ed. 2016, 55, 8431 - 8434 
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3.2 Structure and Regio-selectivity of Arynes. 
The triple bond is highly strained within the ring system and therefore there is a substantial 
deviation from the preferred alkyne bond angle of 180º (Figure 3.1, left). This deviation 
results in a low energy LUMO and leads to rapid reactions with nucleophiles.  This highly 
strained intermediate is polarized by electron donating and withdrawing effects from the 
neighboring groups. For example, the ortho group next to the triple bond exercises more 
influence than one situated on the meta position. 
 
 
It is noteworthy that the reactive π-orbitals are situated in the plane of the ring and 
not in the π-orbitals of the aromatic system, which makes them insusceptible to the 
resonance effects of the substituents on the ring.  However, the polarization occurs due to 
inductive effects via σ-bonds. Hence heteroatoms bearing lone pairs such as oxygen and 
nitrogen behave as electron withdrawing groups due to inductive effects based on 
electronegativity rather than resonance effects (Figure 3.1, right). Interestingly, the 
experiments done by Biehl and coworkers in 1969 revealed that the inductively donating 
and withdrawing groups make benzyne more reactive than the unsubstituted molecule.47 
                                                          
47 Biehl, E. R.; Nieh, E.; Hsu, K. C. J. Org. Chem. 1969, 34, 3595–3599. 
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3.3 Initial Discovery of Arynes 
In 1902, Stoermer and Kahlert48 observed the formation of 2-ethoxybenzofuran as product 
of the reaction of 3-bromobenzofuran with KOH in the presence of ethanol (Scheme 3.1). 
They were not able to explain the reason for this type of reactivity at the time, however an 
aryne intermediate mechanism was proposed later to explain the uncommon 




The benzyne hypothesis was made by Wittig in 1940 and 194250 based on the 
reaction of pheyllithium and flourobenzene and work up with water or benzophenone. In 
the former, biphenyl was isolated; in the latter, 2-biphenyldiphenylcarbinol was observed 
(Scheme 3.2). This led to the assumption that nucleophilic attack on the electrophile in the 
final step (water or benzophenone) via lithiated biphenyl yielded the observed products.  
Although Wittig didn’t propose the shape of the cyclic alkyne, due to the overpowering 
ring strain, he proposed that regio-specific reactions can occur through a zwitterionic 
species. Later on, his studies were proven incorrect, but his contributions significantly 
broadened the knowledge of the subject and led to the discovery of benzyne. 
                                                          
48 R. Stoermer, B. Khalert, Ber. Dtsch. Chem. Ges 1902, 35. 
49 W. E. Bachmann, H. T. Clarke, J. Am. Chem. Soc. 1927, 49, 2089. 
50 Wittig, G.; Pieper, G.; Fuhrmann, G. Ber. Dtsch. Chem. Ges. 1940, 73, 1193–1197. (b) Wittig, G.; 
Fuhrmann, G. Ber. Dtsch. Chem. Ges. 1940, 73, 1197–1218. (c) Wittig, G. Naturwiss. 1942, 30, 696–703. 




Several mechanistic proposals were made in the mid 1940’s majorly concentrated on the 
amination of aryl halides to form anilines.51 SNAr displacement was the commonly 
accepted pathway at the time,52 however, it could not explain the rearrangements that were 
taking place nor the regioisomers being formed. 
Roberts and co-workers in 1953 published an alternative mechanism to describe 
this unusual rearrangements observed (Scheme 3.3).53  The authors proposed an 
elimination-addition mechanism involving an electronically neutral species they labeled 
“benzyne” based on several observations made, such as; a) the amination reactions are very 
fast, b) the amine group is always attached only one carbon away from the leaving halide, 
c) starting materials and products are not isomerized under the reaction conditions, and d) 
                                                          
51 (a) Gilman, H.; Avakian, S. J. Am.Chem. Soc. 1945, 67, 349–351. (b) Gilman, H.; Nobis, J. F. J. Am. 
Chem. Soc. 
1945, 67, 1479–1480. (c) Gilman, H.; Crounse, N. N.; Massie, S. P., Jr.; Benkeser, R. A.; Spatz, S. M. J. 
Am. Chem. Soc. 1945, 67, 2106–2108. (d) Urner, R. S.; Bergstrom, F. W. J. Am. Chem. Soc. 1945, 67, 
2108–2109. (e) Gilman, H.; Kyle, R. H.; Benkeser, R. A. J. Am. Chem. Soc. 1946, 68, 143–144. 
52 For a review of nucleophilic aromatic substitution reactions, see: Bunnett, J. F.; Zahler, R. E. Chem. Rev. 
1951, 49, 273–412. 
53 Roberts, J. D.; Simmons, H. E., Jr.; Carlsmith, L. A.; Vaughan, C. W. J. Am. Chem. Soc. 1953, 75, 3290–
3291. 
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They have tested this hypothesis by performing amination reactions using 
isotopically labelled aryl halide, chlorobenzene-1-14C (Scheme 3.3, red color carbon).54  
According to the proposed scheme 3.3, if the proposed intermediate “benzyne” is indeed 
the electrophile, then amination should yield a product with a mixture of aniline-1-14C and 
aniline-2-14C.  After performing the reaction, the desired aniline-1-14C was isolated in 43% 
yield and the rearranged product aniline-2-14C was formed in 52% yield. This is in line 
with the formation of a symmetrical intermediate, benzyne. However, at the time the 
authors did not rule out the formation of other potential intermediates (Figure 3.2).  
Subsequently, they performed several experiments to determine the rates of the 




                                                          
54 Roberts, J. D.; Semenow, D. A.; Simmons, H. E., Jr.; Carlsmith, L. A. J. Am. Chem. Soc. 1956, 78, 601–
611. 
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is the key intermediate in these reactions.55  
Later on, other labs published results in the support of the aryne intermediate. In 
1955, Witting and Pohmer trapped the aryne intermediate using furan to form naphthalene-
1,4-epoxide likely via a Diels-Alder cycloaddition reaction, when bromoflourobenzene 




After this support for the benzyne intermediate was offered, several researchers discovered 
different ways to generate benzyne to overcome the harshness of the reaction and to enable 
further studies. 
 
3.4 Types of Methods to Generate Arynes 
Generation of benzynes can occur in two ways: 1) β-elimination from an aryl anion that 
was generated from a 1,2-subsititued aryl precursor and 2) retro-cycloaddition of benzo-
fused heterocycles (Figure 3.3). 
                                                          
55 Hall, G. E.; Piccolini, R.; Roberts, J. D. J. Am. Chem. Soc. 1955, 77, 4540–4543. 
Panar, M.; Roberts, J. D. J. Am. Chem. Soc. 1960, 82, 3629–3632. 
56 (a) Wittig, G.; Pohmer, L. Angew. Chem. 1955, 67, 348. (b) Wittig, G.; Pohmer, L. Chem. Ber. 1956, 89, 
1334–1351. 
 











In the early stages, benzyne was mostly generated by using a strong base on a mono 
halide aryl group (Figure 3.3, left top) until Witting and Pohmer (1955)57 showed a method 
using 2-bromoflourobenzene – a dihalogenated benzene – instead of mono halogenated 
benzene which effectively promoted the formation of benzyne when treated with lithium 
or magnesium metal (Figure 3.3. left bottom). This method of generating arynes was 
employed in several transformations involving enamines, sulfides, phosphorous and dienes 
compounds.58  
                                                          
57 (a) Wittig, G.; Pohmer, L. Angew. Chem. 1955, 67, 348. (b) Wittig, G.; Pohmer, L. Chem. Ber. 1956, 89, 
1334–1351. 
58 Kuehne, M. E. J. Am. Chem. Soc. 1962, 84, 837–847. 
(a) Wittig, G.; Härle, H. Justus Liebigs Ann. Chem. 1959, 623, 17–34. (b) Huisgen, R.; Knorr, R. 
Tetrahedron Lett. 1963, 4, 1017–1021. c) Hellmann, H.; Eberle, D. Justus Liebigs Ann. Chem. 1963, 662, 
188–201.  d) Seyferth, D.; Burlitch, J. M. J. Org. Chem. 1963, 28, 2463–2464. (e) Griffin, C.; Castellucci, 
N. J. Org. Chem. 1961, 26, 629–630. 
 51   
 
 
Between 1960 and 1964, a different way to generate benzyne was invented using 
the concept of retro-cycloaddition of benzo fused rings, ultimately evolving a gas to yield 
benzyne. Stiles and Miller applied this type of pathway using an anthranilic acid derivative, 
phenyldiazonium-2-carboxylate which, upon heating, released two different gases (CO2 
and N2) to produce benzyne.
59 Then Wittig used benzo-1,2,3-thiadiazole-1,1-dioxide 
which decomposes at room temperature to yield benzyne, whereas Huang used (2-
carboxyphenyl)phenyliodonium salts which require high temperatures and a longer 
reaction period to fully furnish benzyne (Figure 3.3, right bottom). Regardless of the 
drawbacks of these compounds, including careful handling and low temperature storage to 
avoid the evolution of gases, this technique was used over several years as it avoids the use 
of strong base and organometallic reagents.60 Campbell and Rees, using a similar principle, 
applied the methodology to 1-aminobenzotriazole under mild conditions at room 
temperature to form benzyne in the presence of lead(IV) tetraacetate.61 Although this 
reaction is instantaneous, the use of a stoichiometric amount of toxic metal led to the 
limitation of this method in large scale synthesis. 
For the next 30 years after the discovery of benzyne, it was extensively used as a 
key intermediate to undergo several reaction transformations and as a facile route to natural 
                                                          
59 Stiles, M.; Miller, R. G. J. Am. Chem. Soc. 1960, 82, 3802. 
60 For examples of aryne precursors employed in synthesis using retro-cycloaddtion of benzofused rings, 
see: (a) 
Huisgen, R.; Knorr, R.; Möbius, L.; Szeimies, G. Chem. Ber. 1965, 4014–4021. (b) Nair, V.; Kim, K. H. J. 
Org. Chem. 1975, 40, 3784–3786. (c) Saá, C.; Guitián, E.; Castedo, L.; Suau, R.; Saá, J. M. J. Org. Chem. 
1986, 51, 2781–2784. (d) Atanes, N.; Castedo, L.; Guitián, E.; Saá, C.; Saá, J. M.; Suau, R. J. Org. Chem. 
1991, 56, 2984–2988. (e) Matsumoto, K.; Katsura, H.; Uchida, T.; Aoyama, K.; Machiguchi, T. J. Chem. 
Soc., Perkin Trans. 1 1996, 2599–2602. (f) Yamabe, S.; Minato, T.; Ishiwata, A.; Irinimihira, O.; 
Machiguchi, T. J. Org. Chem. 2007, 72, 2832–2841. 
61 (a) Campbell, C. D.; Rees, C. W. Proc. Chem. Soc. 1962, 296. (b) Campbell, C.D.; Rees, C. W. J. Chem. 
Soc. C 1969, 742–747. 
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product synthesis. However, the methods available by that time to make benzyne still 
demanded either strong bases, metallic reagents, high temperatures, and/or extreme caution 
during their synthesis.  This changed in 1983, when Kobayashi developed a mild and 
convenient method for the generation of arynes by the fluoride-induced 1,2-elimination of 
2-(trimethylsilyl)aryl triflates (Figure 3.3 right top).62  The mild conditions applied in this 
procedure are tolerant of a wide variety of reagents, substrates, functional groups, and even 
transition metal catalysts. The authors showed that a wide range of fluoride sources (TBAF, 
TMAF, CsF, KF) could be used in this reaction with several solvents (MeCN, THF, DME).  
Because of these attributes, this protocol has been the most widely used and effective 
method for the generation of arynes. Recent examples of aryne generation have been 
developed by Suzuki and Kitamura and are similar in concept, but  using (phenyl)[o-
(trimethylsilyl) phenyl] iodonium triflate.63 
Henceforth, utilizing the method developed by Kobayashi and also with other previously 
developed methods, a significant amount of research has been published utilizing 





                                                          
62 Himeshima, Y.; Sonoda, T.; Kobayashi, H. Chem. Lett. 1983, 1211–1214. 
63 A) Matsumoto, T.; Hosoya, T.; Katsuki, M.; Suzuki, K. Tetrahedron Lett. 1991, 32, 6735–6736. b) 
Kitamura, T.; Yamane, M. J. Chem. Soc., Chem. Commun. 1995, 983–984. 
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3.5 Representative Reactions of Arynes 
Due to the distorted structure and poor orbital overlap, arynes are highly electrophilic; they 
react with nucleophiles in a wide variety of reaction classes such as pericyclic reactions, 
transition metal-catalyzed reactions, σ-bond insertion reactions, nucleophilic addition 
reactions, and multi-component coupling reactions (Figure 3.4, bonds in red are formed by 
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3.5.1 Pericyclic Reactions 
Due to their highly strained nature, arynes act as excellent dienophiles in pericyclic 
reactions.  Specifically, they are compatible in [2+2], [3+2], and [4+2] cycloaddition 
reactions to form diverse polycyclic products. The earliest cyclo addition reaction dates 
back to 1955 when Wittig and Pohmer trapped benzyne with furan to form a cycloadduct 
in a Diels-Alder type reaction representing a classic [4+2] cycloaddition. Several reactions 
have been shown to utilize [4+2] cycloaddition and thus the use of aryne became popular, 
especially in natural product synthesis.64 In addition to [4+2] cycloadditions, arynes have 
been shown to undergo [3+2] cycloaddition reactions with a range of 1,3-dipolar 
compounds, such as organic azides to form benzotriazoles.65 Nitrones, nitrile oxides, α-
diazoketones, and azomethine ylides, etc., showed [3+2] cycloadditions with aryne.66 
Finally, [2+2] cycloaddition reactions also have been reported over the years.67 
 
 
                                                          
64 For selected total syntheses featuring aryne annulation via [4 + 2] cycloaddition, see: (a) Best, W. M.; 
Wege, D. Aust. J. Chem. 1986, 39, 647–666. (b) Rigby, J. H.; Holsworth, D. D. Tetrahedron Lett. 1991, 32, 
5757–5760. (c) Matsumoto, T.; Hosoya, T.; Suzuki, K. J. Am. Chem. Soc. 1992, 114, 3568–3570. (d) Pérez, 
D.; Guitián, E.; Castedo, L. J. Org. Chem. 1992, 57, 5911–5917. (e) Hosoya, T.; Chapter 2 – Orthogonal 
Synthesis of Indolines and Isoquinolines via Aryne Annulation 100 Takashiro, E.; Matsumoto, T.; Suzuki, 
K. J. Am. Chem. Soc. 1994, 116, 1004–1015. (f) González, C.; Pérez, D.; Guitián, E.; Castedo, L. J. Org. 
Chem. 1995, 60, 6318–6326. (g) Venkatram, A.; Colley, T.; DeRuiter, J.; Smith, F. J. Heterocycl. Chem. 
2005, 42, 297–301. 
65 Huisgen, R.; Knorr, R.; Möbius, L.; Szeimies, G. Chem. Ber. 1965, 4014–4021,  
66 (a) Minisci, F.; Quilico, A. Chimica e Industria 1964, 46, 428. (b) Kitamura, T.; Mansei, Y.; Fujiwara, Y. 
J. Organomet. Chem. 2002, 646, 196–199. C) Huisgen, R.; Knorr, R. Naturwiss. 1961, 48, 716. (d) 
Matsumoto, T.; Sohma, T.; Hatazaki, S.; Suzuki, K. Synlett 1993, 843–846. e) Matsumoto, K.; Uchida, T.; 
Sugi, T.; Yagi, Y. Chem. Lett. 1982, 869–870. f) Yamazaki, T.; Shechter, H. Tetrahedron Lett. 1972, 13, 
4533–4536 
67 For a review of methods for the synthesis of benzocyclobutenes, including [2 + 2] cycloadditions 
between arynes and olefins, see: Klundt, I. L. Chem. Rev. 1970, 70, 471–487. 
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3.5.2 σ-bond Insertion Reactions 
This new technique of using arynes to insert into a σ-bond of the nucleophiles emerged just 
over a decade ago.  In 2002, Shirakawa and Hiyama were the first to report insertion of 
arynes into a C-N bond of cyclic urea to yield benzannulated diazocines in good yields.68 
The Stoltz group in 2005 presented an aryne insertion into a C-C bond of cyclic β-
ketoesters to form benzannulated and dibenzannulated carbocycles.69 Similar contributions 
to the subject were made by Kunai, Li, and Huang using cyclic malonates, β-
ketophosphonates, and β-ketosulfones, respectively, to form a variety of benzannulated 
rings.70 
 
3.5.3 Transition Metal-catalyzed Annulations 
Arynes have also been reported to show reactivity in the presence of transition-metal 
complexes to undergo various annulation or insertion type reactions. Transition metal 
complexes along with aryne intermediates have shown an interesting [2+2+2] 
cyclotrimerzation annulation with diynes and benzyne. One such approach was 
investigated by Pérez and co-workers in 2003 in an effort to develop kinamycin antibiotics 
and formed substituted benzo[b]fluorenones.71 Analogous to σ-bond insertion, Kunai et al. 
                                                          
68 Yoshida, H.; Shirakawa, E.; Honda, Y.; Hiyama, T. Angew. Chem., Int. Ed. 2002, 41, 3247–3249. 
69 Tambar, U. K.; Stoltz, B. M. J. Am. Chem. Soc. 2005, 127, 5340–5341. 
70 a)Yoshida, H.; Watanabe, M.; Ohshita, J.; Kunai, A. Chem. Commun. 2005, 3292–3294.  b) Liu, Y.-L.; 
Liang, Y.; Pi, S.-F.; Li, J.-H. J. Org. Chem. 2009, 74, 5691–5694. c) Zhang, T.; Huang, X.; Xue, J.; Sun, S. 
Tetrahedron Lett. 2009, 50, 1290–1294, d) Ebner, D. C.; Tambar, U. K.; Stoltz, B. M. Org. Synth. 2009, 
86,161. 
71 Peña, D.; Escudero, S.; Pérez, D.; Guitián, E.; Castedo, L. Angew. Chem., Int. Ed. 1998, 37, 2659–2661. 
(b) Peña, D.; Pérez, D.; Guitián, E.; Castedo, L. Org. Lett. 1999, 1, 1555–1557. (c) Peña, D.; Cobas, A.; 
Pérez, D.; Guitián, E.; Castedo, L. Org. Lett. 2000, 2, 1629–1632. (d) Peña, D.; Cobas, A.; Pérez, D.; 
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developed a Pd-catalyzed reactions to insert aryne in Si-Si bonds of 5-membered disilanes 
to form benzannulated disilacarbocycles.72 Subsequently in 2007, Zhang synthesized 
indolo[1,2-f]phenanthridines from N-aryl indoles and arynes73 and in 2008 Larock et al. 
prepared fluoren-9-ones from ortho-halobenzaldehydes and arynes.74 
 
3.5.4 Nucleophilic addition reactions 
Due to the highly strained ring system and their highly electrophilic nature, arynes undergo 
nucleophilic addition even with neutral nucleophiles. Neutral amine nucleophiles such as 
morpholine and N-methyl anilines have added to arynes.75 
 
3.5.5 Multicomponent Reactions (MCRs) 
A unique feature of arynes is their ability to participate in multi-component reactions, 
which have received attention recently. These reactions usually are initiated by 
nucleophilic addition followed by electrophile addition to trap the generated partial 
negative charge.  This method of using two different reagents as nucleophile and 
electrophile enables the formation of complex molecules.  The use of isocyanides and 
                                                          
Guitián, E.; Castedo, L. Org. Lett. 2003, 5, 1863–1866. Peña, D.; Pérez, D.; Guitián, E.; Castedo, L. Eur. J. 
Org. Chem. 2003, 1238–1243. 
72 Yoshida, H.; Ikadai, J.; Shudo, M.; Ohshita, J.; Kunai, A. J. Am. Chem. Soc. 2003, 125, 6638–6639. 
73 Xie, C.; Zhang, Y.; Huang, Z.; Xu, P. J. Org. Chem. 2007, 72, 5431–5434. 
74 Waldo, J. P.; Zhang, X.; Shi, F.; Larock, R. C. J. Org. Chem. 2008, 73, 6679–6685. 
75 Adam E. Goetz and Neil K. Garg. Nat. Chem. 2013, 5, 54–60. 
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aldehydes leading to the formation of benzannulated iminofurans on reaction with aryne 
was demonstrated by Kunai et al.76  
 
3.6 Limitations to Kobayashi’s Method need to be addressed 
In many recent strategies, generation of arynes was achieved using Kobayashi’s method 
via fluoride induced 1,2-elimination of 2-(trimethylsilyl)aryl triflate.  However, a major 
limitation of the approach is the synthesis of the starting material 2-(trimethylsilyl)aryl 
triflate. Typically, 3-5 steps are required to install the TMS and OTf groups ortho to each 
other on the aryl ring (Scheme 3.5).  In addition, it requires the usage of harsh reagents 
such as n-butyl lithium, LDA and triflic anhydride. All these harsh reagents significantly 
reduce the functional group tolerance, which ultimately results in poor access to complex 
aryl groups. Furthermore, the method shown in scheme 3.5 requires the isolation of product 
using column chromatography to furnish the 2-(trimethylsilyl)aryl triflate; precursor of the 
aryne.78,77 
                                                          
76 H. Yoshida, H. Fukushima, J. Ohshita and A. Kunai, Angew. Chem., Int. Ed., 2004, 116, 4025–4028. 
77  S. M. Bronner, N. K. Garg, J. Org. Chem. 2009, 74, 8842 – 8843. 





Consequently, it is mostly used to generate 2-(trimethylsilyl)phenyl triflate, the 
simplest aryne possible. However, relatively few examples with additional substitutions 
have been reported and fluoride sensitive functional groups such as silanes and sulfonates 
are not tolerated.  Although this method is the most widely used as aryne precursor, an 
alternative method that allows the scientific community to access complex and multi-
substituted functional groups containing aryl rings that are easy to prepare would advance 
the current field of  arynes. This would ultimately allow for late-stage benzyne reactions. 
 
3.7 Diaryliodonium Salts as Aryne Precursors 
Using diaryliodonium salts offers advantages over Kobayashi’s method, especially with 
reference to accessing complex arynes and their ease of synthesis.  Diaryliodonium salts 
can be generated through a convenient one-pot method using aryl iodides or arylboronic 
acids (Scheme 1.4.4).  Many different functional groups have been installed on these 
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diaryliodonium salts, which offers further functionalization opportunity.  Substitution 
patterns that were not accessed through Kobayashi’s method could be achieved. 
 
3.8 Literature Precedent for the Generation of Arynes via C-H Deprotonation of Aryl 
Halides 
The generation of benzyne via C-H deprotonation from diaryliodonium salt was first 
observed in 1974.78 In the seminal reports of reactions of diaryliodonium salts by Beringer 
and Forgione, which proposed the mechanisms of radical-pair and nucleophilic 
substitution, aryne pathway was also suggested but without sufficient compelling 
evidence.79 Hence the authors from Kyoto University pursued a mechanistic investigation 
to demonstrate a plausible pathway taking place with diaryliodonium salts. 
They treated ditolyliodonium bromide with tetrazole in the presence of tert-butanol in 
reflux conditions and observed benzyne reactivity yielding a mixture of products. (Scheme 
3.6, top reaction). To further confirm that the reaction products were indeed formed by a 
benzyne pathway, they conducted another experiment wherein ditolyliodonium bromide 
was treated with sodium tert-butoxide in tert-butanol. In this experiment, a 1:1 ratio of both 
meta and para isomers of tert-butyltolyether in a total of 27% yield was observed. (Scheme 
3.6, bottom reaction). 
                                                          
78 Akiyama, T.; Imasaki, Y.; Kawmisi, M. Chem. Lett. 1974, 3, 229–230. 
79 F. M. Beringer and P. S. Forgione, Tetrahedron, 19, 739 (1963). b) Y. Yamada and M. Okawara, Bull. 
Chem. Soc. Japan, 1972, 45, 1860. 




Later, another work was published that further confirmed this type C-H deprotonation of 
diaryliodonium salts. In this work, diphenyliodonium chloride was reacted with sodium 
acetate and a benzyne trap, 1,2,3,4-tetraphenylcyclopentadienone, was added in the 
reaction mixture. The authors isolated a mixture of compounds and also the benzyne adduct 
1,2,3,4-tetraphenylnaphthalene in 3% yield.80 (Scheme 3.7) 
                                                          
80  Sharp, J. T. ; Sledzinski, B; Wilson, N.; Cadogan, J.I.G J.C.S, Perkin Transactions 1, 1975, 11, 1072-
1074. 




Both of these reactions shed some light on a new type of reactivity of diaryliodonium salts. 
However, they were very low yielding and suffered from selectivity problems. While other 
examples of aryne pathway as a side reaction have been observed in the reaction of 
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3.9 Generation of Arynes using Unsymmetrical Aryl(mesityl)iodonium salts via C-H 
Deprotonation 
 
Herein, we describe an efficient method to access highly functionalized arynes using 
aryl(mesityl)iodonium salts, which are conveniently prepared by a one-pot method either 
from aryl iodides or arylboronic acids. The generated aryne was trapped with furan in 
moderate to high yields (Scheme 3.8).  Other nucleophiles, such as alicyclic amines, and 
1,3-dipoles such as benzyl azide, were also shown to work with this method. The 
mechanism is believed to proceed via C-H deprotonation on the ortho position to the 
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3.10 Reaction Discovery 
3.10.1 Preliminary experiments showing benzyne type reactivity 
Soon after our success with the development of a Caryl-Oalkyl bond forming arylation 
reaction (Chapter 2), we further envisioned the application of this direct and metal-free 
reaction to other heteroatom nucleophiles.  Nitrogen nucleophiles were chosen as the 
molecules of interest due to their prevalence in many industrially important compounds. 
The secondary alkyl anime morpholine was selected as the model molecule for this 
chemistry due to its inclusion in biologically active compounds. The diaryliodonium salt 
3-bromophenyl(mesityl) bromide (1) was chosen as this aryl ring stands in the region 
between electron donating and electron withdrawing aryl groups. After initial experiments 
applying similar conditions as in the previously developed etherification standard 
conditions, we have witnessed the formation of Caryl-Nalkyl bond between the 
unsymmetrical diaryliodonium salt and the alicyclic amine morpholine to form the product 
1a in 48% yield.81 Upon optimization of the reaction’s conditions with various bases and 
counter anions, we arrived at a 74% yield of the product 1a using NaOt-Bu as the base and 
the triflate counter anion (Scheme 3.10, top reaction).  Intriguingly, up on the careful 
analysis of the crude 1H NMR spectrum, we found morpholine peaks corresponding to 
another regioisomer, which we initially thought was unreacted morpholine; it had been 
added in 2 equivalents to that of the diaryliodonium salt. After isolation of the products, 
we were surprised to see that there were indeed two regioisomers formed in this reaction. 
                                                          
81 Yield determined from 1H NMR spectrum of the crude reaction mixture versus 1,3,5-trimethoxybenzene 
as an internal standard 
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One was the expected ipso-substitution product 1a and the other was an unexpected cine-
substitution product 1b in the ratio 5:1. The overall yield of the reactions was 91% 
calculated using crude 1H NMR (Scheme 3.10, top reaction).   
Despite the formation of the other regioisomer, the desired product was formed in 
synthetically useful yield. We also examined into other aryl groups, and the pattern of the 
regioisomer formation remained the same when the substituent was on the meta-position 
of the iodonium salt.  However, when the unsymmetrical para-substituted diaryliodonium 
salt (2) was used, the regioisomers were formed in a 1:1 ratio with an overall yield of 89% 
(Scheme 3.10, bottom reaction).  On the contrary, we have not observed regioisomers in 
the previously developed etherification chemistry, which led us to suspect that this 
chemistry may not be following the same mechanism as the etherification.  
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This unusual reactivity of diaryliodonium salts resembles the type of reactivity observed 
by Roberts in 1953 when he first discovered arynes.82 The ratio of isomers formed by 4-
substituted and 3-subsitituted benzynes are in line with the ratios formed by this reaction 









3.10.2 Trapping experiments of aryne with furan 
To determine whether the formation of regioisomers is the result of generation arynes, 
furan, a classic aryne trap, was added to the unsymmetrical diaryliodonium salt 2 instead 
of morpholine. In this experiment, the aryne was successfully trapped by furan to form the 
cycloadduct 6-(trifluoromethyl)-1,4-dihydro-1,4-epoxynaphthalene 2c in high yield 
(Scheme 3.12). The reaction was highly selective in forming only one aryne product in 
                                                          
82 J. D. Roberts, H. E. Simmons, Jr., L. A. Carlsmith, C. W. Vaughan, J. Am. Chem. Soc., 1953, 75, 3290 – 
3291. 
83 Adam E. Goetz and Neil K. Garg. Nat. Chem. 2013, 5, 54–60. 
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addition to the by-product mesityl iodide 2d in 1:1 ratio. To the best of our knowledge, this  
is the highest yield reported for the C-H deprotonation product of diaryliodonium salts 
since the first seminal reports in 1974-75 discussed in the above literature precedent section 
(Scheme 3.6).  We envisioned this opportunity to address the challenges of the current 
aryne generating methods which limit highly functionalized arynes or poly substituted aryl 
groups.  Hence, using unsymmetrical diaryliodonium salts as aryne precursors may offer a 






3.11 Reaction Development 
The electron rich 4-phenyl(mesityl)iodonium triflate salt 3 was chosen to optimize this 
reaction as electron rich diaryliodonium salts are challenging substrates in the coupling 
reactions of  hypervalent iodine chemistry. Success with these substrates would indicate 
that the reaction should work using electron neutral and electron poor salts as well. Furan 
was chosen as it is widely used as an aryne trap. 
 




With an initial yield of 22% (Scheme 3.13), we imagined that there is a lot of room 
for improvement.  This reaction landscape had several parameters such as auxiliary groups, 
counter anions, type of base, solvents, temperature, and concentration that can be optimized 
to increase the % yield (Table 3.1). For example, when the base was switched to an amide 
base (e.g., NaHMDS) and the counter anion to tosylate, a significant increase in the yield 
from 22% to 39% was observed vs NaOt-Bu (entries 7 and 8). Among the amide bases, 
LiHMDS provided about a 10% increase in the yield. The solvent had also been switched 
to toluene as the amide bases were solutions in toluene. A slight increase in the yield to 
52% was observed when the temperature was lowered to 13 oC from room temperature. 
After this point, it became immensely challenging to increase the % yield of the reaction. 
Other counter anions OTf, Br, and, BF4 had little effect and OTs provided the highest yield 
(entries 1-3). Other auxiliary groups such as phenyl (entry 4, 20% and trimethoxyphenyl 
(TMP) (entry 5, 67%) furnished lower product than mesitylene (Mes). 
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 Finally, we learned that the equivalents 
of base and furan had the highest impact 
on the % yield. Lower equivalents of 
furan (1.0 equiv) and higher equivalents 
of base (3.0 equiv) were detrimental to the 
reaction and only produced a 14% yield 
(entry 11). Higher equivalents of furan 
(4.0 equiv) and lower equivalents of base 
(1.0 equiv) furnished 62% of the 
cycloadduct, which was further increased 
to 78% upon increasing the equivalents of 
the furan to 5.5. Further increments didn’t 
increase the yield, but we with all 
parameter optimized, the yield increased 
from 22% to a synthetically useful yield 
of 78%. We have isolated the cycloadduct 
using these reaction conditions and 
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3.12 Scope of the Reaction 
With optimized conditions at hand, we explored the scope of this reaction. As this method 
highlights an efficient aryne reaction pathway and offers opportunity for a broader 
substrate scope with reference to the aryl group, more focus was emphasized on the 
diaryliodonium salt substrates. The scope of this reaction is categorized in to two; 
depending on the preparation of unsymmetrical diaryliodonium salts: either from 
commercially available aryl iodides or from arylboronic acids in a one-pot method (see 
section 1.4.4 for synthesis). This simple and practical method provides these salts in good 
yield (70% average) by easy trituration and filtration and completely avoids the use of 
column chromatography or further purification. 
 
3.12.1 From aryl iodides 
This scope represents the cycloaddition products trapped by furan, that are formed by the 
ortho C-H deprotonation of the unsymmetrical diaryliodonium salts, which were 
synthesized using aryl iodides is shown in table 3.2. The scope table demonstrates that all 
the different halogens are well tolerated resulting in moderate to excellent yields. Poly-
substituted functional groups have also shown good reactivity and highlight opportunity 
for further elaboration of these formed substrates. All the positions, ortho, meta, and para 
have been shown to work in this cycloaddition reaction. Pentafluorosulfanyl (SF5) group,  
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which is recognized as an important moiety in biomedical and materials chemistry,84 was 
easily introduced via its aryl iodide and shown to react in C-H deprotonation chemistry to 
form its cycloadduct. Both meta and para substituted SF5 products were obtained in decent 
yield. Heteroaromatic substrate 2-chloropyridyl demonstrates that this chemistry could be 
applied to heteroaromatic compounds, which are vital in pharmaceutical industries. It is 
                                                          
84 For a review, see: S. Altomonte , M. Zanda , J. Fluorine Chem., 2012 , 143 , 57 –93 . 
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worth mentioning that the presence of two or more electron withdrawing groups, such as 
ester functional groups, on the aryl group resulted in poor yield (~30%). 
 
3.12.2 From arylboronic acids 
This scope represents the cycloaddition products trapped by furan which are formed by the 
ortho C-H deprotonation of the unsymmetrical diaryliodonium salts that were synthesized 
using arylboronic acids is shown in table 3.3. These scope entries highlight the aryl groups 
which have electron donating groups on the arynes and seamlessly undergo cycloaddition 
reaction with furan to produce moderate to good yields.  The dibenzofuran substrate shows 
that this reaction can be used at a late stage synthesis to form structures with complex 
substitutions (e.g., 2,3-dichlorophenyl and 3,4-dichlorophenyl substrate, both of which 
form the same cycloadduct products). This example demonstrates that the iodonium group 
is the only preferred leaving group, which undergoes reductive elimination to form aryne. 















3.13 Aryne Formation with Selective Iodonium Elimination 
This study represented in table 3.4 demonstrates that the iodonium group is selectively 
eliminated even in the presence of halide or pseudo halide after the ortho C-H 
deprotonation step to form the aryne. In the top row of table 3.4, it is shown that 4-
substituted diaryliodonium salts are only deprotonated selectively on the 2-position 
(indicated with arrows), as evidenced by the observation that only one cyclo adduct product 
is observed in the crude 1H NMR spectrum. This is the result of deprotonation at the 2-
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postion to eliminate the iodonium group to form the arynes which leaves the halide or 
pseudo halide group on the 4th position intact. However, in the bottom row of the table 3.4, 
where the halide is situated on the 3-position, selective elimination of iodonium group takes 















                                                          
85 Joseph F. Bunnett, Francis J. Kearley Jr, J. Org. Chem., 1971, 36, 184–186. 
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3.14 Auxiliary and Temperature Controlled Selectivity of C-H Deprotonation 
Formation of two regioisomers 4a 
and 4b was observed when an 
electron donating and sterically 
bulky salt, 3-
methlyphenyl(aux)iodonium 
tosylate 4, was employed in the 
trapping reaction with furan. This is 
in contrast to the result observed 
with electron withdrawing group in 
the 3-postion. In the case of electron 
withdrawing groups, a single 
regioisomer is observed and we 
hypothesize that this is due to 
proximity induced acidity.86  Deprotonation at 2-postion and the 6-postion led to the 
formation of two products in 4.2:1 ratio when Mes was used as the auxiliary.  A study of 
auxiliaries revealed that the ratio of the desired isomer increased to 5.3:1 if 2,4,6-
triisopropylphenyl auxiliary was used (Table 3.5, entry 2). Lowering the temperature to -
10 oC further improved to the selectivity to 6.7:1 (Table 3.5, entry 3). This was probably 
due to restricting the access to 6-position proton because of its sterically hindering groups.  
 
                                                          
86 K. Shen, Y. Fu, J.-N. Li, L. Liu, Q.-X. Guo, Tetrahedron, 2007, 63, 1568 – 1576. 
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3.15 Representative Examples of Cycloaddition and Nucleophilic Addition Reactions 
To further demonstrate the synthetic utility of this method, other reaction classes have been 
shown under slightly modified conditions. The reaction of unsymmetrical diaryliodonium 
salt 4 with benzyl azide in a cycloaddition reaction produced a mixture of benzotriazole in 
3.8:1 regioisomeric ratio with a total yield of 63%. Other nitrogen nucleophiles were added 
in a nucleophilic addition type pathway to form the respective product in an expected 
regioisomeric ratio.87 Addition of morpholine to trap the aryne resulted the major isomer 
in 58% yield (72% combined yield) and piperidine gave a 62% yield of major isomer (78% 
combined yield) respectively. 
 
                                                          
87 J. M. Medina, J. L. Mackey, N. K. Garg, K. N. Houk, J. Am. Chem. Soc. 2014, 136, 15798 – 15805, b) 
E. Picazo, K. N. Houk, N. K. Garg, Tetrahedron 2015, 56, 3511 – 3514, and references therein. 















A novel and efficient method to access highly functionalized arynes is demonstrated, which 
avoids the usage of transition metals or multistage syntheses. The aryne intermediates were 
trapped by furan, benzyl azide, and secondary amine nucleophiles to show the synthetic 
utility of this protocol. The utilization of hypervalent iodine compounds in this new and 
unique way highlights their use as emerging transition metal-free compounds to undergo 





















          
     Chapter 4 
Mechanistic Investigations of Different Modes of Reactivity of 
Unsymmetrical Diaryl iodonium Salts 
 
4.1 Investigation of Product Distribution for Some Electron Rich Unsymmetrical 
Diaryliodonium salts 
We wanted to further explore the cause of moderate yielding unsymmetrical 
diaryliodonium salts in the etherification reactions.  4-Toyl(TMP)iodonium tosylate 5 was 
chosen as the substrate to study in this case as it provided 53% yield (lowest yield) in the 
coupling reaction with n-butanol (Scheme 4.1).  Upon careful investigation of the crude 1H 
NMR spectrum we identified several side products that shed light on reactions that compete 
with formation of the desired coupling product (A, 53%) and co-product TMP-I, (E, 90%). 
The formation of tolyl iodide (B, 13%) and TMB (D, 19%) were also observed. An unusual 
side product (C, 8%) was additionally observed and has been tentatively assigned by 1H 
NMR and GC-MS as 2-butoxy-1-iodo-4-methylbenzene. 




4.2 Addition of Aryne Trap 
In our work shown in scheme 4.1, the 4-tolyl moiety is not fully accounted for in the mass 
balance. Moreover, with the previous knowledge that alkoxide nucleophiles generate 
arynes, we sought to quantify the amount of aryne produced in this reaction, which may 
account for the lower yield of ipso product compared to other salts. Interestingly when 
furan was added as an aryne trap, 11% of the cycloadduct was observed in the crude 1H 
NMR spectrum along with a similar yield (50%) of the desired product relative to without 
addition of furan (Scheme 4.2, top reaction). We hypothesized that the presence of 
stoichiometric alkoxide leads to C-H deprotonation and aryne formation.  However, when 
milder bases, such as Cs2CO3, were employed in the reaction similar product distribution 
was observed (Scheme 4.2, bottom reaction).  Despite the fact that carbonate base is not 
basic enough to stoichiometrically deprotonate an alcohol. The product distribution is 
consistent with a common intermediate (described in Scheme 4.3). This key intermediate 
containing the butoxide on the λ3-iodane can undergo two different pathway to furnish the 
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ipso-substituted product via the attack of butoxide on the ipso carbon and cycloaddition 
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4.3 Influence of the “Position and Electronics” of the Functional Group on the 
Iodonium salt 
We were interested to see if the competition between the two pathways shown in scheme 
4.3 is affected by the position and electronic effect of ring substituents. Three different 
functional groups Me, Cl, and NO2 were chosen as their electronic effects differ 
significantly.  Intriguing observations were made when these different substrates were 
subjected to coupling reaction with n-butanol and furan. 
 
4.3.1 Effect arising due to ortho groups 
Ortho substituted iodonium salts exclusively formed only the ipso substitution product. No 
cycloadduct was observed in the crude 1H NMR spectrum of any of the three functional 
groups.  The yield of ortho NO2 was lower than that of Me and Cl, which is unusual because 
NO2 substituted iodonium salts typically furnish better yields compared to the other 
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functional groups. This disparity might be arising due to the ortho effect 88(interaction of 
ortho groups with the iodonium group favoring reductive elimination). 
4.3.2 Effect arising due to meta groups 
When the functional groups were situated on the meta position, the selectivity of the 
reaction changed dramatically, especially with Cl and NO2 groups. Methyl substituted 
iodonium salt majorly generated ipso product (50%) and only 2% and 6% of the 
cycloadduct isomers. However, in the case of iodonium salts which contain Cl and NO2 
functional groups, cycloaddition products are formed in a significantly higher quantity 43% 
and 65% respectively than the ipso products 23% and 21%.   
 
4.3.3 Effect arising due to para groups 
Finally, para substituted iodonium salts were tested in the reaction, and competition 
between the two mechanistic pathways was observed for the Me and Cl substituted salts. 
                                                          
88 Joel Malmgren, Stefano Santoro, Nazli Jalalian, Fahmi Himo* and Olofsson, B., Chem. Eur. J., 2013, 19, 
10334–10342. 
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The electronic effects of the NO2 group may have overridden the formation of aryne in this 
case yielding only ipso substituted product. 
 
Both Me and Cl substituted salts furnished similar yields with respect to ipso 
product however, higher percentage of aryne cycloadduct was observed in the later (29%, 
compared to 11%). 
 
4.4 Computational Studies are needed (future outlook) 
We believe that the selectivity of these reactions can be better explained with the help of 
computational studies in determining the effect of electronic and steric parameters. They 
could be playing a huge roll in lowering or raising the energy barriers for the formation of 
ipso or aryne pathways leading to the respective products. With the knowledge gained from 
these computations we believe that we can design reaction conditions to dictate where the 
salt should undergo ipso or aryne pathway.  
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4.5 Nature of the Nucleophile and its pKa effects on the Aryne formation  
We have performed a study to understand what nucleophiles actually trigger aryne pathway 
and also to see if the pKa of these nucleophiles could be the reason for the C-H 
deprotonation of iodonium salt.  So, we have selected a few reactions reported in the 
literature of diaryliodonium salts with different types of nucleophiles and added furan as 
the aryne trap (Scheme 4.7). Interesting observations were made in this study. 4-
chlorophenyl(TMP) triflate was chosen as the common iodonium salt in all the cases. 
Aryne formation was not observed when carbon nucleophiles and phenolic nucleophiles 
were employed. Amide nucleophiles resulted in the formation of aryne in 7% yield. 
Alkoxide nucleophiles, as we have observed from our previous study, also gave aryne in 
12% yield. Finally, strong base LiHMDS furnished arynes as well.  It was interesting to 
learn that when pKa values reached around 21, the formation of aryne pathway was 
triggered and it continued to do so when the pKa was increased. This study definitely needs 
more experimental data and different nucleophiles to make conclusive results.  
 The knowledge gained from this study can be very beneficial to the iodonium salt 
community to inform the researchers that nature and pKa of the nucleophiles could be a key 
parameter to avoid or trigger aryne pathway. 
 































5.1 General Considerations 
Materials: Commercially available reagents and solvents were used without further 
purification unless otherwise stated.   tert-Butyl methyl ether (TBME), dimethylformamide 
(DMF) and dichloromethane (DCM) were purchased from Acros Organics.  
Tetrahydrofuran was purchased from Omnisolv. Anhydrous DCM was obtained from 
Sigma-Aldrich which was dried through an MBRAUN solvent purification system.  
Arylboronic acids were purchased from either Sigma-Aldrich or Frontier Scientific.  
Iodobenzene diacetate and iodomesitylene diacetate were purchased from TCI America 
and stored at 5 °C.  BF3•OEt2 was purchased from Acros Organics and stored at 5 °C under 
a nitrogen atmosphere.  Alcohols were purchased from Sigma-Aldrich or TCI America.  
Potassium bromide (KBr) was purchased from Fisher Scientific, sodium triflate (NaOTf) 
was purchased from TCI America, sodium tetrafluoroborate (NaBF4) was purchased from 
Sigma-Aldrich.   m-Chloroperoxybenzoic acid (~ 70% oxidant), sodium hydride and 
magnesium sulfate were purchased from Sigma-Aldrich.  All other materials were prepared 
by known literature procedures or are described in detail below. 




Methods: Reactions performed above ambient room temperature were done so in an oil 
bath or aluminum block heated externally by a Heidolph MR Hei-Standard heating/stirring 
mantel equipped with a Heidolph EKT HeiCON temperature control.  Crude reaction 
mixtures were analyzed by 1H NMR or 19F NMR spectroscopy and thin-layer 
chromatography (TLC) on Selecto Scientific Flexible TLC plates (silica gel 60 Å F-254) 
and visualized by UV.  Crude material was purified by flash column chromatography on 
Silicycle silica gel SiliaFlash P60, unless otherwise stated.  1H, 13C, and 19F NMR spectra 
were recorded in CDCl3 or DMSO-d6 (with tetramethylsilane as an internal standard) on a 
Bruker Avance II 400 MHz spectrometer; the following notation is used: br – broad, s – 
singlet, d – doublet, t – triplet, q – quartet, m – multiplet, dd – doublet of doublets.  FTIR 
spectra were recorded on Thermo Scientific Nicolet iS5 Infra-red spectrometer.  High 
resolution mass spectrometry (HRMS (ESI+)) data were recorded on Thermo Scientific 
LTQ Orbitrap Mass Spectrometer by electrospray ionization (ESI) and JEOL MSRoute by 
Positive Electron impact detector (EI+).    Melting points were recorded on Mel-Temp 
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5.2 Synthesis of aryl(mesityl)iodonium bromide salts 
5.2.1: Representative procedure A:1   
  Scheme 5.1: Representative procedure A   
 
3-Cyanophenylboronic acid (0.8810 g, 6.0 mmol, 1.0 equiv.) was weighed and transferred 
to a pear-shaped flask equipped with a magnetic stir bar and rubber septa.  The flask was 
flushed with nitrogen and left under a static nitrogen atmosphere.  DCM (60 mL) is added 
via syringe to the arylboronic acid and the solution is cooled to ~ 0° C in an ice-water bath 
with stirring.  BF3•OEt2 (0.81 mL, 6.6 mmol, 3.0 equiv.) is added via syringe to the 
arylboronic acid solution and the reaction mixture was stirred for 10 minutes at 0° C.  
Iodomesitylene diacetate (2.4035 g, 6.6 mmol, 1.1 equiv.) was weighed and transferred to 
a separate pear-shaped flask equipped with rubber septa.  The flask was flushed with 
nitrogen and left under a static nitrogen atmosphere.  DCM (20 mL) was added to the 
iodomesitylene diacetate.  The iodomesitylene diacetate solution was added to the 
arylboronic acid/BF3•OEt2 solution drop-wise via syringe at ~ 0° C.  The reaction mixture 
was allowed to warm to ambient room temperature and stirred overnight.  The septa was 
removed and an aqueous saturated solution of KBr (100 mL) was added with vigorous 
stirring for ~ 30 minutes.  The biphasic mixture was added to a separatory funnel and the 
DCM/water layers separated.  The water layer was extracted with DCM (3 × 30 mL).  The 
combined DCM layers were dried over MgSO4, filtered, and the DCM removed on a 
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rotovap.  The crude residue was triturated with diethyl ether to yield analytically pure 
bromo-3-cyanophenyl(mesityl)-λ3-iodane.  See below for yield and characterization data. 
5.2.2 Representative procedure B: 90 




Step 1: To a stirred solution of 1-iodo-3-nitrobenzene (2.5055 g, 10.0 mmol, 1.0 equiv.) in 
DCM (100 mL) was added m-CPBA (2.720 g, 11.0 mmol, 1.1 equiv.). The resulting 
solution was cooled to 0oC.  BF3•OEt2 (3.7 mL, 30.0 mmol, 3.0 equiv.) is added slowly via 
syringe to the above solution and the reaction mixture was stirred for 2 hours at 0° C.  
Mesitylene (1.5 mL, 11.0 mmol, 1.1 equiv.) was added and the reaction mixture was 
allowed to warm to ambient room temperature and stirred overnight.  The septa was 
removed and an aqueous saturated solution of KBr (200 mL) was added with vigorous 
stirring for ~ 30 minutes.  The biphasic mixture was added to a separatory funnel and the 
DCM/water layers separated.  The water layer was extracted with DCM (3 × 50 mL).  The 
combined DCM layers were dried over MgSO4, filtered, and the DCM removed on a 
rotovap.  The crude residue was triturated with diethyl ether to yield analytically pure 
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5.2.3: Representative procedure C:91 





To a solution of the 4-iodotoluene (4.3700 g, 20.0 mmol, 1.0 equiv.) and dried m-CPBA 
(3.7900 g, 22.0 mmol, 1.1 equiv.) in DCM (85 mL) at 0 °C was added 
trifluoromethanesulfonic acid (3.5 mL, 40 mmol, 2.0 equiv.) dropwise over 2 minutes. The 
ice bath was removed and the reaction stirred for 2 hours at room temperature. It was then 
cooled to 0 °C and toluene (2.3 mL, 22.0 mmol, 1.1 equiv.) was added dropwise over 2 
minutes. The reaction was allowed to warm to room temperature and stirred overnight. The 
solvent was removed in vacuo and diethyl ether added. The resulting solid was filtered and 
washed with diethyl ether to give the iodonium triflate as a solid that was dried under 
vacuum for 1 hour. See below for yield and characterization data. 
 
5.2.4: Representative procedure D 





To a stirred solution of crude diaryl iodonium triflate in DCM (0.1 M) a saturated solution 
of KBr was added and stirred for 30 minutes at room temperature.  The organic layer was 
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separated and the aqueous layer was extracted with DCM.  The combined organic layer is 
dried over MgSO4 and evaporated on the rotovap.  The resulting solid was triturated with 
diethyl ether and isolated by filtration to give diaryl iodonium bromide.  See below for 
yield and characterization data. 
Compound 1.1 
 
Prepared according to representative procedure A on 10.0 mmol-scale and obtained in 49% 
isolated yield (2.1000 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 7.86-7.83 (m, 1H), 7.90 (d, J = 8.2 Hz, 1H), 
7.50-7.38 (m, 2H), 7.16 (s, 2H), 2.58 (s, 6H), 2.27 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 161.9 (d, JC-F = 252.9 Hz), 142.3, 140.8, 132.9 
(d, JC-F = 7.9 Hz), 129.5 (d, JC-F = 3.0 Hz), 129.4, 125.8 120.7 (d, JC-F = 24.8 Hz), 118.9 
(d, JC-F = 7.2 Hz), 118.1 (d, JC-F = 21.1 Hz), 26.1, 20.4. 
19F NMR (377 MHz, DMSO-d6): δ (ppm) -108.38 
FTIR: 3061, 1585, 1468, 1213 cm-1  
HRMS (ESI+): Calculated for C15H15FI
+ [M – Br] +: 341.0197; observed: 341.0214 





Prepared according to representative procedure B 10.0 mmol-scale and obtained in 72% 
isolated yield (3.2400g) 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.70 (t, J = 1.8 Hz, 1H) 8.35-8.33 (m, 1H), 8.10-
8.08 (m, 1H), 7.68 (t, J = 8.8 Hz, 1H), 7.20 (s, 2H), 2.60 (s, 6H) 2.29 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 148.3, 142.6, 140.9, 138.9, 132.3, 129.5, 128.0, 
125.7, 125.5, 119.2, 26.2, 20.4. 
FTIR: 3106, 2223, 1524, 1346, 1293 cm-1 
HRMS (ESI+): Calculated for C15H15INO2
+ [M – Br] +: 368.0142; observed: 368.0157 










Prepared according to representative procedure A on 5.0 mmol-scale and obtained in 87% 
isolated yield (1.9659 g). 
1H NMR (400 MHz, DMSO-d6): 8.01 (d, J = 1.93 Hz, 1H), 7.65-7.63 (dd, J = 6.5 Hz, 1.6 
Hz, 1H), 7.39 (d, J = 8.34 Hz, 1H), 7.16 (s, 2H) 2.58 (s, 6H), 2.31 (s, 3H), 2.27 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 142.3, 140.8, 139.1, 134.9, 133.5, 133.2, 132.1, 
129.4, 125.4, 115.3, 26.1, 20.4, 19.3 
FTIR: 2950, 2920, 1465, 1055 cm-1 
HRMS (ESI+): Calculated for C16H17ClI
+ [M – Br] +: 371.0058; observed: 371.0075 
MP (DCM/Et2O): 151.3 – 153.9 °C 
 
Compound 1.4 - Mes 
 
 
Prepared according to representative procedure A on 10.0 mmol-scale and obtained in 71% 
isolated yield (3.4260 g).  The 1H NMR spectra of the corresponding triflate and 
tetrafluoroborate counter ions are consistent with that of the bromide salt. 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.15 (t, J = 1.6 Hz, 1H), 7.74 (m, 2H), 7.36 (t, 
J = 8.0 Hz, 1H), 7.17 (s, 2H), 2.60 (s, 6H), 2.29 (s, 3H) 
13C NMR (100 MHz, DMSO-d6):  δ (ppm) 142.4, 140.9, 135.4, 133.8, 133.1, 132.2, 129.5, 
125.4, 123.1, 119.3, 26.1, 20.4 
FTIR : 2976, 2936, 1587, 1474 cm-1 
HRMS (ESI+): Calculated for C15H15BrI
+ [M – Br] +: 400.9396; observed: 400.9418 
MP (DCM/Et2O): 145.4 – 146.8 °C 
 
The corresponding compounds with triflate and tetrafluoroborate counter ions had identical 
1H NMR and 13C NMR spectra. 
19F NMR (377 MHz, DMSO-d6) of the OTf: δ (ppm) -77.75 
19F NMR (377 MHz, DMSO-d6) of the BF4: δ (ppm) -148.26 
 
Compound 1.4 – Ph 
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Prepared according to representative procedure A using benzene diacetate on 1.0 mmole 
scale and obtained in 83% isolated yield (0.03806g). 
1H NMR (400 MHz, DMSO) δ 8.59 (t, J = 1.6 Hz, 1H), 8.28 (t, J = 8.5 Hz, 3H), 7.87 
(dd, J = 8.1, 1.0 Hz, 1H), 7.69 (t, J = 7.4 Hz, 1H), 7.56 (t, J = 7.7 Hz, 2H), 7.49 (dd, J = 
14.9, 6.9 Hz, 1H) 
13C NMR (100 MHz, DMSO) δ 136.8, 135.1, 134.9, 133.9, 133.3, 132.1, 131.7, 123.1, 
116.9, 116.7 
FTIR: 1238, 11673, 1026, 769 cm-1 
HRMS (ESI+): Calculated for [M – Br] +: 358.8926; observed: 358.8935 
MP (DCM/Et2O): 166oC -169 oC 
 




Prepared according to representative procedure F and converted to bromide salt using 
representative procedure D on 2 mmol scale and obtained in 17% isolated yield (0.1516g) 
1H NMR (400 MHz, DMSO) δ 8.11 (t, J = 1.8 Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.76 (dd, 
J = 8.0, 0.9 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 6.44 (s, 2H) 
13C NMR (101 MHz, DMSO) δ 165.7, 159.1, 135.7, 133.7, 132.9, 132.6, 122.6, 119.0, 
91.9, 90.4, 57.1, 55.9 
 FTIR: 2948, 2839, 1581, 1453, 1221, 1122, 769 cm-1 
HRMS (ESI+): Calculated for [M – Br] +: 448.9243; observed: 448.9234 
MP (DCM/Et2O): 175oC -179 oC 
 




Prepared according to representative procedure F and converted to bromide salt using 
representative procedure D on 2 mmol scale and obtained in 53% isolated yield (0.5611g) 
1H NMR (400 MHz, DMSO) δ 8.50 (t, J = 1.8 Hz, 1H), 8.26 – 8.17 (m, 1H), 8.03 – 7.93 
(m, 1H), 7.89 (dd, J = 5.3, 1.3 Hz, 1H), 7.84 – 7.76 (m, 1H), 7.48 – 7.38 (m, 1H), 7.18 – 
7.08 (m, 1H) 
13C NMR (100 MHz, DMSO) δ 139.1, 136.2, 136.0, 134.1, 133.2, 132.9, 129.1, 122.6, 
122.6, 106.3 
FTIR: 1224, 777 cm-1  
HRMS (ESI+): Calculated for [M – Br] +: 364.8491; observed: 364.8495 
MP (DCM/Et2O): 149oC -159 oC 




Compound 1.5  
 
 
Prepared according to representative procedure A on 6.0 mmol-scale and obtained in 20% 
isolated yield (0.5100 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.49 (s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 8.05 (d, 
J = 8.8 Hz, 1H), 7.62 (t, J = 8.3 Hz, 1H), 7.19 (s, 2H), 2.58 (s, 6H), 2.28 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 142.4, 140.9, 138.1, 137.01, 134.6, 131.9, 
129.5, 125.6, 119.1, 117.0, 113.5, 26.2, 20.4. 
FTIR: 3020, 2226, 1457 cm-1 
HRMS (ESI+): Calculated for C16H15IN
+ [M – Br] +: 348.0244; observed: 348.0259 





Prepared according to representative procedure A on 4.8 mmol-scale and obtained in 51% 
isolated yield (1.200 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.00 (s, 1H), 7.77-7.74 (m, 1H), 7.59 (m, 2H), 
7.18 (s, 2H), 2.59 (s, 6H), 2.28 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 148.6, 142.4, 140.8, 132.9, 132.2, 129.5, 126.2, 
125.76, 123.5, 119.8 (q, JC-F = 254.7 Hz), 119.2, 26.1, 20.4. 
19F NMR (377 MHz, DMSO-d6): δ (ppm) -57.02 
FTIR: 2924, 1579, 1468, 1257, 1218, 1202, 1163 cm-1  
HRMS (ESI+): Calculated for C16H15F3IO
+ [M – Br] +: 407.0114; observed: 407.0130 



















Prepared according to representative procedure C using mesitylene instead of toluene and 
converted to bromide salt using representative D on 4.1 mmol-scale and obtained in 79% 
isolated yield (1.4480 g).  
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.21 (d, J = 9.2 Hz, 2H), 8.10 (d, J = 9.1 Hz, 
2H), 7.20 (s, 2H), 2.59 (s, 6H), 2.30 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 148.7, 142.6, 140.9, 134.8, 129.6, 125.7, 125.4, 
125.1, 26.1, 20.4. 
FTIR: 3084, 3047, 1532, 1354 cm-1 
HRMS (ESI+): Calculated for C15H15INO2
+ [M – Br] +: 368.0142; observed Mass: 
368.0157 





Prepared according to representative procedure A on 3.7 mmol-scale and obtained in 81% 
isolated yield (1.4157 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.07 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.5 Hz, 
2H), 7.20 (s, 2H), 2.59 (s, 6H), 2.29 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 142.5, 140.9, 134.4, 130.8 (q, JC-F = 31.7 Hz), 
129.5, 127.8 (q, JC-F = 3.7 Hz), 125.5, 123.6 (q, JC-F = 270.5 Hz), 123.1, 26.1, 20.4. 
19F NMR (377 MHz, DMSO-d6): δ (ppm) -61.61 
FTIR: 2920, 1593, 1329, 1127, 1066, 1002 cm-1 
HRMS (ESI+): Calculated for C16H15F3I
+ [M – Br] + 391.0165; observed: 391.0183 

















Prepared according to general procedure A on 5.0 mmol-scale and obtained in 82% isolated 
yield (1.9326 g). 
1H NMR (400 MHz, DMSO-d6): δ 8.36 (dd, J = 23.3, 1.2 Hz, 1H), 8.05 – 7.95 (m, 2H), 
7.17 (s, 2H), 3.32 (s, 1H), 2.67 (s, 6H), 2.28 (s, 3H). 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 142.5, 141.1, 138.4, 136.4, 134.9, 129.7, 128.6, 
126.2, 125.3, 117.6, 115.1, 26.2, 20.3,  
FTIR: 2976, 2947, 2288, 1444 cm-1 
HRMS (ESI+): Calculated for C16H17ClIO
+ [M – Br] + : 425.9348; observed: 425.9347 





Prepared according to representative procedure A on 3.2 mmol-scale and obtained in 40% 
isolated yield (0.6036 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 7.86 (d, J = 1.8 Hz, 2H), 7.8 (t, J = 1.2 Hz, 1H), 
7.18 (s, 2H), 2.60 (s, 6H), 2.29 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 142.5, 140.9, 135.5, 131.4, 130.8, 129.5, 125.8, 
120.7, 26.2, 20.4 
FTIR: 3042 1577, 1574, 1404 cm-1 
HRMS (ESI+): Calculated for C15H14Cl2I
+ [M – Br] +: 390.9512; observed: 390.9533 





Prepared according to representative procedure A on 3.9 mmol-scale and obtained in 79% 
isolated yield (1.4395 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.22-8.20 (dd, J = 4.7 Hz, 2.3 Hz, 1H), 7.78-
7.75 (m, 1H), 7.47 (t, J = 9.0 Hz, 1H), 7.16 (s, 2H), 2.59 (s, 6H), 2.28 (s, 3H) 
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13C NMR (100 MHz, DMSO-d6): δ (ppm) 158.5 (d, J = 251.1 Hz), 142.4, 140.8, 135.5, 
134.5 (d, JC-F = 8.11 Hz), 129.4, 125.9, 121.8 (d, JC-F = 18.54 Hz), 119.6 (d, JC-F = 22.0 
Hz), 113.7, 26.1, 20.4 
19F NMR (377 MHz, DMSO-d6): δ (ppm) -111.31 
FTIR: 3011, 1474, 1263, 1063 cm-1 
HRMS (ESI+): Calculated for C15H14ClFI
+ [M – Br] +: 374.9807; observed: 374.9826 






Prepared according to representative procedure A on 5.0 mmol-scale and obtained in 46% 
isolated yield (1.0523 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.5 (d, J = 1.9 Hz, 1H), 7.97-7.94 (dd, J = 6.4 
Hz, 2.0 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.18 (s, 2H), 2.60 (s, 6H), 2.48 (s, 3H), 2.29 (s, 
3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 149.5, 142.4, 140.9, 137.4, 135.7, 135.2, 129.5, 
129.1, 125.6, 115.6, 26.18, 20.4, 19.1 
FTIR: 3028, 2365, 1524, 1340 cm-1 
HRMS (ESI+): Calculated for C16H17INO2
+ [M – Br] +: 382.0299; observed: 382.0316 





Prepared according to general procedure A on 5.0 mmol-scale and obtained in 82% 
isolated yield (1.9326 g). 
1H NMR (400 MHz, DMSO-d6): δ (ppm) 8.00 (t, J = 2.0 Hz, 1H), 7.76 (d, J = 8.8 
Hz, 1H), 7.19-7.15 (m, 3H), 3.87 (s, 3H), 2.59 (s, 6H), 2.27 (s, 3H) 
13C NMR (100 MHz, DMSO-d6): δ (ppm) 156.6, 142.3, 140.8, 134.6, 134.4, 129.4, 
125.28, 122.9, 115.31, 106.4, 56.4, 26.1, 20.3 
FTIR: 3014, 1568, 1304, 1279, 1063 cm-1 
HRMS (ESI+): Calculated for C16H17ClIO
+ [M – Br] + : 387.0007; observed: 387.0025 











Prepared from the corresponding aryl boronic acid on a 5.0 mmol-scale and obtained in 
81% isolated yield as a white powder (1.7 g).  
1H NMR (400 MHz, DMSO-d6) δ 9.99 (s, 1H), 8.08 (d, J = 8.3 Hz, 2H), 7.90 (d, J = 8.3 
Hz, 2H), 7.18 (s, 2H), 2.59 (s, 6H), 2.29 (s, 3H).  
13C NMR (101 MHz, DMSO-d6): δ 192.4, 142.1, 140.7, 137.0, 134.2, 131.4, 129.4, 
126.3, 125.8, 26.1, 20.4.  
FTIR: 3102, 1699, 1264, 728 cm−1.  
HRMS (ESI) : [M − Br]+ calculated for C16H16IO
+ 351.0240; observed 351.0255. 































 99   
 
 
5.3: Synthesis of alkyl-aryl ethers 
  
5.3.1: General procedure for the synthesis of alkyl-aryl ethers E: 
  




Sodium hydride (0.75 mmol, 1.5 equiv. based on 60 wt % dispersion in mineral oil) was 
weighed out to air and transferred to an oven-dried vial equipped with a magnetic stir bar. 
The vial was sealed with a cap and Teflon-lined septum and purged with nitrogen. A 
solution of the alcohol (1 mmol, 2 equiv) in TBME (2.5 mL) was added dropwise to the 
sodium hydride and the cloudy white mixture stirred at ambient room temperature for at 
least 15 min. Compound 1 (0.5 mmol, 1 equiv) was powdered into the reaction vial. The 
vial was sealed with a solid cap and placed into a preheated (50 °C) aluminum block for 1 
h. The reaction was then removed from the heat and quenched with 5 mL of a saturated 
solution of ammonium chloride. The biphasic mixture was transferred to a separatory 
funnel and the aqueous layer extracted with DCM (3 × 10 mL). The combined DCM layers 
were dried over MgSO4, filtered, and the DCM removed on a rotary evaporator. The crude 
residue was purified by flash column chromatography on silica gel (see below for specific 
eluent composition). In cases where duplicate experiments were performed on the same 









Reaction conducted according to general procedure E on 0.1 mmol-scale.  Due to the 
volatility of this compound, the yield was obtained from the crude 1H NMR spectra versus 
1,3,5-trimethoxybenzene as an internal standard in 88% and 86% yield (87% average of 
two runs).  This compound is commercially available, CAS: 1340125-14-5.   
1H NMR (400 MHz, CDCl3): δ (ppm) 7.23-7.67 (m, 1H), 6.68-6.53 (m, 3H), 4.31-4.23 
(m, 1H), 1.80-1.57 (m, 2H), 1.29 (d, J = 6.0 Hz, 3H), 0.98 (t, J = 8.5 Hz, 3H) 
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13C NMR (100 MHz, CDCl3): δ (ppm) 163.8 (d, JC-F = 243.2 Hz) 160.7 (d, JC-F = 11.4 Hz), 
130.0 (d, JC-F = 9.2 Hz) 110.4 (d, JC-F = 2.9 Hz), 107.2 (d, JC-F = 21.2 Hz), 102.1 (d, JC-F = 
24.9 Hz), 72.3, 34.5, 24.8, 18.5 
19F NMR (377 MHz, CDCl3): δ (ppm) -111.99 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 78% 
(0.0899g) and 67% (0.0765g) isolated yields (72% average of two runs).  This compound 
is commercially available, CAS: 1042560-11-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.13 (t, J = 8.1 Hz, 1H), 7.05-7.03 (m, 2H), 6.83-
6.80 (m, 1H), 4.30-4.23 (m, 1H), 1.79-1.56 (m, 2H), 1.28 (d, J = 6.3 Hz, 3H), 0.97 (t, J = 
8.1 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.1, 130.5, 123.4, 122.7, 119.0, 114.7, 75.4, 
29.1, 19.1, 9.7 





Prepared according to general procedure E on 0.5 mmol-scale and obtained in 70% (0.0614 
g) and 65% (0.057g) isolated yields (67% average of two runs).  This compound is 
commercially available, CAS: 902093-86-1 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.34 (t, J = 8.1 Hz, 1H), 7.20-7.18 (m, 1H), 7.12-
7.08 (m, 2H), 4.34-4.26 (m, 1H), 1.80-1.58 (m, 2H), 1.30 (d, J = 6.1 Hz, 3H), 0.97 (t, J = 
7.4 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.1, 130.5, 123.4, 122.7, 119.0, 114.7, 75.4, 
29.1, 19.1, 9.7 (one signal missing due to overlapping peaks) 







Prepared according to general procedure E on 0.5 mmol-scale and obtained in 47% 
(0.0528g) isolated yield.  Due to the volatility of this compound, the yield was obtained 
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from the crude 1H NMR spectra versus 1,3,5-trimethoxybenzene as an internal standard in 
82% and 79% (80% average of two runs).   
1H NMR (400 MHz, CDCl3): δ (ppm) 7.24 (t, J = 16.5 Hz, 1H), 6.81-6.73 (m, 3H), 4.31-
4.24 (m, 1H), 1.79-1.57 (m, 2H) 1.29 (d, J = 6.2 Hz, 3H) 0.97 (t, J = 7.4 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.3, 150.2, 130.1, 120.1 (q, JC-F = 260.8 Hz) 
114.0, 112.5, 108.8, 75.4, 29.0, 19.0, 9.7 
19F NMR (377 MHz, CDCl3): δ (ppm) -57.75 
FTIR: 2976, 2936, 1589, 1260, 1008 cm-1 
HRMS (EI+): Calculated; 234.08677; observed: 234.08763 






Prepared according to general procedure E on 1.0 mmol-scale and obtained in 79% 
(0.1537g) and on 5.0 mmole and obtained in 76% (0.7820g) isolated yields (77% average 
of two runs).  
1H NMR (400 MHz, CDCl3): δ (ppm) 7.78-7.75 (m, 1H), 7.70 (t, J = 2.3Hz, 1H), 7.39 (t, 
J = 7.7 Hz, 1H), 7.20-7.17 (m, 1H), 4.42-4.34 (m, 1H), 1.82-1.60 (m, 2H), 1.32 (d, J = 6.2 
Hz, 3H), 0.98 (t, J =5.5 Hz, 3H)  
13C NMR (101 MHz, CDCl3): δ (ppm) 158.8, 149.2, 129.9, 122.6, 115.3, 109.9, 75.9, 
29.0, 18.9, 9.6 
FTIR: 2976, 2936, 1529, 1349, 1150 cm-1 
HRMS (EI+): Calculated: 195.0895; observed: 195.0903 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 77% 
(0.0754g) and 83% (0.0833g) isolated yields (80% average of two runs). Spectroscopic 
data was consistent with that previously reported.92  
1H NMR (400 MHz, CDCl3): δ (ppm) 8.17 (d, J = 9.3 Hz, 2H), 6.91 (d, J = 9.3 Hz, 2H), 
4.45-4.37 (m, 1H), 1.83-1.61 (m, 2H), 1.33 (d, J = 6.2 Hz, 3H), 0.98 (t, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.4, 135.3, 120.6, 114.6, 75.8, 29.0, 19.0, 9.6 












Prepared according to general procedure E on 0.5 mmol-scale and obtained 39% (0.0422g) 
isolated yield. Due to the volatility of this compound the yield was obtained from the crude 
1H NMR spectra versus 1,3,5-trimethoxybenzene as an internal standard in 67% and 68% 
(67% average of two runs).  Spectroscopic data was consistent with that previously 
reported.93 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.52 (d, J = 8.7 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 
4.40-4.32 (m, 1H), 1.82-1.59 (m, 2H), 1.31 (d, J = 6.0 Hz, 3H), 0.98 (t, J = 7.3 Hz, 3H),  
13C NMR (100 MHz, CDCl3): δ (ppm) 160.8, 129.4, 126.8 (q, JC-F = 3.8 Hz), 122.3 (q, 
JC-F = 32.3 Hz), 115.4, 75.2, 29.0, 19.0, 9.7 
19F NMR (377 MHz, CDCl3): δ (ppm) -61.45 






Prepared according to general procedure E on 0.4 mmol-scale and obtained in 69% (0.0751 
g) and 0.5 mmole scale and obtained 70% (0.0882g) isolated yields (69% average of two 
runs). 
1H NMR (400 MHz, CDCl3) δ 7.43 – 7.36 (m, 1H), 7.14 – 7.12 (m, 1H), 7.12 – 7.08 (m, 
1H), 4.40 (m, 1H), 1.92 – 1.63 (m, 2H), 1.36 (d, J = 6.1 Hz, 3H), 1.01 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 160.5, 134.5, 128.5, 123.8, 117.1, 115.9, 101.9, 76.7, 
28.9, 18.9, 9.5, 
FTIR: 2976, 2936, 2278, 1444, 1220 1070 cm-1 
HRMS (EI+): Calculated: 253.0102; observed: 253.0102 




















Prepared according to general procedure E on 0.5 mmol-scale and obtained in 72% (0.0787 
g) and 82% (0.0903g) isolated yields (77% average of two runs). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.06 (t, J = 1.2 Hz, 1H), 6.98 (d, J = 1.9 Hz, 2H), 
4.50-4.43 (m, 1H), 1.67-1.49 (m, 2H), 1.19 (d, J = 6.0 Hz, 3H), 0.88 (t, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.4, 135.3, 120.6, 114.6, 75.5, 29.0, 19.0, 9.6 
FTIR: 2976 2936 1588 1444 1230 1090 cm-1 
HRMS (EI+): Calculated: 218.0265; observed: 218.0207 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 68% 
(0.0700g) and 77% (0.078g) isolated yields (72% average of two runs).  This compound is 
commercially available, CAS: 1548170-27-9 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.01 (t, J = 3.7 Hz, 1H), 6.92-6.90 (m, 1H), 6.75-
6.71 (m, 1H), 4.22-4.15 (m, 1H), 1.73-1.55 (m, 2H), 1.27 (d, J = 6.0 Hz, 3H), 0.96 (t, J = 
7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 154.4 (d, JC-F = 2.1 Hz), 152.5 (d, JC-F = 241.1 Hz), 
121.0 (d, JC-F = 20.4 Hz), 117.7, 116.7 (d, JC-F = 22.1 Hz), 115.6 (d, JC-F = 6.7 Hz), 76.3, 
29.0, 19.0, 9.7 
19F NMR (377 MHz, CDCl3): δ (ppm) -111.31 






Prepared according to general procedure E on 0.5 mmol-scale and obtained 79% (0.0835g) 
and 84% (0.0874g) isolated yields (81% average of two runs). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.45 (d, J = 2.8  Hz, 1H), 7.35 (d, J = 8.4  Hz, 1H), 
7.20-7.18 (dd, J = 7.4 Hz, 2.3 Hz, 1H),  4.48-4.10 (m, 1H), 2.39 (s, 3H), 1.70-1.51 (m, 
2H),1.21 (d, J = 6.3  Hz, 3H), 0.90 (t, J = 7.5 Hz, 3H) 
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13C NMR (100 MHz, CDCl3): δ (ppm) 156.7, 149.4, 133.4, 125.1, 121.4, 111.1, 75.8, 
29.0, 19.7, 19.0, 9.6 
 FTIR: 2970, 2934, 1710, 1626, 1527, 1243, 1024 cm-1 
HRMS (EI+): Calculated: 209.1051; observed: 209.1053 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 70% 
(0.0702g) and 1.0 mmole and obtained in 65% (0.1321g) isolated yields (67% average of 
two runs). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.09 (d, J = 8.6 Hz, 1H), 6.91 (d, J = 2.6 Hz, 1H), 
6.72-6.69 (dd, J = 5.6 Hz, 2.0 Hz, 1H), 4.25-4.21 (m, 1H), 2.29 (s, 3H), 1.76-1.56 (m, 2H), 
1.26 (d, J = 6.0 Hz, 3H), 0.97 (t, J = 7.5 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 156.9, 134.5, 131.1, 127.6, 116.5, 114.6, 75.5, 
29.1, 19.1, 19.0, 9.74   
FTIR: 2975, 2935, 1609, 1493, 1240 1040 cm-1 






Prepared according to general procedure F on 0.35 mmol-scale and obtained in 67% 
(0.0508g) isolated yield.   
1H NMR (400 MHz, CDCl3): δ (ppm) 7.02 (d, J = 9.1 Hz 1H), 6.99 (d, J = 3.0 Hz, 1H), 
6.87-6.84 (dd, J = 6.0 Hz, 2.1 Hz, 1H), 4.30-4.23 (m, 1H), 3.77 (s, 3H), 1.65-1.46 (m, 2H), 
1.17 (d, J = 6.0 Hz, 3H), 0.89 (t, J = 7.8 Hz, 3H) 
13C NMR (100 MHz, DMSO): δ (ppm) 156.6, 135.5, 131.5, 126.7, 115.9, 114.6, 74.5, 
28.4, 18.3, 18.5, 9.3 
FTIR: 2973, 2936, 2838, 1497, 1272, 1211, 1059 
HRMS (EI+): Calculated: 214.0760; observed: 214.0762 














Prepared according to general procedure E on 0.5 mmol-scale and obtained in 77% 
(0.073g) and 71% (0.0666g) isolated yields (74% average of two runs).  Spectroscopic data 
was consistent with that previously reported.94  
1H NMR (400 MHz, CDCl3): δ (ppm) 7.13 (t, J = 5.2 Hz, 1H), 7.08-7.04 (m, 2H) 6.83-
6.80 (m, 1H) 3.70 (s, 3H)  
13C NMR (100 MHz, CDCl3): δ (ppm) 160.3, 130.5, 123.7, 122.8, 117.1, 113.0, 55.4 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 78% 
(0.0837g) and 77% (0.0774g) isolated yields (77% average of two runs).  Spectroscopic 
data was consistent with that previously reported.95 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.11 (t, J = 16.1 Hz, 1H), 7.06-7.03 (m, 2H), 6.82-
6.79 (m, 1H) 4.01-3.96 (q, J = 7.0 Hz, 2H) 1.39 (t, J = 7.0 Hz, 3H)   
13C NMR (100 MHz, CDCl3): δ (ppm) 159.7, 130.4, 123.5, 122.7, 117.6, 113.5, 63.6, 14.7 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 77% 
(0.084g) and 81% (0.0881g) isolated yields (79% average of two runs).  This compound is 
commercially available, CAS: 149557-17-5. 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.10 (t, J = 8.3 Hz, 1H), 7.05-7.03 (m, 2H), 6.82-
6.80 (m, 1H) 3.87 (t, J = 6.6 Hz, 2H) 1.89-1.73 (m, 2H) 1.01 (t, J = 7.4 Hz, 3H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.9, 130.4, 123.5, 122.7, 117.7, 113.5, 69.7, 
22.4, 10.4 













Prepared according to general procedure E on 0.5 mmol-scale and obtained in 81% 
(0.087g) and 86% (0.0933g) isolated yields (83% average of two runs). Spectroscopic data 
was consistent with that previously reported96 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.10 (t, J = 8.3 Hz, 1H), 7.05-7.02 (m, 2H) 6.81-
6.78 (m, 1H) 4.54-4.45 (septet, J = 6.23 Hz, 1H) 1.31 (d, J = 6.24 Hz, 6H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 158.7, 130.5, 123.5, 122.7, 119.0, 114.7, 70.2, 21.9 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 65% 
(0.0832g) and 65% (0.0832g) isolated yields (65% average of two runs).  This compound 
is commercially available, CAS: 888327-41-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.21-7.18 (m, 2H), 7.12-7.11 (m, 1H) 6.91-6.86 (m, 
1H), 4.36-4.30 (m, 2H)  
13C NMR (100 MHz, CDCl3): 157.9, 130.8, 127.9, 125.7, 123.0, 123.8 (q, J = 277.8 Hz), 
118.4, 65.9 (q, J = 35.6 Hz),  
19F NMR (377 MHz, CDCl3): δ (ppm) -73.94 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 44% 
(0.0463g) and 45% (0.0474g) isolated yields (44% average of two runs). 
1H NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 8.2, 2.2 Hz, 1H), 7.82 (t, J = 2.2 Hz, 1H), 
7.41 (t, J = 8.2 Hz, 1H), 7.33 – 7.27 (m, 1H), 1.79 – 1.65 (m, 2H), 1.33 (s, 6H), 1.02 (t, J 
= 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3):  δ 156.5, 148.7, 129.7, 129.4, 118.0, 117.7, 82.6, 34.5, 
26.0, 8.5. 
FTIR: 2970, 2934, 1710,  1243, 1026 m-1 
HRMS (EI+): Calculated : 209.1051; observed: 209.1048 
Rf : 0.32 in 10% Ether/ Hexane 
 







Prepared according to general procedure E on 0.5 mmol-scale and obtained in 69% 
(0.0625g) and 74% (0.0670g) isolated yields (72% average of two runs).  This compound 
is commercially available, CAS: 1344108-50-4. 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.20-7.14 (m, 1H), 6.64-6.55 (m, 3H), 4.73-4.68 
(m, 1H), 1.93-1.73 (m, 6H) 1.66-1.55 (m, 2H)  
13C NMR (100 MHz, CDCl3): δ (ppm) 163.6 (d, JC-F=245.2 Hz), 159.5 (d, JC-F= 10.8 Hz), 
130.0 (d, JC-F=10.3 Hz), 111.3 (d, JC-F=2.8 Hz), 106.9 (d, JC-F=21.9), 103.0 (d, JC-F=24.2 
Hz), 79.7, 32.7, 24.0 
19F NMR (377 MHz, CDCl3): δ (ppm) -111.98  






Prepared according to general procedure E on 0.5 mmol-scale and obtained 78% (0.1136g) 
and 86% (0.1227g) isolated yields (82% average of two runs). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.57-7.42 (m, 4H), 7.25-7.19 (m, 1H), 6.70-6.60 
(m, 3H) 4.18 (t, J = 6.8 Hz, 2H) 13.16 (t, J = 6.7 Hz, 2H) 
13C NMR (100 MHz, CDCl3):  δ (ppm) 163.6 (d, JC-F = 245.6 Hz), 159.5 (d, JC-F = 10.3 
Hz), 139.1, 132.4 (d, JC-F = 1.4 Hz), 130.8 (q, J = 31.8 Hz), 130.2 (d, JC-F = 9.5 Hz), 128.9, 
125.7 (q, JC-F = 3.7 Hz), 124.3 (q, JC-F = 274.3 H), 123.4 (q, JC-F = 3.6 Hz),  110.3 (d, JC-F 
= 3.1 Hz), 107.6 (d, JC-F = 21.2 Hz), 102.3 (d, JC-F = 24.7 Hz), 68.3, 35.4 
19F NMR (377 MHz, CDCl3): δ (ppm) -111.59, -62.60 
FTIR:  3086, 2961, 2936, 2867, 1607, 1488, 1124, 1066 cm-1 
HRMS (EI+): Calculated: 284.0824; observed: 284.0822 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 76% 
(0.086g) and 78% (0.090g) isolated yields (77% average of two runs).  This compound is 
commercially available, CAS: 1477672-83-5. 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.22-7.14 (m, 2H), 6.95-6.89 (m, 2H), 6.69-6.59 
(m, 3H), 4.15 (t, J = 6.6 Hz, 2H), 3.29 (t, J = 6.7 Hz, 2H)  
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13C NMR (100 MHz, CDCl3):  163.7 (d, JC-F = 252.8 Hz), 159.9 (d, JC-F = 11.4 Hz), 140.0 
130.2 (d, JC-F =10.3 Hz), 126.8, 125.5, 124.0, 110.3 (d, JC-F = 2.4 Hz), 107.6 (d, JC-F = 21.5 
Hz), 102.3 (d, JC-F = 25.0 Hz), 68.6, 29.8  
19F NMR (377 MHz, CDCl3): δ (ppm) -111.63 






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 77% 
(0.0804g) and 79% (0.080g) isolated yields (78% average of two runs).  Spectroscopic data 
was consistent with that previously reported.97 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.41-7.28 (m, 5H), 7.22-7.16 (m, 1H), 6.75-6.62 
(m, 3H), 5.00 (s, 2H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 163.7 (d, JC-F = 246.4 Hz), 160.1 (d, JC-F = 10.5 
Hz), 136.4, 130.2 (d, 1C, JC-F = 10.3 Hz), 128.6, 128.1, 127.4, 110.6 (d, JC-F = 2.8 Hz), 
107.7 (d, JC-F = 22.4 Hz), 102.6 (d, JC-F = 24.7 Hz), 70.2. 
19F NMR (377 MHz, CDCl3): δ (ppm) -111.50 





Prepared according to general procedure E on 0.5 mmol-scale and obtained in 73% 
(0.112g) and 67% (0.0996g) isolated yields (70% average of two runs). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.41-7.38 (m, 2H), 7.34-7.23 (m, 4H), 6.89-6.86 
(dd, J = 6.4 Hz, 2.1 Hz, 1H) 6.83-6.81(m, 2H), 6.73 (d, J = 15.9 Hz, 1H), 6.41-6.34 (m, 
1H), 4.68-4.67 (dd, J = 7.6 Hz, 3.2Hz, 2H) 
13C NMR (100 MHz, CDCl3): δ (ppm) 159.6, 150.1 (d, JC-F =1.4 Hz), 136.2, 133.5, 130.2, 
128.6, 128.0, 126.6, 123.6, 123.7, 120.5 (q, J = 258.2 Hz), 113.1 (d, JC-F= 7.02 Hz), 107.9, 
68.9 
19F NMR (377 MHz, CDCl3): δ (ppm) – 57.71  
FTIR: 3028, 2936, 1610 1490 1259 1142 cm-1  
HRMS (EI+): Calculated: 294.0867; observed: 294.0862 
MP (DCM/Et2O): 38.6 – 39.8 °C 
Rf : 0.27 in 100% hexane 
Compound 1.39 
 





Prepared according to general procedure E on 0.5 mmol-scale and obtained in 50% 
(0.087g) and 53% (0.0955g) isolated yields (51% average of two runs). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.12-7.06 (m, 3H), 6.85 (br, 1H), 4.13- 4.08 (b, 
2H), 3.83 (b, 1H), 3.37 (br, 2H), 1.99-1.82 (m, 4H), 1.469 (s, 1H)  
13C NMR (100 MHz, CDCl3): δ (ppm) 159.6, 154.5, 130.5, 123.8, 122.7, 118.0, 113.3, 
79.6, 68.3, 55.8, 46.7, 28.5, 28.4, 23.4 
FTIR: 2970, 2937, 1691, 1590, 1476, 1392, 1167, 1034 cm-1 
HRMS (ESI+): Calculated for C16H22BrNNaO3
+ [M+Na]+: 378.0675; observed: 378.0675  






Prepared according to general procedure E on 0.5 mmol-scale and obtained in 68% 
(0.0618g) and 71% (0.0665g) isolated yields (69% average of two runs). Spectroscopic 
data was consistent with that previously reported. 98 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.33 (t, J = 8.0 Hz, 2H), 7.24-7.20 (m, 1H), 7.12 (t, 
J = 7.4 Hz, 1H), 7.02-7.00 (dd, J = 8.7, 1.2 Hz, 2H), 6.78-6.73 (m, 2H), 6.69-6.65 (m, 1H)  
13C NMR (100 MHz, CDCl3): δ (ppm) ) 163.4 (d, JC-F = 246.2 Hz), 158.9 (d, JC-F = 10.4 
Hz), 156.2, 130.4 (d, JC-F  = 9.6 Hz), 129.9, 124.0, 119.5, 113.9 (d, JC-F = 3.9 Hz), 109.9 (d, 
JC-F = 21.0), 105.9 (d, JC-F = 24.8 Hz).  
19F NMR (377 MHz, CDCl3): δ (ppm) -110.99 





Prepared according to general procedure E on 0.5 mmol-scale and obtained in 56% 
(0.071g) and 57% (0.0722g) isolated yields (56% average of two runs). Spectroscopic data 
was consistent with that previously reported.99 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.37 (t, J = 8.0 Hz, 2H), 7.24-7.14 (m, 4H), 7.05-
7.02 (dd, J = 8.5, 0.9 Hz, 2H), 6.96-6.93 (m, 1H)  
13C NMR (100 MHz, CDCl3): δ (ppm) 158.3, 156.2, 130.7, 129.9, 126.0, 123.9, 122.8, 
121.6, 119.3, 117.1  
Rf : 0.42 in 100% Hexane 
 
 







Prepared according to the general procedure above on a 0.51 mmol scale and obtained in 
45% (0.059 g) isolated yield as a colorless oil. Spectroscopic data were consistent with 
those previously reported.100 
1H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 8.41 (d, J = 1.9 Hz, 1H), 7.80 (d, J = 8.0 
Hz, 2H), 7.47 (dd, J = 7.9, 2.3 Hz, 1H), 7.27 (s, 1H), 7.19 (d, J = 7.9 Hz, 1H), 7.0 (d, J = 
8.2 Hz, 2H), 4.44 (t, J = 6.5 Hz, 2H), 3.27 (t, J = 6.7 Hz, 2H), 2.64 (q, J = 7.6 Hz, 2H), 
1.25 (t, J = 9.4, 3H).  
13C NMR (101 MHz, CDCl3): δ (ppm) 190.8, 163.9, 155.0, 149.0, 137.3, 136.0, 131.9, 
129.9, 123.4, 114.8, 67.6, 37.2, 25.7, 15.3. 
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5.4: Synthesis and Characterization of aryl(TMP)iodonium salts 
 
5.4.1: General procedure to synthesize diaryliodonium tosylates A101 
Literature procedure cited was followed to make the diaryliodonium tosylate salts with a 
slight modification. Oxidation was performed at room temperature instead of 78 oC and the 
temperature was slowly increased to 55 oC until the reaction turned clear.  
 
5.4.2: General procedure to synthesize diaryliodonium trifluoroacetates B102  
Literature procedure cited was followed to make the diaryliodonium trifluoroacetate salts. 




Prepared according to the general procedure A on 5.0 mmol scale and obtained in 65% 
yield (2.04 g).101 
Compound 1.43 - Br 
 
Prepared according to the ion exchange method described in the literature101 on 2.5 mmol 
and obtained in 96% yield (1.28 g). 
Compound 1.43- OTf 
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Prepared according to the ion exchange method described in the literature101 on 1.0 mmol 
and obtained in 85% yield (0.511 g). 
 
Compound 1.43 – BF4 
 
Prepared according to the ion exchange method described in the literature101 on 1.0 mmol 
and obtained in 72% yield (0.388 g). 
Compound 1.43 - TFA 
 
Prepared according to the ion exchange method described in the literature101 on 1.0 mmol 
and obtained in 86% yield (0.481 g). 
Compound 1.43 - Mes 
 
 
Prepared according to the general procedure A on 3.0 mmol scale using mesitylene 
instead of TMB and obtained in 78% isolated yield (1.72 g). 
Spectral data were consistent with previously reported compound48 
Compound 1.43 - anisole 
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Prepared according to the general procedure A on 2.0 mmol scale using anisole instead of 
TMB and obtained in 54% yield (0.602 g). 
Melting point (Ethyl acetate/Et2O):  143.2 – 144.6 °C 
1H NMR (400 MHz, DMSO) δ 8.25 (dd, J = 22.3, 8.7 Hz, 4H), 7.79 (d, J = 8.5 Hz, 2H), 
7.69 (d, J = 7.4 Hz, 2H), 7.55 – 7.37 (m, 5H), 7.10 (dd, J = 12.5, 8.5 Hz, 4H), 3.80 (s, 
3H), 2.28 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 162.4, 146.1, 143.9, 138.6, 138.1, 137.8, 135.9, 130.1, 
129.6, 129.1, 128.5, 127.5, 126.0, 117.9, 116.0, 106.1, 56.2, 21.3. 
FTIR: 3091, 3051, 3040, 2962, 2901, 2859, 2840, 1395, 1254, 1181, 815  cm-1 
HRMS (ESI+) m/z: [M − OTs]+: Calculated: 387.0240 Observed: 387.0248 
 
Compound 1.43 - thienyl 
 
Prepared according to the general procedure A on 2.0 mmol scale using thiophene instead 
of TMB and obtained in 79% yield (0.842 g). 
Melting point (Ethyl acetate/Et2O): 152.2 – 153.1 °C 
1H NMR (400 MHz, DMSO) δ 8.33 (d, J = 8.5 Hz, 2H), 8.12 (d, J = 3.1 Hz, 1H), 7.99 
(d, J = 4.8 Hz, 1H), 7.81 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 7.4 Hz, 2H), 7.55 – 7.39 (m, 
5H), 7.20 (dd, J = 5.1, 4.0 Hz, 1H), 7.11 (d, J = 7.9 Hz, 2H), 2.28 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 146.1, 144.1, 140.9, 138.5, 138.1, 137.8, 135.7, 130.2, 
130.1, 129.6, 129.1, 128.5, 127.6, 126.0, 118.3, 101.4, 21.3. 
FTIR: 3092, 3060, 2962, 2922, 2867, 1652, 1392, 1214, 1190, 1022, 811 cm-1 




Prepared according to the general procedure 2 on 3.03 mmol scale and obtained 84% 
yield (1.427 g).2 
Melting point (Ethyl acetate/Et2O): 159.0 – 160.8 °C 
1H NMR (400 MHz, DMSO) δ 8.33 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.60 – 
7.39 (m, 7H), 6.29 (s, 2H), 3.82 (s, 3H), 3.66 (s, 6H). 
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13C NMR (101 MHz, DMSO) δ = 166.3, 159.7, 145.1, 141.5, 138.6, 132.8, 131.7, 130.4, 
129.7, 128.9, 128.8, 119.9, 119.3, 116.3, 92.0, 57.3, 56.5. 
19F NMR (376 MHz, DMSO) δ = -73.4. 
FTIR: 3065, 2937, 2836, 1683, 1423, 1344, 1242, 1198, 1122, 828, 799, 719 cm-1 





Prepared according to the general procedure B on 1.0 mmol scale and converted to TFA 
salt using ion exchange method and obtained in 87% yield (0.500 g) 
Melting point (MeCN/Et2O): 150.9 – 152.5 °C 
1H NMR (400 MHz, DMSO) δ 7.49 (d, J = 7.7 Hz, 3H), 7.40 (dt, J = 16.0, 7.9 Hz, 2H), 
7.17 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 7.9 Hz, 2H), 6.48 (s, 2H), 3.96 (s, 6H), 3.88 (s, 3H), 
3.78 (s, 3H), 2.29 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.7, 160.7, 159.9, 138.1, 132.7, 128.5, 126.4, 125.9, 
120.0, 117.6, 116.5, 92.5, 57.8, 56.6, 56.2, 21.2. 
FTIR: 3082, 3020, 2938, 2901, 1630, 1567, 1331, 1220, 1177, 1032, cm-1 
HRMS (ESI+) m/z: [M − OTs]+: Calculated: 401.0244; observed: 401.0249 
Compound 1.46 
 
Prepared according to the general procedure B on 3.0 mmol scale and obtained in 80% 
yield (1.295 g). 
Melting point (Ethyl acetate/Et2O): 159.8 – 162.6 °C 
1H NMR (400 MHz, DMSO) δ 8.21 (d, J = 1.8 Hz, 1H), 7.71 (dd, J = 8.2, 1.8 Hz, 1H), 
7.53 – 7.41 (m, 3H), 7.10 (d, J = 7.9 Hz, 2H), 6.45 (s, 2H), 3.95 (s, 6H), 3.85 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.5, 159.7, 146.1, 140.3, 138.9, 138.1, 135.4, 133.1, 
128.5, 125.9, 122.3, 120.0, 107.5, 92.6, 57.7, 56.6. 
19F NMR (376 MHz, DMSO) δ = -73.4.  
FTIR: 3048, 3014, 2959, 2839, 1679, 1583, 1341, 11570, 1124, 826, 718 cm-1 
HRMS (ESI+) m/z: [M − TFA]+: Calculated: 421.0295; observed: 421.0292 
 
 







Prepared according to the general procedure B on 1.0 mmol scale and converted to OTs 
salt with ion exchange method obtained in 62% yield (0.3748) 
Melting point (Ethyl acetate/Et2O): 159.0 – 160.8 
oC 
1H NMR (400 MHz, DMSO) δ 8.49 (d, J = 7.1 Hz, 1H), 8.23 (m, 2H), 8.03 (d, J = 7.9 
Hz, 1H), 7.85 (t, J = 7.3 Hz, 1H), 7.70 (t, J = 7.2 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.48 
(d, J = 7.5 Hz, 2H), 7.10 (d, J = 7.3 Hz, 2H), 6.39 (s, 2H), 3.96 (s, 6H), 3.80 (s, 3H), 2.28 
(s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.4, 159.8, 156.4, 154.0, 142.2, 137.1, 134.2, 130.4, 
129.4, 127.9, 123.5, 123.4, 121.6, 114.8, 92.5, 88.0, 57.7, 56.6, 47.7, 26.8. 
FTIR: 3087, 3058,2962, 2871, 1642, 1586, 1468, 1332, 1209, 1033, 816, 765 cm-1 






Prepared according to the general procedure A on 10.0 mmol scale and obtained in 90% 
yield (5.041 g) 
Melting point (Ethyl acetate/Et2O): 177.2 – 179.1 °C 
1H NMR (400 MHz, DMSO) δ 8.06 (d, J = 8.0 Hz, 1H), 7.56 – 7.40 (m, 4H), 7.22 (td, J 
= 7.1, 5.9, 3.2 Hz, 1H), 7.10 (d, J = 7.9 Hz, 2H), 6.44 (s, 2H), 3.95 (s, 6H), 3.85 (s, 3H), 
2.60 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.4, 159.8, 146.3, 140.9, 138.0, 137.6, 132.8, 131.5, 
129.3, 128.5, 125.9, 121.8, 92.5, 87.1, 57.7, 56.6, 25.3, 21.2. 
FTIR: 3023, 1642, 1585, 1458, 1414, 1207, 1185, 1035, 816 cm-1 













Prepared according to the general procedure A on 5.0 mmol scale and obtained in 94% 
yield (2.649 g) 
Melting point (Ethyl acetate/Et2O): 172.6 – 173.8 °C 
1H NMR (400 MHz, DMSO) δ 7.78 (s, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 8.0 
Hz, 2H), 7.41 (d, J = 7.6 Hz, 1H), 7.35 (t, J = 7.7 Hz, 1H), 7.11 (d, J = 8.0 Hz, 2H), 6.47 
(s, 2H), 3.96 (s, 5H), 3.87 (s, 3H), 2.32 (s, 3H), 2.29 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.6, 159.9, 146.2, 141.9, 138.1, 134.9, 132.7, 131.9, 
131.7, 128.5, 126.0, 116.4, 92.5, 87.4, 57.8, 56.6, 21.2, 21.2. 
FTIR: 3028, 1645, 1584, 1459, 1415, 1206, 1189, 1035, 817 cm-1 
HRMS (ESI+) m/z: [M − OTs]+: Calculated: 385.0295 ; observed: 385.0298 
Compound 1.50 
 
Prepared according to the general procedure A on 4.0 mmol scale and obtained in 76% 
yield (1.94 g) 
Melting point (Ethyl acetate/Et2O) 182.5 – 183.4 °C 
1H NMR (400 MHz, DMSO) δ 8.22 (d, J = 1.9 Hz, 1H), 7.73 (dd, J = 8.2, 1.9 Hz, 1H), 
7.48 (t, J = 7.5 Hz, 3H), 7.11 (d, J = 7.9 Hz, 2H), 6.46 (s, 2H), 3.96 (s, 6H), 3.86 (s, 3H), 
2.55 (s, 3H), 2.29 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.6, 159.8, 146.1, 140.3, 138.9, 138.1, 135.4, 133.1, 
128.5, 125.9, 122.3, 120.0, 92.6, 87.3, 57.7, 56.6, 24.7, 21.3. 
FTIR: 3026, 1641, 1589, 1457, 1413, 1210, 1189, 1037, 815 cm-1 
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Prepared according to the general procedure B on 1.0 mmol scale and converted to OTs 
salt with ion exchange method and obtained in 71% yield (0.454 g) 
Melting point (MeCN/Et2O): 177.2 – 177.9 
oC 
1H NMR (400 MHz, DMSO) δ 8.47 (d, J = 7.4 Hz, 1H), 8.22 (dd, J = 13.4, 8.4 Hz, 2H), 
8.03 (d, J = 8.1 Hz, 1H), 7.84 (t, J = 7.6 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.56 (t, J = 7.8 
Hz, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 7.9 Hz, 2H), 6.39 (s, 2H), 3.95 (s, 6H), 
3.80 (s, 3H), 3.33 (s, 6H), 2.28 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.5, 159.8, 156.4, 154.0, 146.3, 142.2, 138.0, 137.1, 
134.3, 130.4, 129.5, 128.5, 127.9, 126.0, 123.6, 123.4, 121.7, 114.7, 92.5, 57.7, 56.6, 
47.7, 26.8, 21.2.  
FTIR: 3023, 1642, 1585, 1458, 1414, 1207, 1185, 1035, 816 cm-1 




Prepared according to the general procedure B on 3.0 mmol scale and obtained in 78% 
yield (1.261 g) 
1H NMR (400 MHz, DMSO) δ 7.92 (d, J = 8.9 Hz, 2H), 7.45 (t, J = 7.9 Hz, 2H), 7.25 (t, 
J = 7.4 Hz, 1H), 7.09 (d, J = 8.0 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 6.47 (s, 2H), 3.96 (s, 
6H), 3.88 (s, 3H). 
13C NMR (101 MHz, DMSO) δ = 166.5, 160.3, 158.3, (q, JC-F = 30.9 Hz), 159.8, 155.1, 
137.2, 130.9, 125.5, 120.6, 120.5, 117.9 (q, JC-F = 301.0 Hz), 108.3, 92.5, 88.2, 57.7, 
56.6. 
19F NMR (376 MHz, DMSO) δ = -73.4. 
FTIR: 3066, 2947, 2846, 1680, 1583, 1479, 1413, 1345, 1243, 1198, 1124, 826, 797, 718  
cm-1 
HRMS (ESI+) m/z: [M − OTs]+: Calculated: 463.0400 ; observed: 463.0401 
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5.4.3: General procedure C; Synthesis of alkyl-aryl ethers 
 
Sodium hydride (60 wt% dispersion in mineral oil) (0.060g, 1.5 mmol, 3.0 equiv.) was 
weighed out to air and transferred to an oven-dried vial equipped with a magnetic stir bar.  
The vial was sealed with a cap and Teflon-lined septa and purged with nitrogen.  Toluene 
(2.5 mL) was added to the vial followed by the addition of alcohol (3.0 equiv.). The reaction 
was stirred for 30 mins at room temperature.  Diaryliodonium salts (0.5 mmol, 1 equiv.) 
was transferred at once into the reaction vial after 30 mins.  The vial was sealed with a 
solid cap and placed into a pre-heated (55 °C) aluminum block for 2 hours.  The reaction 
was then removed from the heat and quenched with 2.5 mL of a saturated solution of 
ammonium chloride. The biphasic mixture was extracted with DCM (3 x 5 mL).  This 
combined DCM extracts were dried using MgSO4 and the solvent removed on a rotary 
evaporator.  The crude residue was purified by flash column chromatography on silica gel 
(see below for specific eluent composition). 
Compound 1.53 
 
Prepared according to General procedure C on 0.5 mmol-scale and obtained in 81% 
(0.0918 g) isolated yield. 
Spectral data matches to the previously reported compound102 
1H NMR (400 MHz, CDCl3) δ 7.54-7.48 (m, 4H), 7.41 - 7.37 (m, 2H), 7.29 – 7.25 (m, 
1H), 6.96 – 6.94 (m, 2H), 3.97 (t, J = 6.5 Hz, 2H), 1.84 – 1.69 (m, 2H), 1.50 (h, J = 7.4 
Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.8, 140.9, 133.4, 128.7, 128.1, 126.7, 126.5, 116.1, 











Prepared according to General procedure C on 0.49 mmol-scale and obtained in 71% 
(0.0818 g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 7.2 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.35 – 
7.23 (m, 3H), 7.02 - 6.95 (m, 2H), 3.94 (t, J = 6.4 Hz, 2H), 1.74 – 1.61 (m, 2H), 1.46 – 
1.33 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 156.0, 138.6, 130.9, 130.8, 129.6, 128.5, 127.8, 126.7, 
120.7, 112.5, 68.1, 31.2, 19.3, 13.8. 
FTIR: 3060, 2958, 2933, 2871, 1596, 1483, 1433, 1261, 1235, 1125, 1070, 752, 731 cm-1 
HRMS (ESI+): Calculated: 227.1430; observed: 227.1434  





Prepared according to General procedure C on 0.5 mmol-scale and obtained in 79% 
(0.0717 g) isolated yield.  Regioisomers are observed in 5:1 ratio. 
Spectral data matches to the previously reported compound. 103 
1H NMR (400 MHz, CDCl3) δ 7.17 (t, J = 8.1 Hz, 1H), 6.55 – 6.40 (m, 3H), 3.94 (t, J = 
6.5 Hz, 2H), 3.79 (s, 3H), 1.81 – 1.69 (m, 2H), 1.54 – 1.42 (m, 2H), 0.97 (t, J = 7.3 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ = 160.8, 160.4, 129.8, 106.7, 106.1, 100.9, 67.7, 55.2, 






Prepared according to General procedure C on 0.5 mmol-scale and obtained in 70% 
(0.0707 g) isolated yield.   
Regioisomers are observed in 20:1:1 ratio. 
Spectral data matches to the previously reported compound.104 
1H NMR (400 MHz, CDCl3) δ 7.78 – 7.66 (m, 3H), 7.41 (t, J = 7.5 Hz, 1H), 7.30 (t, J = 
7.4 Hz, 1H), 7.15 – 7.11 (m, 2H), 4.05 (t, J = 6.5 Hz, 2H), 1.85 – 1.78 (m, 2H), 1.55 – 
1.50 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.1, 134.6, 129.3, 128.9, 127.6, 126.7, 126.2, 123.4, 
119.0, 106.5, 67.7, 31.3, 19.3, 13.9. 







Prepared according to General procedure C on 0.5 mmol-scale and obtained in 70% 
(0.0706 g) isolated yield.  
Spectral data matches to the previously reported compound. 106 
1H NMR (400 MHz, CDCl3) δ 8.35 – 8.22 (m, 1H), 7.82 – 7.71 (m, 1H), 7.51 – 7.27 (m, 
4H), 6.77 (d, J = 7.4 Hz, 1H), 4.10 (t, J = 6.4 Hz, 2H), 1.94 – 1.83 (m, 2H), 1.63 - 1.53 
(m, 2H), 1.01 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 154.9, 134.5, 127.4, 126.3, 125.9, 125.8, 125.0, 122.1, 





Prepared according to General procedure C on 0.5 mmol-scale and obtained in 50% (0.042 
g) isolated yield.   
Spectral data matches to the previously reported compound.107 
1H NMR (400 MHz, CDCl3) δ 7.15 - 7.11 (m, 2H), 6.87 – 6.77 (m, 2H), 3.96 (t, J = 6.4 
Hz, 2H), 2.22 (s, 3H), 1.83 – 1.71 (m, 2H), 1.58 – 1.42 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.2, 130.5, 126.8, 126.7, 120.0, 110.9, 67.6, 31.5, 




Prepared according to General procedure C on 0.46 mmol-scale and obtained in 60% 
(0.046 g) isolated yield.   
Spectral data matches to the previously reported compound.108 
1H NMR (400 MHz, CDCl3) δ 7.15 (t, J = 7.7 Hz, 1H), 6.77 – 6.67 (m, 3H), 3.94 (t, J = 
6.5 Hz, 2H), 2.32 (s, 3H), 1.81 – 1.71 (m, 2H), 1.53 - 1.44 (m, 2H), 0.97 (t, J = 7.4 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ = 159.2, 139.4, 129.1, 121.3, 115.4, 111.3, 67.5, 31.4, 










Prepared according to General procedure C on 0.5 mmol-scale and obtained in 45% (0.036 
g) isolated yield.   




Prepared according to General procedure C on 0.5 mmol-scale and obtained in 82% 
(0.1005 g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 6.94 – 6.91 (m, 3H), 3.92 (t, J = 6.4 Hz, 2H), 2.15 (s, 
3H), 1.83 – 1.70 (m, 2H), 1.55 – 1.45 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.9, 131.5, 125.8, 122.8, 119.4, 114.3, 67.9, 31.3, 
19.3, 15.9, 13.9. 
FTIR: 2957, 2929, 2871, 1591, 1491, 1471, 1304, 1241, 1190, 836, 799 cm-1 
HRMS (ESI+): Calculated: 243.0379 ; observed: 243.0378 





Prepared according to General procedure C on 0.5 mmol-scale and obtained in 87% (0.101 
g) isolated yield. 
Regioisomers are observed in 6:1 ratio.   
1H NMR (400 MHz, CDCl3) δ 7.60 (t, J = 7.3 Hz, 2H), 7.38 (d, J = 7.3 Hz, 1H), 7.33 – 
7.18 (m, 2H), 6.97 (d, J = 2.2 Hz, 1H), 6.86 (dd, J = 8.3, 2.3 Hz, 1H), 4.07 – 3.94 (m, 
2H), 1.89 – 1.73 (m, 2H), 1.58 – 1.48 (m, 2H), 1.46 (s, 6H), 0.99 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 159.2, 155.4, 153.1, 139.2, 131.9, 126.9, 126.0, 122.4, 
120.7, 119.1, 112.9, 109.2, 67.9, 46.8, 31.5, 27.3, 23.8, 19.3, 13.9. 
FTIR: 2958, 2930, 2870, 1609, 1581, 1491, 1459, 1428, 1286, 1270, 1191, 1074, 757, 734 
cm-1 
HRMS (ESI+): Calculated: 267.1743 ; observed: 267.1742 









Prepared according to General procedure C on 0.5 mmol-scale and obtained in 55% 
(0.0674 g) isolated yield.   
Regioisomers are observed 10: 1 ratio 
Spectral data matches to the previously reported compound.109 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.24 (m, 2H), 6.99 – 6.83 (m, 7H), 3.94 (t, J = 6.5 
Hz, 2H), 1.82 – 1.69 (m, 2H), 1.57 – 1.44 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 158.6, 155.5, 149.9, 129.6, 122.3, 120.8, 117.5, 115.5, 




Prepared according to General procedure C on 0.5 mmol-scale and obtained in 70% 
(0.0802 g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.48 (m, 4H), 7.39 (t, J = 7.7 Hz, 2H), 7.27 (t, J = 
7.3 Hz, 1H), 6.95 (d, J = 8.7 Hz, 2H), 4.35 – 4.28 (m, 1H), 1.77 – 1.59 (m, 2H), 1.31 (d, J 
= 6.1 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.8, 140.9, 133.4, 128.7, 128.1, 126.7, 126.5, 116.1, 
75.1, 29.2, 19.3, 9.8. 
FTIR: 3030, 2971, 2933, 2876, 1607, 1517, 1485, 1433, 1267, 1244, 761, 697 cm-1 
HRMS (ESI+): Calculated: 227.1430; observed: 227.1431 






Prepared according to General procedure C on 0.5 mmol-scale and obtained in 61% (0.073 
g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 18.7, 8.1 Hz, 4H), 7.40 (t, J = 7.6 Hz, 2H), 
7.28 (t, J = 7.3 Hz, 1H), 6.93 (d, J = 8.6 Hz, 2H), 4.84 – 4.73 (m, 1H), 2.00 – 1.74 (m, 
6H), 1.70 – 1.57 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 157.7, 140.9, 133.2, 128.7, 128.0, 126.7, 126.5, 115.8, 
79.2, 32.9, 24.0. 
FTIR: 3030, 2963, 2871, 1604, 1581, 1487, 1269, 1247, 1169, 984, 831, 759, 689 cm-1 
HRMS (ESI+): Calculated: 239.1430; observed: 239.1424 
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Rf: 0.42 in 2% Ether/ Hexane 






Prepared according to General procedure C on 0.5 mmol-scale and obtained in 81% 
(0.0967 g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.58 – 7.47 (m, 4H), 7.38 (t, J = 7.7 Hz, 2H), 7.27 (t, J = 
7.2 Hz, 1H), 6.95 (d, J = 8.6 Hz, 2H), 3.93 (d, J = 6.7 Hz, 2H), 2.80 – 2.73 (m, 1H), 2.22 
– 2.07 (m, 2H), 1.99 – 1.8 (m, 4H). 
13C NMR (101 MHz, CDCl3) δ = 158.8, 140.8, 133.5, 128.7, 128.0, 126.7, 126.6, 114.8, 
72.1, 34.6, 24.9, 18.6. 
FTIR: 3031, 2972, 2935, 2864, 1605, 1522, 1488, 1253, 1024, 816, 762, 689 cm-1 
HRMS (ESI+): Calculated: 239.1430 ; observed: 239.1423 
Rf: 0.42 in 2% Ether/ Hexane 







Prepared according to General procedure C on 0.5 mmol-scale and obtained in 61% (0.094 
g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.48 (m, 4H), 7.40 (t, J = 7.7 Hz, 2H), 7.28 (t, J = 
7.4 Hz, 1H), 6.96 (d, J = 8.6 Hz, 2H), 4.09 – 4.03 (m, 1H), 2.30 – 2.14 (m, 2H), 1.81 – 
1.65 (m, 2H), 1.59 – 1.40 (m, 2H), 1.17 – 0.98 (m, 2H), 0.93 (t, J = 6.5 Hz, 7H), 0.79 (d, 
J = 7.0 Hz, 3H). Overlapping signals 
13C NMR (101 MHz, CDCl3) δ = 157.9, 140.9, 133.4, 128.7, 128.2, 126.7, 126.5, 116.0, 
77.5, 48.1, 40.3, 34.5, 31.4, 26.1, 23.7, 22.1, 20.8, 16.6. 
FTIR: 2957, 2920, 2865, 1604, 1582, 1468, 1265, 1245, 835, 762, 713 cm-1 
HRMS (ESI+): Calculated: 309.2213 ; observed: 309.2216  
Rf: 0.38 in 2% Ether/ Hexane 
Melting point (CDCl3): 126.8 – 127.2 
oC 
 







Prepared according to General procedure C on 0.5 mmol-scale and obtained in 63% (0.089 
g) isolated yield.   
Spectral data matches to the previously reported compound109 
1H NMR (400 MHz, CDCl3) δ 7.55 – 7.48 (m, 4H), 7.39 (t, J = 7.7 Hz, 2H), 7.28 (t, J = 
7.2 Hz, 1H), 6.96 (d, J = 8.6 Hz, 2H), 4.30 – 4.24 (m, 1H), 2.08 – 1.91 (m, 2H), 1.87 – 
1.72 (m, 2H), 1.62 – 1.47 (m, 3H), 1.45 – 1.23 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.3, 140.9, 133.5, 128.7, 128.1, 126.7, 126.5, 116.2, 






Prepared according to General procedure C on 0.5 mmol-scale and obtained in 86% 
(0.1091 g) isolated yield.   
Spectral data matches to the previously reported compound 110 
1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.4 Hz, 4H), 7.41 (t, J = 7.7 Hz, 2H), 7.31 (t, 
J = 7.3 Hz, 1H), 6.99 (d, J = 8.6 Hz, 2H), 4.35 (q, JC-F = 8.1 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ = 156.9, 140.3, 135.7, 128.8, 128.4, 127.1, 126.8, 123.6 






Prepared according to General procedure C on 0.5 mmol-scale and obtained in 77% (0.109 
g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.47 (m, 4H), 7.37 (t, J = 7.7 Hz, 2H), 7.26 (t, J = 
7.3 Hz, 1H), 7.13 (d, J = 5.1 Hz, 1H), 6.99 – 6.86 (m, 4H), 4.17 (t, J = 6.7 Hz, 2H), 3.28 
(t, J = 6.7 Hz, 2H). 
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13C NMR (101 MHz, CDCl3) δ = 158.3, 140.9, 140.5, 134.1, 128.9, 128.3, 127.0, 
126.8(4), 126.8(1), 125.7, 124.1, 115.0, 68.6, 30.1. 
FTIR: 3060, 2952, 2871, 1606, 1489, 1270, 1251, 1197, 1043, 832, 763, 693 cm-1 
HRMS (ESI+): Calculated: 281.0995 ; observed: 281.0997  
Rf: 0.46 in 5% Ether/ Hexane 





Prepared according to General procedure C on 0.5 mmol-scale and obtained in 63% 
(0.0952 g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 1.6 Hz, 1H), 7.56 – 7.35 (m, 7H), 7.28 (t, J = 
7.3 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 6.97 (d, J = 8.6 Hz, 2H), 4.38 (t, J = 6.7 Hz, 2H), 
3.25 (t, J = 6.7 Hz, 2H), 2.61 (q, J = 7.6 Hz, 2H), 1.23 (t, J = 7.6 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 158.4, 155.6, 149.0, 140.8, 137.0, 135.8, 133.7, 128.7, 
128.1, 126.7, 126.6, 123.3, 114.9, 67.4, 37.6, 25.7, 15.3. 
FTIR: 3033, 2965, 2930, 2872, 1602, 1520, 1487, 1285, 1268, 1248, 1030, 835, 763 cm-1 
HRMS (ESI+): Calculated: 304.1696 ; observed: 304.1701 
Rf:  0.19 in 30% Ethyl acetate/ Hexane 




Prepared according to General procedure C on 0.5 mmol-scale and obtained in 75% (0.105 
g) isolated yield. 
Small amount of trimethoxy benzene is present.   
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.49 (m, 4H), 7.39 (t, J = 7.7 Hz, 2H), 7.35 – 7.25 
(m, 3H), 7.19 – 7.14 (m, 2H), 7.00 (d, J = 8.7 Hz, 2H), 5.05 (s, 2H). 
13C NMR (101 MHz, CDCl3) δ 164.1, 161.7, 140.6, 139.5 (d, JC -F = 7.3 Hz), 134.2, 
130.1 (d, JC -F = 8.2 Hz), 128.7, 128.1, 126.7, 126.7, 122.6 (d, JC -F = 2.9 Hz), 115.0, 
114.7 (d, JC -F = 21.1 Hz), 114.1 (d, JC –F =22.0 Hz), 69.1. 
19F NMR (376 MHz, CDCl3) δ = -112.6. 
FTIR: 3035, 2907, 2869, 1591, 1490, 1450, 1258, 1146, 1024, 825, 757, 711 cm-1 
HRMS (ESI+): Calculated: 279.1180; observed: 279.1196 
Rf :  0.5 in 5% Ether/ Hexane 
Melting point (CDCl3): 112.5 – 113.8 
oC 






Prepared according to General procedure C on 0.5 mmol-scale and obtained in 89% (0.180 
g) isolated yield.   
1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.2 Hz, 2H), 7.53 – 7.47 (m, 4H), 7.39 (t, J = 
7.7 Hz, 2H), 7.28 (t, J = 7.3 Hz, 1H), 7.02 (d, J = 8.2 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 
4.14 (t, J = 6.8 Hz, 2H), 3.02 (t, J = 6.8 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ = 158.1, 140.7, 137.9, 137.5, 133.9, 131.0, 128.8, 128.7, 
128.1, 126.8, 126.6, 114.8, 68.2, 35.2. 
FTIR: 3021, 2943, 2921, 2868, 1680, 1583, 1483, 1249, 1201, 1030, 831, 760 cm-1 
HRMS (ESI+): Calculated: 401.0397 ; observed: 401.0398 
Rf :  0.52 5% Ether/ Hexane 
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5.5: Synthesis and Characterization of aryl(mesityl)iodonium tosylate salts. 
5.5.1: General procedure from aryl iodides101 
Aryl iodide (3.0 mmol, 1.0 equiv.) and acetonitrile (3 mL) were added to a 12 mL oven 
dried vial, equipped with a magnetic stir bar.  p-toluenesulfonic acid (3.3 mmol, 1.1 equiv.) 
was added in one portion, followed by one portion of m-CPBA (3.3 mmol, 1.1 equiv.) and 
sealed with a closed cap.  The reaction was transferred to a pre heated aluminum block set 
to 77 °C and stirred vigorously.  After 30 min, added 1,3,5-trimethylbenzene (3.3 mmol, 
1.1 equiv.) in one portion and stirring was continued at 77 °C for 3h. The reaction was 
removed from heat and concentrated under reduced pressure. The resulting crude residue 
was triturated with diethyl ether and isolated by filtration to give analytically pure 
aryl(mesityl) iodonium tosylate.  See below for the specific scale of reactions and 
characterization data of individual compounds. 
5.5.2: General procedure from arylboronic acids111 
Arylboronic acid (3.0 mmol, 1.0 equiv.) was weighed and transferred to a pear-shaped flask 
equipped with a magnetic stir bar and rubber septum. The flask was flushed with nitrogen 
and left under a static nitrogen atmosphere. DCM (30 mL) was added via syringe to the 
aryl boronic acid and the solution was cooled to ∼0 °C in an ice−water bath with stirring. 
BF3•OEt2 (1.1 mL, 9.0 mmol, 3.0 equiv.) is added via syringe to the aryl boronic acid 
solution and the reaction mixture was stirred for 10 min at 0 °C. Mesitylene iododiacetate 
(1.20 g, 3.3 mmol, 1.1 equiv) was weighed and transferred to a separate pear-shaped flask 
equipped with rubber septum. The flask was flushed with nitrogen and left under a static 
nitrogen atmosphere. DCM (9 mL) was added to the mesitylene iododiacetate. The 
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mesitylene iododiacetate solution was added to the aryl boronic acid/BF3•OEt2 solution 
dropwise via syringe at ∼0 °C. The reaction mixture was allowed to warm to ambient room 
temperature and stirred overnight. The septum was removed, and an aqueous solution of 
NaOTs (60 mmol, 20 equiv. in 30 mL of water) was added with vigorous stirring for ∼30 
min. The biphasic mixture was added to a separatory funnel, and the DCM/water layers 
separated. The water layer was extracted with DCM (3 × 30 mL). The combined DCM 
layers were dried over MgSO4, filtered, and the DCM removed on a rotovap. The crude 
residue was triturated with diethyl ether to yield analytically pure aryl(mesityl)iodonium 




Prepared according to the general procedure A on 5.0 mmol and obtained an isolated yield 
of 71% (1.8143 g) as a a white powder. 
Melting point (MeCN/Et2O): 152.3 – 154.6 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 7.85 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 
7.29 (d, J = 8.2 Hz, 2H), 7.19 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.59 (s, 6H), 2.32 (s, 3H), 
2.28 (s, 6H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.7, 142.9, 142.1, 141.4, 137.5, 134.4, 132.4, 
129.6, 128.0, 125.4, 122.7, 110.9, 26.2, 20.7, 20.7, 20.5. 
FTIR: 3023, 2921, 1455, 1173, 1120, 1032, 1008 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H18I










Prepared according to the general procedure A on 3.0 mmol and obtained an isolated yield 
of 82% (2.460 g) as a white powder. 
Melting point (MeCN/Et2O):  172.4 – 174.4 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.12 – 7.96 (m, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.37 
(t, J = 8.9 Hz, 2H), 7.21 (s, 2H), 7.11 (d, J = 7.9 Hz, 2H), 2.59 (s, 6H), 2.30 (s, 3H), 2.29 
(s, 3H).  
13C NMR (101 MHz, [D6] DMSO) δ = 163.6 (d, JC-F = 251.0 Hz), 145.3 , 143.0 , 141.3 , 
137.6 , 137.1 (d, JC-F = 9.0 Hz), 129.6 , 127.9 , 125.3 , 122.8 , 119.1 (d, JC-F = 22.8 Hz), 
108.5 (d, JC-F = 3.1 Hz), 26.1 , 20.6 , 20.4. 
19F NMR (377 MHz, CDCl3) δ = -107.8 
FTIR: 3005, 2921, 1739, 1366, 1275, 1261, 750 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15FI






Prepared according to the general procedure A on 3.0 mmol and obtained an isolated yield 
of 83% (1.440 g) as a white powder. 
Melting point (MeCN/Et2O): 150.0 – 153.7 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 7.88 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 
7.46 (d, J = 8.1 Hz, 2H), 7.21 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.58 (s, 6H), 2.30 (s, 3H), 
2.29 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.5, 143.0, 141.4, 137.5, 136.2, 134.5, 129.7, 
127.9, 125.6, 125.4, 122.7, 113.0, 26.2, 20.7, 20.4. 
FTIR: 3010, 2921, 1469, 1380, 1168, 1031, 1008 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15BrI











Prepared according to the general procedure A on 4.18 mmol and obtained an isolated yield 
of 60% (1.629 g) as a white powder. 
Melting point (MeCN/Et2O):  162.6 – 170.7 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.14 (d, J = 9.0 Hz, 2H), 7.67 (d, J = 9.0 Hz, 2H), 
7.47 (d, J = 8.1 Hz, 2H), 7.24 (s, 2H), 7.11 (d, J = 7.6 Hz, 2H), 2.59 (s, 6H), 2.31 (s, 3H), 
2.29 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 150.7, 145.4, 143.2, 141.6, 137.6, 136.9, 129.8, 
128.0, 125.4, 124.9, 122.9, 118.1 (q, JC-F = 323 Hz), 114.0, 26.2, 20.7, 20.5,  
19F NMR (377 MHz, [D6] DMSO) δ = -73.1 
FTIR:  2987, 1423, 1275, 1269, 1208, 1139, 749 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H15F3IO3S






Prepared according to the general procedure B on 3.0 mmol and obtained an isolated yield 
of 84% (1.346 g) as a white powder. 
Melting point (MeCN/Et2O): 153.2 – 153.9 °C. 
1H NMR (400 MHz, [D6] DMSO): δ = 8.14 (t, J = 1.7 Hz , 1H), 7.85 (d, J=8.1 Hz, 1H), 
7.70 (d, J = 8.1 Hz, 1H), 7.53 – 7.46 (m, 3H), 7.22 (s, 2H), 7.11 (d, J = 7.7 Hz, 2H), 2.59 
(s, 6H), 2.30 (s, 3H), 2.29 (s, 3H).  
13C NMR (101 MHz, [D6] DMSO) δ = 141.5, 133.4, 133.1, 132.7, 131.7, 129.7, 127.9, 
125.3, 39.9, 39.7, 39.5, 39.3, 39.1, 38.9, 38.7, 26.2, 20.4. 
FTIR: 3058, 2982, 2921, 1569, 1457, 1169, 1031, 1007 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15ClI













Prepared according to the general procedure B on 5.0 mmol and obtained an isolated yield 
of 67% (1.919 g) as a white powder. 
Melting point (MeCN/Et2O): 151.2 – 153.9 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.26 (t, J = 1.8 Hz, 1H), 7.91 – 7.77 (m, 2H), 7.49 
– 7.39 (m, 3H), 7.22 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.59 (s, 6H), 2.30 (s, 3H), 2.28 (s, 
3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.4, 143.1, 141.6, 137.5, 136.0, 134.6, 133.4, 
133.0, 129.7, 127.9, 125.3, 123.3, 122.6, 114.9, 26.2, 20.7, 20.4. 
FTIR: 2986, 2970, 1555, 1453, 1180, 1050, 750 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15BrI






Prepared according to the general procedure B on 3.0 mmol and obtained an isolated yield 
of 90% (1.677 g) as a white powder. 
Melting point (MeCN/Et2O): 163.1 – 166.5 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.38 (t, J = 1.6 Hz, 1H), 7.98 (d, J = 8.4 Hz, 1H), 
7.86 (d, J = 10.5 Hz, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.26 (t, J = 8.0 Hz, 1H), 7.22 (s, 2H), 
7.10 (d, J = 7.8 Hz, 2H), 2.60 (s, 6H), 2.30 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 141.6, 141.3, 133.5, 133.1, 129.7, 127.9, 125.3, 
40.0, 39.8, 39.6, 39.4, 39.2, 39.0, 38.8, 26.2, 20.7, 20.4. 
FTIR: 2987, 1736, 1451, 1275, 1189, 750 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15I2








Prepared according to the general procedure A on 3.0 mmol and obtained an isolated yield 
of 76% (1.279 g) as a white powder.  
Melting point (MeCN/Et2O): 181.0 – 182.5 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.15 (d, J = 8.3 Hz, 2H), 7.85 (d, J = 8.5 Hz, 2H), 
7.46 (d, J = 8.1 Hz, 2H), 7.23 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.59 (s, 6H), 2.31 (s, 3H), 
2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.4, 143.3, 141.6, 137.6, 135.0, 131.5 (q, JC-F = 
32.6 Hz), 129.8, 128.2 (q, JC-F = 4.0 Hz), 128.0, 125.4, 123.3 (q, JC-F = 273.0 Hz), 122.7, 
118.8, 26.2, 20.7, 20.5. 
19F NMR (376 MHz, [D6] DMSO) δ = -61.7. 
FTIR: 3000, 2970, 1738, 1367, 1323, 1199, 1132, 750 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H15F3I






Prepared according to the general procedure A on 3.03 mmol and obtained an isolated yield 
of 73% (1.3773 g) as a white powder. (~94% pure bases on 1H NMR integration).  
Melting point (MeCN/Et2O): 180.4 – 182.1 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.12 (d, J = 8.9 Hz, 2H), 8.02 (d, J = 9.2 Hz, 2H), 
7.46 (d, J = 8.1 Hz, 2H), 7.25 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.59 (s, 6H), 2.31 (s, 3H), 
2.29 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 154.4, 145.4, 143.4, 141.7, 137.6, 135.0, 129.8, 
128.8, 128.0, 125.4, 122.6, 118.3, 26.2, 20.7, 20.5. 
19F NMR (377 MHz, [D6] DMSO) δ = 84.80 (p, JF-F = 151.9 Hz), 63.72 (d, JF-F = 151.2 
Hz). 
FTIR: 3010, 2970, 1738, 1456, 1215, 1168, 842 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15F5IS









Prepared according to the general procedure A on 2.99 mmol and obtained an isolated yield 
of 66% (1.233 g) as a white powder. 
Melting point (MeCN/Et2O): 182.4 – 183.9 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.67 (t, J = 1.8 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 
1H), 8.03 (d, J = 8.3 Hz, 1H), 7.70 (t, J = 8.2 Hz, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.24 (s, 
2H), 7.10 (d, J = 7.8 Hz, 2H), 2.60 (s, 6H), 2.31 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 153.3, 145.5, 143.4, 141.7, 137.5, 133.0, 131.3, 
129.8, 128.8, 127.9, 125.4, 122.8, 114.4, 26.2, 20.7, 20.4.  One carbon signal is missing 
due to overlapping signals. 
19F NMR (377 MHz, [D6] DMSO) δ = 84.74 (p, JF-F = 152.0, 150.6 Hz), 64.09 (d, JF-F = 
151.6 Hz). 
FTIR: 3006, 1734, 1275, 1261, 750 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H15F5IS





Prepared according to the general procedure A on 3.0 mmol and obtained an isolated yield 
of 72% (1.130 g) as a white powder. 
Melting point (MeCN/Et2O): 172.3 – 174.9 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.11 (d, J = 8.6 Hz, 2H), 7.93 (d, J = 8.6 Hz, 2H), 
7.46 (d, J = 8.1 Hz, 2H), 7.23 (s, 2H), 7.11 (d, J = 7.9 Hz, 2H), 2.57 (s, 6H), 2.30 (s, 3H), 
2.29 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.2, 143.3, 141.6, 137.7, 134.9, 129.8, 128.0, 
125.4, 122.7, 119.4, 117.4, 114.2, 26.2, 20.7, 20.4. One carbon signal is missing due to 
overlapping signals. 
FTIR: 3010, 2231, 1651, 1474, 1215, 1189 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H15IN
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Prepared according to the general procedure A on 5.0 mmol and obtained an isolated yield 
of 71% (1.867 g) as a white powder. 
Melting point (MeCN/Et2O): 171.3 – 172.7 °C. 
1H NMR (600 MHz, [D6] DMSO) δ = 8.55 (t, J = 1.5 Hz, 1H), 8.25 – 8.19 (m, 1H), 8.08 
(d, J = 7.8 Hz, 1H), 7.66 (t, J = 8.0 Hz, 1H), 7.45 (d, J = 8.1 Hz, 2H), 7.21 (s, 2H), 7.10 (d, 
J = 7.9 Hz, 2H), 2.59 (s, 6H), 2.29 (s, 3H), 2.28 (s, 3H). 
13C NMR (151 MHz, [D6] DMSO) δ = 145.8, 143.8, 142.2, 139.4, 138.3, 138.2, 135.9, 
132.9, 130.3, 128.6, 125.9, 123.4, 117.4, 115.1, 114.5, 26.8, 21.3, 21.0. 
FTIR: 3009, 2233, 1661, 1464, 1211, 1190 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H15IN





Prepared according to the general procedure A on 5.0 mmol and obtained an isolated yield 
of 83% (2.446 g) as a white powder. 
Melting point (MeCN/Et2O): 180.8 – 183.6 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.25 (d, J = 1.8 Hz, 1H), 7.79 (dd, J = 8.2, 1.9 Hz, 
1H), 7.47-7.43 (m, 3H), 7.21 (s, 2H), 7.10 (d, J = 7.9 Hz, 2H), 2.59 (s, 6H), 2.35 (s, 3H), 
2.29 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.4, 143.0, 141.8, 141.5, 137.7, 136.7, 133.8, 
133.3, 129.7, 127.9, 125.8, 125.4, 122.7, 111.3, 26.2, 22.2, 20.7, 20.4. 
FTIR: 3011, 2922, 1461, 1214, 1188, 1032 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H17BrI






Prepared according to the general procedure A on 5.0 mmol and obtained an isolated yield 
of 78% (2.127 g) as a white powder. 
Melting point (MeCN/Et2O): 163.8 – 164.1 °C. 
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1H NMR (400 MHz, [D6] DMSO) δ = 8.35 (dd, J = 6.8, 2.2 Hz, 1H), 7.94-7.90 (m, 1H), 
7.55 (t, J = 9.0 Hz, 1H), 7.46 (d, J = 8.1 Hz, 2H), 7.21 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 
2.60 (s, 6H), 2.30 (s, 3H), 2.29 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 159.07 (d, JC-F = 253.1 Hz), 145.3, 143.2, 141.5, 
137.6, 136.3, 135.5 (d, JC-F = 8.2 Hz), 129.7, 127.9, 125.3, 122.9, 122.2 (d, JC-F = 18.7 Hz), 
120.1 (d, JC-F = 22.2 Hz), 108.6 (d, JC-F = 3.9 Hz), 26.2, 20.6, 20.4. 
19F NMR (376 MHz, [D6] DMSO) δ = -110.8. 
FTIR: 3080, 2921, 1476, 1171, 1120, 1031, 1008, 815 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H14ClFI






Prepared according to the general procedure A on 5.0 mmol and obtained an isolated yield 
of 50% (1.3264 g) as a light brown powder. 
Melting point (MeCN/Et2O): 160.2 – 162.7 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.91 (d, J = 2.0 Hz, 1H), 8.41 (dd, J = 8.6, 2.5 Hz, 
1H), 7.66 (d, J = 8.5 Hz, 1H)), 7.46 (d, J = 8.1 Hz, 2H), 7.21 (s, 2H), 7.11 (d, J = 7.8 Hz, 
2H), 2.60 (s, 6H), 2.30 (s, 3H), 2.29 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 153.5, 152.9, 145.3, 145.0, 143.2, 141.5, 137.6, 
129.7, 128.0, 127.5, 125.3, 122.9, 112.2, 26.2, 20.7, 20.4. 
FTIR: 3044, 2981, 1554, 1445, 1216, 1169, 1008, 749 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C14H14ClIN






Prepared according to the general procedure B on 3.0 mmol and obtained an isolated yield 
of 81% (1.347 g) as a white powder. 
Melting point (MeCN/Et2O): 166.9 – 168.9 °C.  
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1H NMR (400 MHz, [D6] DMSO) δ = 7.88 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 
7.28 (d, J = 8.4 Hz, 2H), 7.20 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.59 (s, 6H), 2.47 (d, J = 
7.2 Hz, 2H), 2.29 (s, 3H), 2.28 (s, 3H), 1.80 (sept, 1H), 0.82 (d, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.7, 145.5, 142.9, 141.5, 137.5, 134.4, 132.4, 
129.7, 128.0, 125.4, 122.6, 111.2, 43.8, 29.4, 26.2, 21.9, 20.7, 20.5. 
FTIR: 2955, 2923, 1458, 1172, 1120, 1032, 1008 680 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C19H24I






Prepared according to the general procedure B on 5.09 mmol and obtained an isolated yield 
of 71% (2.065 g) as a white powder. 
Melting point (MeCN/Et2O): 183.5 – 186.4 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.04 (d, J = 8.6 Hz, 2H), 7.77 (d, J = 8.7 Hz, 2H), 
7.68 (d, J = 7.1 Hz, 2H), 7.54 – 7.38 (m, 5H), 7.23 (s, 2H), 7.10 (d, J = 7.8 Hz, 2H), 2.63 
(s, 6H), 2.30 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.7, 143.3, 143.0, 141.5, 138.0, 137.5, 134.9, 
129.8, 129.7, 129.1, 128.6, 128.0, 127.0, 125.4, 122.6, 113.0, 26.3, 20.7, 20.5. 
FTIR: 2978, 2966, 1474, 1176, 1009, 680 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C21H20I






Prepared according to the general procedure B on 3.05 mmol and obtained an isolated yield 
of 50% (0.804 g) as grey powder. 
Melting point (MeCN/Et2O): 164.9 – 168.9 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 7.91 (d, J = 9.1 Hz, 2H), 7.45 (d, J = 8.1 Hz, 2H), 
7.18 (s, 2H), 7.09 (d, J = 7.8 Hz, 2H), 7.02 (d, J = 9.1 Hz, 2H), 3.77 (s, 3H), 2.59 (s, 6H), 
2.28 (s, 6H, overlapping methyl signals). 
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13C NMR (101 MHz, [D6] DMSO) δ = 161.6, 145.6, 142.8, 141.3, 137.6, 136.5, 129.6, 
128.0, 125.4, 123.1, 117.4, 103.4, 55.6, 26.2, 20.7, 20.4.  
FTIR: 2919, 1573, 1487, 1298, 1255, 1174, 1031, 1009, 817 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H18IO





Prepared according to the general procedure B on 3.0 mmol and obtained an isolated yield 
of 56% (0.925 g) as light orange powder. 
Melting point (MeCN/Et2O): 163.5- 165.2 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.76 (d, J = 1.8 Hz, 1H), 8.09 – 7.99 (m, 3H), 7.96 
(dd, J = 8.8, 1.9 Hz, 1H), 7.72 – 7.63 (m, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.19 (s, 2H), 7.09 
(d, J = 7.8 Hz, 2H), 2.67 (s, 6H), 2.28 (s, 6H, overlapping methyl signals). Two carbon 
signals are missing due to overlapping signals. 
13C NMR (101 MHz, DMSO) δ = 145.4, 142.9, 141.5, 137.6, 135.3, 133.9, 133.2, 131.3, 
129.6, 128.7, 128.0, 127.9, 127.7, 125.4, 122.7, 111.5, 26.3, 20.7, 20.4. 
FTIR: 3053, 2998, 1576, 1455, 1173, 1120, 1031, 1008, 814 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C19H18I





Prepared according to the general procedure B on 3.0 mmol and obtained an isolated yield 
of 36% (0.788 g) as a light orange powder. 
Melting point (MeCN/Et2O): 169.5 – 171.8 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.45 (d, J = 7.6 Hz, 1H), 8.33 (d, J = 7.9 Hz, 1H), 
8.23 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.69 – 7.60 (m, 1H), 7.54 – 7.49 (m, 
2H), 7.47 (d, J = 8.2 Hz, 2H), 7.14 (s, 2H), 7.10 (d, J = 7.9 Hz, 2H), 2.76 (s, 6H), 2.28 (s, 
3H), 2.22 (s, 3H). 
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13C NMR (101 MHz, [D6] DMSO) δ = 154.8, 153.3, 145.5, 142.7, 141.5, 137.5, 134.0, 
129.5, 129.0, 127.9, 125.5, 125.5, 125.4, 125.3, 124.3, 123.4, 123.1, 122.1, 111.8, 96.1, 
26.2, 20.7, 20.3. 
FTIR: 3008, 2989, 1576, 1455, 1173, 1120, 1031, 1008, 814 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C21H18IO






Prepared according to the general procedure B on 3.22 mmol and obtained an isolated yield 
of 68% (1.120 g) as a white powder. 
Melting point (MeCN/Et2O): 181.4 – 183.7 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.11 (d, J = 1.9 Hz, 1H), 7.56 (dd, J = 8.3, 1.9 Hz, 
1H), 7.09 (d, J = 8.5 Hz, 1H), 6.95 (d, J = 8.1 Hz, 2H), 6.73 (s, 2H), 6.60 (d, J = 7.8 Hz, 
2H), 2.10 (s, 6H), 2.02 (s, 3H), 1.81 (s, 3H), 1.79 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 149.6, 145.5, 143.2, 141.6, 138.0, 137.5, 136.6, 
135.6, 129.9, 129.7, 127.9, 125.3, 122.8, 110.9, 26.2, 20.7, 20.4, 19.1. 
FTIR: 2988, 1524, 1345, 1174, 1120, 1007, 680 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H17INO2





Prepared according to the general procedure B on 2.99 mmol and obtained an isolated yield 
of 84% (1.410 g) as a white powder. 
Melting point (MeCN/Et2O): 185.2 – 187.5 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.15 (d, J = 2.3 Hz, 1H), 7.89 (dd, J = 8.9, 2.3 Hz, 
1H), 7.46 (d, J = 8.1 Hz, 2H), 7.23 (d, J = 9.0 Hz, 1H), 7.20 (s, 2H), 7.10 (d, J = 7.8 Hz, 
2H), 3.89 (s, 3H), 2.60 (s, 6H), 2.29 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 157.1, 145.6, 142.9, 141.4, 137.5, 135.2, 135.2, 
129.6, 127.9, 125.4, 123.1, 123.1, 115.6, 102.8, 56.6, 26.2, 20.7, 20.4. 
FTIR: 3018, 2918, 1736, 1457, 1373, 1216, 1008 cm-1 
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HRMS (ESI) m/z: [M − OTs]+ calculated for C16H17ClIO




Prepared according to the general procedure B on 3.02 mmol and obtained an isolated yield 
of 85% (1.4485 g) as a white powder. 
Melting point (MECN/Et2O): 161.5 – 163.2 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.18 (dd, J = 8.0, 1.3 Hz, 1H), 7.92 (dd, J = 8.1, 1.3 
Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 7.5 Hz, 2H), 7.21 (s, 2H), 7.10 (d, J = 7.9 
Hz, 2H), 2.61 (s, 6H), 2.29 (s, 6H, overlapping methyl signals). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.3, 143.1, 141.8, 137.6, 137.4, 134.3, 133.8, 
132.3, 131.2, 129.9, 127.9, 125.3, 123.1, 117.9, 26.1, 20.7, 20.4. 
FTIR: 3012, 2990, 1456, 1403, 1168, 1119, 1030, 1007 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C15H14Cl2I





Prepared according to the general procedure A on 3.0 mmol and obtained an isolated yield 
of 81% (1.236 g) as a white powder. 
Melting point (MeCN/Et2O): 167.2 – 169.1 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 7.84 (s, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.45 (m, 3H), 
7.37 (t, J = 7.8 Hz, 1H), 7.19 (s, 2H), 7.10 (d, J = 7.9 Hz, 2H), 2.60 (s, 6H), 2.31 (s, 3H), 
2.28 (s, 6H, overlapping methyl signals). 
13C NMR (101 MHz, [D6] DMSO) δ = 145.5, 142.8, 141.8, 141.4, 137.5, 134.5, 132.3, 
131.5, 131.4, 129.6, 127.9, 125.4, 122.4, 114.2, 26.2, 20.7, 20.6, 20.4. 
FTIR: 3017, 2921, 1595, 1452, 1172, 1120, 1032, 1008 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C16H18I













Prepared according to the general procedure A on 3.0 mmol and tri-isopropyl benzene (0.79 
mL, 3.3mmol, 1.1 equiv.) was used instead of mesitylene.  After the reaction, MeCN was 
evaporated and KBr (sat) was added (10 mL) and extracted the organic layer with DCM (3 
X 5 mL).  The organic layer was evaporated and triturated with diethyl ether and obtained 
an isolated yield of 50% (0.755 g) as a white powder. 
 
Melting point (MeCN/Et2O): 163.5 – 165.2 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 7.77 (s, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.42 – 7.30 
(m, 2H), 7.26 (s, 2H), 3.52 – 3.32 (m, 2H), 2.96 (m, 1H), 2.29 (s, 3H), 1.24 (d, J = 6.7 Hz, 
12H), 1.21 (d, J = 6.9 Hz, 6H). 
13C NMR (101 MHz, [D6] DMSO) δ = 153.3, 150.5, 141.2, 133.7, 131.6, 131.2, 130.3, 
125.8, 124.2, 118.1, 38.5, 33.2, 23.8, 23.4, 20.7. 
FTIR: 3019, 2998, 1277, 1189, 1008 cm-1 
HRMS (ESI) m/z: [M − Br]+ calculated for  C22H30I





Prepared according to the general procedure A on 3.0 mmol and anisole (0.36 mL, 3.3 
mmol, 1.1 equiv.) was used instead of mesitylene and obtained an isolated yield of 84% 
(1.2612 g) as a white powder. 
Melting point (MeCN/Et2O): 122.3 – 123.1 °C. 
1H NMR (400 MHz, [D6] DMSO) δ = 8.16 (d, J = 9.0 Hz, 2H), 8.08 (s, 1H), 8.00 (d, J = 
7.9 Hz, 1H), 7.49 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 7.6 Hz, 1H), 7.38 (t, J = 7.7 Hz, 1H), 
7.11 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 9.1 Hz, 2H), 3.78 (s, 3H), 2.32 (s, 3H), 2.28 (s, 3H). 
13C NMR (101 MHz, [D6] DMSO) δ = 161.8, 145.5, 141.4, 137.5, 137.1, 134.9, 132.3, 
131.8, 131.1, 127.9, 125.4, 117.3, 116.7, 105.3, 55.6, 20.7, 20.6. 
FTIR: 3058, 2922, 1574, 1488, 1256, 1177, 1120, 1031, 1009 cm-1 
HRMS (ESI) m/z: [M − OTs]+ calculated for C14H14IO
+: 325.0084; found: 325.0078 
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5.6: General procedure for the coupling reaction with furan 
 
The iodonium salt (0.5 mmol, 1 equiv.) is weighed out in air and placed in an oven-dried 
vial containing a magnetic stir bar and is sealed with a Teflon-lined septum cap.  The vial 
is purged with nitrogen gas for approximately 10 minutes.  Toluene (7 mL) and furan (200 
µL, 2.75 mmol, 5.5 equiv.) are added sequentially via syringe through the septum.  The 
vial is placed in an ice-cooled water bath maintained at 13 °C.  LiHMDS (0.5 mL (1 M in 
toluene), 0.5 mmol, 1 equiv.) is added via syringe through the septum and the reaction is 
stirred for 3 hours.  The vial is removed from the ice-bath and the reaction is quenched 
with an aqueous solution of ammonium chloride (5 mL).  The biphasic mixture is placed 
in a separatory funnel and washed with DCM (3 × 5 mL).  The combined organic phases 
are dried with MgSO4, the drying agent removed by suction filtration, and the solvent 
removed on the rotary evaporator.  The crude residue is purified by flash column 




Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 70% (0.0563 g) as a yellow liquid.  Spectral data is consistent with that of 
previously reported.112 
1H NMR (400 MHz, CDCl3) δ = 7.11 (d, J = 7.2 Hz, 1H), 7.08 (s, 1H), 7.04 – 6.95 (m, 
2H), 6.76 (dd, J = 7.2, 0.7 Hz, 1H), 5.66 (m, 2H), 2.28 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 149.3, 146.0, 143.2, 142.7, 134.7, 125.0, 121.6, 119.9, 






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 58% (0.047 g) as yellow liquid. Spectral data is consistent with that of previously 
reported.113  
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1H NMR (600 MHz, CDCl3) δ = 7.17 – 7.11 (m, 1H), 7.08 – 6.95 (m, 3H), 6.63 (m, 1H), 
5.69 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 160.5 (d, JC-F = 244.8 Hz), 151.9 (d, JC-F = 8.5 Hz), 144.2 
(d, JC-F = 2.5 Hz), 143.5, 142.5, 120.6 (d, JC-F = 8.8 Hz), 110.3 (d, J = 22.6 Hz), 109.6 (d, 
JC-F = 25.3 Hz), 82.3 (d, JC-F = 2.6 Hz), 82.0. 





Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 79% (0.085 g) as yellow liquid. Spectral data is consistent with that of previously 
reported.114 
1H NMR (400 MHz, CDCl3) δ = 7.37 (s, 1H), 7.12-7.08 (m, 2H), 7.05 – 6.95 (m, 2H), 5.67 
(m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 151.7, 148.2, 143.1, 142.6, 127.6, 123.9, 121.4, 118.7, 






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 67% (0.0984 g) as yellow liquid. 
Rf = 0.21 in 20% diethyl ether in hexanes 
1H NMR (600 MHz, CDCl3) δ = 7.25 (d, J = 7.6 Hz, 1H), 7.16 (s, 1H), 7.05 (s, 2H), 6.88 
(d, J = 7.8 Hz, 1H), 5.73 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 152.4, 149.4, 146.8, 143.1, 142.8, 120.9, 118.7 (q, JC-F = 
321.0 Hz), 117.6, 114.5, 82.2, 82.0. 
19F NMR (376 MHz, CDCl3) δ = -72.8. 
FTIR: 3019, 1419, 1209, 1139, 845 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H8F3O4S











Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 69% (0.062 g) as yellow liquid.   
Rf = 0.36 in 20% diethyl ether in hexanes 
1H NMR (600 MHz, CDCl3) δ = 7.13 – 7.09 (m, 1H), 7.09 – 7.02 (m, 2H), 6.91 (m, 2H), 
5.87 (br, 1H), 5.74 (br, 1H). 
13C NMR (101 MHz, CDCl3) δ = 151.6, 149.8, 143.4, 142.5, 128.4, 127.1, 119.0, 114.6, 
83.2, 82.8. 
FTIR: 3071, 3017, 1588, 1450, 1279, 1115, 854 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C10H8ClO






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 84% (0.0945 g) as pale yellow liquid. Spectral data is consistent with that of 
previously reported.115 
1H NMR (400 MHz, CDCl3) δ = 7.14 (d, J = 7.0 Hz, 1H), 7.09 – 7.00 (m, 3H), 6.83 (dd, J 
= 8.2, 7.0 Hz, 1H), 5.80 – 5.78 (m, 1H), 5.78 – 5.75 (m, 1H). 







Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 89% (0.1207 g) as yellow liquid. 
Rf = 0.41 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.25 (dd, J = 8.1, 0.7 Hz, 1H), 7.15 (d, J = 7.0 Hz, 1H), 
7.10 – 7.03 (m, 2H), 6.74 – 6.65 (m, 1H), 5.83 (m, 1H), 5.63 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 154.6, 151.1, 143.4, 142.4, 133.8, 127.1, 119.7, 86.3, 
85.6, 83.5. 
FTIR: 3009, 2948, 1574, 1447, 1278, 1098, 1053 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C10H8IO
+: 270.9614; found: 270.9606 







Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 65% (0.063 g) as yellow liquid. Spectral data is consistent with that of previously 
reported.116 
1H NMR (400 MHz, CDCl3) δ = 7.45 (s, 1H), 7.35 – 7.25 (m, 2H), 7.08 – 6.99 (m, 2H), 
5.75 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 153.2, 150.3, 143.1, 142.7, 127.5 (q, JC-F = 33.0 Hz), 
124.3 (q, JC-F = 272.0 Hz), 123.0 (q, JC-F = 4.0 Hz), 120.0, 116.9 (q, JC-F = 4.0 Hz), 82.1. 
One carbon signal is missing due to overlapping signals. 






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 67% (0.0906 g) as colorless liquid. 
Rf = 0.31 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.60 (d, J = 1.8 Hz, 1H), 7.43 (dd, J = 7.8, 1.9 Hz, 1H), 
7.28 (d, J = 7.8 Hz, 1H), 7.09 – 7.01 (m, 2H), 5.78 – 5.72 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 152.8, 151.0 (p, J = 17.0 Hz), 150.3, 143.2, 142.5, 123.6 
(p, J = 5.0 Hz), 118.0 (p, J = 4.7 Hz), 82.2, 81.9. 
19F NMR (377 MHz, CDCl3) δ = 86.02 – 82.09 (p, JF-F = 151.0 Hz), 64.63 (d, JF-F = 149.7 
Hz). 
FTIR: 3099, 3019, 2919, 1455, 1415, 1281, 1063, 994, 832 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C10H8F5OS








Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 50% (0.0684 g) as colorless liquid. 
Rf = 0.29 in 20% Diethyl ether in hexanes 
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1H NMR (400 MHz, CDCl3) δ = 7.33 (d, J = 7.0 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.10 – 
7.00 (m, 3H), 6.16 – 6.03 (m, 1H), 5.86 – 5.75 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 151.8, 147.2 (p, JC-F = 18.2 Hz), 146.6 (p, JC-F = 3.5 Hz), 
144.1, 142.1, 126.2, 122.7, 122.2 (p, JC-F = 4.2 Hz), 83.4 (p, JC-F = 3.2 Hz), 82.4. 
19F NMR (377 MHz, CDCl3) δ = 85.56 – 83.09 (p, JF-F = 150.0 Hz), 64.63 (d, JF-F = 149.7 
Hz). 
FTIR: 3021, 2919, 1457, 1418, 1282, 1011, 831 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C10H8F5OS






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 65% (0.056 g) as yellow liquid. Spectral data is consistent with that of previously 
reported.117 
1H NMR (400 MHz, CDCl3) δ = 7.49 – 7.42 (m, 1H), 7.38 – 7.29 (m, 2H), 7.04 (m, 2H), 
5.76 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 154.6, 150.5, 143.1, 142.5, 130.9, 122.8, 120.7, 119.1, 






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 40% (0.0345 g) as yellow liquid. 
Rf = 0.27 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.42 (d, J = 7.1 Hz, 1H), 7.19 (dd, J = 8.0, 0.8 Hz, 1H), 
7.14 – 7.04 (m, 3H), 5.94 (m, 1H), 5.79 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 154.6, 150.7, 143.7, 142.2, 127.1, 126.1, 123.8, 116.8, 
105.1, 82.4, 81.5.  
FTIR: 3009, 2971, 2231, 1456, 1278, 1054, 1036cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H8NO
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Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 72% (0.0872 g) as yellow liquid. 
Rf = 0.45 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.11 – 7.00 (m, 3H), 6.83 (dd, J = 7.1, 0.8 Hz, 1H), 5.79 
(m, 1H), 5.75 (m, 1H), 2.32 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 150.5, 148.8, 143.7, 142.2, 134.6, 127.2, 118.7, 117.5, 
83.3, 83.2, 22.1. 
FTIR: 3009, 2971, 1453, 1278, 1102, 1054, 1032, 861 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H10BrO






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 82% (0.0818 g) as yellow liquid. 
Rf = 0.30 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.12 – 6.97 (m, 3H), 6.72 (dd, J = 9.5, 7.7 Hz, 1H), 5.87 
(m, 1H), 5.73 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 155.8 (d, JC-F = 248.1 Hz), 150.2, 146.0 (d, JC-F = 2.8 
Hz), 143.9, 142.0, 118.6 (d, JC-F = 7.8 Hz), 115.2 (d, JC-F = 21.7 Hz), 112.0 (d, JC-F = 22.7 
Hz), 82.7, 81.4 (d, JC-F = 2.8 Hz). 
19F NMR (376 MHz, CDCl3) δ = -121.9. 
FTIR: 3084, 3019, 1598, 1456, 1248, 1125, 867 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C10H7ClFO






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 51% (0.0461 g) as yellow liquid 
Rf = 0.06 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 8.16 (s, 1H), 7.23 (s, 1H), 7.07 (dd, J = 5.6, 1.9 Hz, 1H), 
6.98 (dd, J = 5.6, 1.9 Hz, 1H), 5.83 – 5.77 (m, 1H), 5.74 – 5.68 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 162.6, 148.5, 143.5, 143.5, 141.4, 138.8, 117.3, 81.5, 
80.2. 
FTIR: 3021, 2920, 1605, 1579, 1453, 1342, 1298, 1132, 847 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C9H7ClNO
+: 180.0211; found: 180.0208 
 







Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 72% (0.0730 g) as yellow liquid. 
Rf = 0.36 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.13 (d, J = 7.2 Hz, 1H), 7.05 (s, 1H), 7.03 – 6.97 (m, 
2H), 6.75 – 6.69 (m, 1H), 5.67 (m, 2H), 2.41 (d, J = 7.2 Hz, 2H), 1.81 (m, 1H), 0.88 (m, 
6H, overlapping methyl signals). 
13C NMR (101 MHz, CDCl3) δ = 149.0, 146.2, 143.1, 142.8, 138.6, 125.3, 121.5, 119.7, 
82.3, 82.2, 45.3, 30.2, 22.4, 22.3. 
FTIR: 3008, 2954, 1599, 1465, 1281, 1226, 1090, 950 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C14H17O







Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 67% (0.0738 g) as yellow liquid. 
Rf = 0.16 in 15% Diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.55 – 7.49 (m, 2H), 7.48 – 7.44 (m, 1H), 7.44 – 7.35 (m, 
2H), 7.34 – 7.24 (m, 2H), 7.17 (dd, J = 7.4, 1.5 Hz, 1H), 7.02 (s, 2H), 5.89 – 5.48 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 149.9, 148.0, 142.9, 142.9, 141.2, 138.5, 128.7, 127.2, 
127.1, 124.0, 120.3, 119.6, 82.4, 82.2. 
FTIR:  2948, 2835, 1652, 1455, 1413, 1138, 1031 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C16H13O







Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 67% (0.0596 g) as yellow liquid. Spectral data is consistent with that of previously 
reported.118 
1H NMR (400 MHz, CDCl3) δ = 7.11 (d, J = 7.8 Hz, 1H), 7.05 – 6.94 (m, 2H), 6.90 (d, J 
= 2.2 Hz, 1H), 6.41 (dd, J = 7.8, 2.3 Hz, 1H), 5.69 – 5.62 (m, 2H), 3.76 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ = 157.4, 151.0, 143.5, 142.2, 140.4, 120.3, 109.7, 107.2, 





Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 53% (0.0525 g) as yellow liquid. 
Rf = 0.40 in 20% Diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.85 – 7.73 (m, 2H), 7.59 – 7.48 (m, 2H), 7.45-7.41 (m, 
1H), 7.37-7.33 (m, 1H), 7.17 (m, 2H), 6.24 (m, 1H), 5.90 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 148.3, 147.8, 144.8, 143.4, 131.7, 128.7, 127.6, 126.2, 
125.3, 125.1, 122.6, 119.3, 83.4, 81.2. 
FTIR: 3006, 1517, 1276, 1038, 1003, 823 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C14H11O





Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 75% (0.0879 g) as yellow liquid. 
Rf = 0.34 in 20% Diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.90 – 7.84 (m, 1H), 7.56 (d, J = 7.4 Hz, 1H), 7.51 (d, J 
= 8.2 Hz, 1H), 7.41 (td, J = 8.3, 7.8, 1.3 Hz, 1H), 7.29 (td, J = 7.3, 1.3 Hz, 2H), 7.13-7.09 
(m, 2H), 6.22 (m, 1H), 5.86 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 156.6, 150.0, 149.0, 143.9, 142.7, 131.1, 127.3, 124.2, 
123.5, 122.8, 120.7, 117.3, 115.4, 111.5, 82.9, 80.1. 
FTIR: 3011, 1650, 1459, 1414, 1278, 1182 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C16H11O2





Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 79% (0.0809 g) as brown solid. 
Rf = 0.22 in 20% diethyl ether in hexanes 
Melting point = 87.2 – 88.0 oC 
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1H NMR (400 MHz, CDCl3) δ = 7.28 (d, J = 7.2 Hz, 1H), 7.12 (m, 2H), 6.99 – 6.89 (m, 
1H), 6.12 – 6.07 (m, 1H), 5.77 (s, 1H), 2.49 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 150.0, 147.3, 144.2, 143.7, 142.1, 129.4, 129.1, 123.4, 
82.7, 82.1, 19.7. 
FTIR:  3029, 2990, 1537, 1350, 1278, 1108 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H10NO3






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 83% (0.083 g) and 90% (0.090 g) as brown oil. 
Rf = 0.26 in 15% Diethyl ether in hexanes 
1H NMR (600 MHz, CDCl3) δ = 7.05-7.02 (m, 3H), 6.43 (d, J = 7.7 Hz, 1H), 5.86 (m, 1H), 
5.70 (m, 1H), 3.84 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 152.9, 149.2, 144.1, 143.9, 142.0, 141.7, 118.4, 107.1, 
82.7, 81.6, 56.5. 
FTIR: 3013, 2941, 2836, 1589, 1467, 1432, 1345, 1265, 1082, 1057,863 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H10ClO2






Prepared according to the general procedure C on 0.5 mmol scale and obtained an isolated 
yield of 75% (0.0806 g) as yellow liquid. 
Rf = 0.41 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.12 – 7.00 (m, 4H), 5.86 (m, 1H), 5.73 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ = 149.9, 149.8, 143.7, 142.1, 129.3, 127.1, 125.4, 119.0, 
82.9, 81.9. 
FTIR: 2949, 2837, 1649, 1420, 1031, 861 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C10H7Cl2O
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5.7: General procedure for coupling of arynes with nitrogen arynophiles 
 
The iodonium salt (0.5 mmol, 1 equiv.) is weighed out in air and placed in an oven-dried 
vial containing a magnetic stir bar and is sealed with a Teflon-lined septum cap.  The vial 
is purged with nitrogen gas for approximately 10 minutes.  TBME (1.6 mL) and arynophile 
(1.0 mmol, 2.0 equiv.) are added sequentially via syringe through the septum.  NaOt-Bu 
(0.55 mmol, 1.1 equiv.) was added and the reaction is stirred at 50 oC for 90 mins.  The 
vial is removed from the oil-bath and the reaction is quenched with an aqueous solution of 
ammonium chloride (5 mL).  The biphasic mixture is placed in a separatory funnel and 
washed with DCM (3 × 5 mL).  The combined organic phases are dried with MgSO4, the 
drying agent removed by suction filtration, and the solvent removed on the rotary 
evaporator.  The crude residue is purified by flash column chromatography on silica gel 
with ether/hexane mixture as the eluent. 
 




Prepared according to the general procedure D on 0.5 mmol scale and obtained an isolated 
yield of 50% (0.0703 g) as brown solid. 
Rf = 0.18 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.20 (m, 6H), 7.15 (d, J = 8.4 Hz, 1H), 5.80 (s, 2H), 
2.51 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 146.1, 134.4, 133.7, 132.1, 130.4, 129.0, 128.5, 127.5, 
114.1, 108.4, 52.6, 30.9. 
FTIR: 3031, 2922, 1649, 1495, 1252, 1088 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C14H13BrN3
+: 302.0287; found: 302.0280 
 
Compound 2.51 





Prepared according to the general procedure D on 0.5 mmol scale and obtained an isolated 
yield of 13% (0.0184 g) as brown solid. The isomers were identified using NOESY and 
also from previously reported data.119 
Rf = 0.20 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.4 Hz, 1H), 7.34 – 7.23 (m, 4H), 7.21 – 7.15 
(m, 2H), 6.22 (s, 2H), 2.52 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 146.1, 138.3, 136.6, 132.0, 128.7, 127.9, 127.5, 126.9, 
118.6, 103.9, 52.5, 22.8. 
FTIR: 3032, 2921, 1648, 1488, 1212 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C14H13BrN3






Prepared according to the general procedure D on 0.5 mmol scale and obtained an isolated 
yield of 14% (0.019 g) as yellow oil. 
Rf = 0.5 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.18 (t, J = 7.7 Hz, 1H), 7.02 – 6.94 (m, 1H), 6.94 – 6.87 
(m, 1H), 3.94 – 3.80 (m, 4H), 3.06 – 2.95 (m, 4H), 2.43 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 150.7, 139.8, 127.5, 125.9, 122.8, 118.3, 67.3, 52.4, 24.1. 
FTIR: 2948, 2935, 1650, 1453, 1373, 1229, 1031 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H15BrNO






Prepared according to the general procedure D on 0.5 mmol scale and obtained an isolated 
yield 58% (0.0760 g) as yellow oil. 
Rf = 0.32 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.11 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 2.6 Hz, 1H), 6.77 
(dd, J = 8.4, 2.6 Hz, 1H), 3.90 – 3.79 (m, 4H), 3.16 – 3.04 (m, 4H), 2.31 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 150.5, 130.9, 128.9, 125.4, 119.4, 114.9, 66.8, 49.4, 21.8. 
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FTIR: 2961, 2853, 1606, 1497, 1449, 1379, 1230, 1121, 1025, 941 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C11H15BrNO







Prepared according to the general procedure D on 0.5 mmol scale and obtained an isolated 
yield of 16% (0.0206 g) as yellow liquid. 
Rf = 0.9 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.14 (t, J = 7.7 Hz, 1H), 6.95 – 6.86 (m, 2H), 2.92 (m, 
4H), 2.42 (s, 3H), 1.80 – 1.69 (m, 4H), 1.58 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 152.4, 139.5, 127.2, 125.1, 123.1, 118.4, 53.7, 26.3, 24.3, 
24.2. 
FTIR:  2919, 2850, 1456, 1241, 1116, 1027 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C12H17BrN






Prepared according to the general procedure D on 0.5 mmol scale and obtained an isolated 
yield of 62% (0.078 g) as yellow liquid. 
Rf = 0.83 in 20% diethyl ether in hexanes 
1H NMR (400 MHz, CDCl3) δ = 7.09 (d, J = 2.6 Hz, 1H), 7.06 (d, J = 8.7 Hz, 1H), 6.78 
(dd, J = 8.4, 2.6 Hz, 1H), 3.15 – 3.02 (m, 4H), 2.29 (s, 3H), 1.73 – 1.64 (m, 4H), 1.60 – 
1.51 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 151.4, 130.7, 127.9, 125.3, 120.1, 115.8, 50.7, 25.7, 24.2, 
21.7. 
FTIR: 2920, 2850, 1605, 1495, 1232, 1026 cm-1 
HRMS (ESI) m/z: [M + H]+ calculated for C12H17BrN
+: 254.0539; found: 254.0533 
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5.8: 1H, 13C, 19F NMR spectra of new compounds 
Figure 5.1: 1H NMR of 1.1 at 400 MHz in DMSO-d6 at 298K 
 
 154   
 
 















 155   
 
 
Figure 5.3: 19F NMR of 1.1 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.4: 1H NMR of 1.2 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.5: 13C NMR of 1.2 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.6: 1H NMR of 1.3 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.8: 1H NMR of 1.4 - Mes at 400 MHz in DMSO-d6 at 298K 
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Figure 5.9: 13C NMR of 1.4 - Mes at 100 MHz in DMSO-d6 at 298K 
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Figure 5.13: 13C NMR of 1.4 -TMB at 400 MHz in DMSO-d6 at 298K  
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Figure 5.14: 1H NMR of 1.4 -Th at 400 MHz in DMSO-d6 at 298K  
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Figure 5.15: 13C NMR of 1.4 -Th at 100 MHz in DMSO-d6 at 298K 
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Figure 5.16: 1H NMR of 1.5 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.17: 13C NMR of 1.5 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.18: 1H NMR of 1.6 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.19: 13C NMR of 1.6 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.20: 19F NMR of 1.6 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.21: 1H NMR of 1.7 at 400 MHz in DMSO-d6 at 298K 
 
 174   
 
 
Figure 5.22: 13C NMR of 1.7 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.23: 1H NMR of 1.8 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.24: 13C NMR of 1.8 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.25: 19F NMR of 1.8 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.26: 1H NMR of 1.9 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.27: 13C NMR of 1.9 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.28: 1H NMR of 1.10 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.29: 13C NMR of 1.10 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.30: 1H NMR of 1.11 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.31: 13C NMR of 1.11 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.32: 19F NMR of 1.11 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.33: 1H NMR of 1.12 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.34: 13C NMR of 1.12 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.35: 1H NMR of 1.13 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.36: 13C NMR of 1.13 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.37: 1H NMR of 1.14 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.38: 13C NMR of 1.15 at 100 MHz in DMSO-d6 at 298K 
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Figure 5.39: 1H NMR of 1.16 at 400 MHz in CDl3 at 298K 
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Figure 5.40: 13C NMR of 1.16 at 100 MHz in CDl3 at 298K 
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Figure 5.41: 1H NMR of 1.17 at 400 MHz in CDl3 at 298K 
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Figure 5.42: 13C NMR of 1.17 at 100 MHz in CDl3 at 298K 
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Figure 5.43: 1H NMR of 1.18 at 400 MHz in CDl3 at 298K 
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Figure 5.44: 13C NMR of 1.18 at 100 MHz in CDl3 at 298K 
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Figure 5.45: 19F NMR of 1.18 at 377 MHz in CDl3 at 298K 
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Figure 5.46: 1H NMR of 1.19 at 400 MHz in CDl3 at 298K 
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Figure 5.47: 13C NMR of 1.19 at 100 MHz in CDl3 at 298K 
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Figure 5.48: 1H NMR of 1.20 at 400 MHz in CDl3 at 298K 
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Figure 5.49: 1H NMR of 1.21 at 400 MHz in CDl3 at 298K 
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Figure 5.50: 1H NMR of 1.22 at 400 MHz in CDl3 at 298K 
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Figure 5.51: 13C NMR of 1.22 at 100 MHz in CDl3 at 298K 
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Figure 5.52: 1H NMR of 1.23 at 400 MHz in CDl3 at 298K 
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Figure 5.53: 13C NMR of 1.23 at 100 MHz in CDl3 at 298K 
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Figure 5.54: 1H NMR of 1.24 at 400 MHz in CDl3 at 298K 
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Figure 5.55: 13C NMR of 1.24 at 100 MHz in CDl3 at 298K 
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Figure 5.56: 19F NMR of 1.24 at 377 MHz in CDl3 at 298K 
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Figure 5.57: 1H NMR of 1.25 at  400 MHz in CDl3 at 298K 
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Figure 5.58: 13C NMR of 1.25 at 100 MHz in CDl3 at 298K 
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Figure 5.59: 1H NMR of 1.26 at 400 MHz in CDl3 at 298K 
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Figure 5.60: 13C NMR of 1.26 at 100 MHz in CDl3 at 298K 
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Figure 5.61: 1H NMR of 1.27 at 400 MHz in CDl3 at 298K 
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Figure 5.62: 13C NMR of 1.27 at 100 MHz in CDl3 at 298K 
 
 215   
 
 
Figure 5.63: 1H NMR of 1.28 at 400 MHz in CDl3 at 298K 
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Figure 5.66: 13C NMR of 1.30 at 100 MHz in CDl3 at 298K 
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Figure 5.67: 1H NMR of 1.31 at 400 MHz in CDl3 at 298K 
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Figure 5.68: 1H NMR of 1.32 at 400 MHz in CDl3 at 298K 
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Figure 5.69: 13C NMR of 1.32 at 100 MHz in CDl3 at 298K 
 
 222   
 
 
Figure 5.70: 19F NMR of 1.32 at 377 MHz in CDl3 at 298K 
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Figure 5.71: 1H NMR of 1.33 at 400 MHz in CDl3 at 298K 
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Figure 5.72: 13C NMR of 1.33 at 100 MHz in CDl3 at 298K 
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Figure 5.73: 1H NMR of 1.34 at 400 MHz in CDl3 at 298K 
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Figure 5.74: 13C NMR of 1.34 at 100 MHz in CDl3 at 298K 
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Figure 5.75: 19F NMR of 1.34 at 377 MHz in CDl3 at 298K 
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Figure 5.76: 1H NMR of 1.35 at 400 MHz in CDl3 at 298K 
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Figure 5.77: 13C NMR of 1.35 at 100 MHz in CDl3 at 298K 
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Figure 5.78: 19F NMR of 1.35 at 377 MHz in CDl3 at 298K 
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Figure 5.79: 1H NMR 1.36 at 400 MHz in CDl3 at 298K 
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Figure 5.80: 13C NMR of 1.36 at 100 MHz in CDl3 at 298K 
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Figure 5.81: 19F NMR of 1.36 at 377 MHz in CDl3 298K 
 
 234   
 
 
Figure 5.82: 1H NMR of 1.37 at 400 MHz in CDl3 at 298K 
 
 235   
 
 
Figure 5.83: 1H NMR of 1.38 at 400 MHz in CDl3 at 298K 
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Figure 5.84: 13C NMR of 1.38 at 100 MHz in CDl3 at 298K 
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Figure 5.85: 19F NMR of 1.38 at 377 MHz in CDl3 at 298K 
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Figure 5.86: 1H NMR 1.39 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.87: 1H NMR 1.39 at 400 MHz in DMSO-d6 at 373K 
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Figure 5.88: 1H NMR of 1.39 at 400 MHz in CDl3 at 298K 
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Figure 5.89: 13C NMR of 1.39 at 100 MHz in CDl3 at 298K 
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Figure 5.90: 1H NMR of 1.40 at 400 MHz in CDl3 at 298K 
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Figure 5.91: 1H NMR of 1.41 at 400 MHz in CDl3 at 298K 
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Figure 5.92: 13C NMR of 1.41 at 100 MHz in CDl3 at 298K 
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Figure 5.93: 19F NMR of 1.41 at 377 MHz in CDl3 at 298K    
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Figure 5.162: 1H NMR of 2.3 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.163: 13C NMR of 2.3 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.164: 1H NMR of 2.4 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.167: 1H NMR of 2.5 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.168: 13C NMR of 2.5 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.169: 1H NMR of 2.6 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.170: 13C NMR of 2.6 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.171: 1H NMR of 2.7 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.172: 13C NMR of 2.7 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.173: 1H NMR of 2.8 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.175: 19F NMR of 2.8 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.176: 1H NMR of 2.9 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.178: 19F NMR of 2.9 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.179: 1H NMR of 2.10 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.181: 19F NMR of 2.10 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.184: 1H NMR of 2.12 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.185: 13C NMR of 2.12 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.186: 1H NMR of 2.13 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.187: 13C NMR of 2.13 at 101 MHz in DMSO-d6 at 298K 
 
 
 340   
 
 
Figure 5.188: 1H NMR of 2.14 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.190: 19F NMR of 2.14 at 377 MHz in DMSO-d6 at 298K 
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Figure 5.191: 1H NMR of 2.15 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.192: 13C NMR of 2.15 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.193: 1H NMR of 2.16 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.194: 13C NMR of 2.16 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.195: 1H NMR of 2.17 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.196: 13C NMR of 2.17 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.197: 1H NMR of 2.18 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.198: 13C NMR of 2.18 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.199: 1H NMR of 2.19 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.201: 13C NMR of 2.19 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.201: 1H NMR of 2.20 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.202: 13C NMR of 2.20 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.203: 1H NMR of 2.21 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.204: 13C NMR of 2.21 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.205: 1H NMR of 2.22 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.206: 13C NMR of 2.22 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.207: 1H NMR of 2.23 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.208: 13C NMR of 2.23 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.209: 1H NMR of 2.24 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.210: 13C NMR of 2.24 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.211: 1H NMR of 2.25 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.212: 13C NMR of 2.25 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.213: 1H NMR of 2.26 at 400 MHz in DMSO-d6 at 298K 
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Figure 5.214: 13C NMR of 2.26 at 101 MHz in DMSO-d6 at 298K 
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Figure 5.215: 1H NMR of 2.27 at 400 MHz in CDCl3 at 298K 
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Figure 5.216: 13C NMR of 2.27 at 101 MHz in CDCl3 at 298K 
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Figure 5.217: 1H NMR of 2.28 at 400 MHz in CDCl3 at 298K 
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Figure 5.219: 19F NMR of 2.28 at 377 MHz in CDCl3 at 298k 
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Figure 5.220: 1H NMR of 2.29 at 400 MHz in CDCl3 at 298K 
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Figure 5.221: 13C NMR of 2.29 at 101 MHz in CDCl3 at 298K 
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Figure 5.222: 1H NMR of 2.30 at 400 MHz in CDCl3 at 298K 
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Figure 5.223: 13C NMR of 2.30 at 101 MHz in CDCl3 at 298K 
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Figure 5.224: 19F NMR of 2.30 at 377 MHz in CDCl3 at 298K 
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Figure 5.225: 1H NMR of 2.31 at 400 MHz in CDCl3 at 298K 
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Figure 5.226: 13C NMR of 2.31 at 101 MHz in CDCl3 at 298K 
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Figure 5.227: 1H NMR of 2.32 at 400 MHz in CDCl3 at 298K 
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Figure 5.228: 13C NMR of 2.32 at 101 MHz in CDCl3 at 298K 
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Figure 5.229: 1H NMR of 2.33 at 400 MHz in CDCl3 at 298K 
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Figure 5.230: 13C NMR of 2.33 at 101 MHz in CDCl3 at 298K 
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Figure 5.231: 1H NMR of 2.34at 400 MHz in CDCl3 at 298K 
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Figure 5.232: 13C NMR of 2.34 at 101 MHz in CDCl3 at 298K     
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Figure 5.233: 19F NMR of 2.34 at 377 MHz in CDCl3 at 298K 
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Figure 5.234: 1H NMR of 2.35 at 400 MHz in CDCl3 at 298K 
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Figure 5.235: 13C NMR of 2.35 at 101 MHz in CDCl3 at 298K 
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Figure 5.236: 19F NMR of 2.35 at 377 MHz in CDCl3 at 298K 
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Figure 5.237: 1H NMR of 2.36 at 400 MHz in CDCl3 at 298K 
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Figure 5.238: 13C NMR of 2.36 at 101 MHz in CDCl3 at 298K 
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Figure 5.239: 19F NMR of 2.36 at 377 MHz in CDCl3 at 298K 
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Figure 5.240: 1H NMR of 2.37 at 400 MHz in CDCl3 at 298K 
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Figure 5.241: 13C NMR of 2.37 at 101 MHz in CDCl3 at 298K 
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Figure 5.242: 1H NMR of 2.38 at 400 MHz in CDCl3 at 298K 
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Figure 5.243: 13C NMR of 2.38 at 101 MHz in CDCl3 at 298K 
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Figure 5.244: 1H NMR of 2.39 at 400 MHz in CDCl3 at 298K 
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Figure 5.245: 13C NMR of 2.39 at 101 MHz in CDCl3 at 298K 
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Figure 5.246: 1H NMR of 2.40 at 400 MHz in CDCl3 at 298K 
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Figure 5.247: 13C NMR of 2.40 at 101 MHz in CDCl3 at 298K 
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Figure 5.248: 19F NMR of 2.40 at 377 MHz in CDCl3 at 298K 
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Figure 5.249: 1H NMR of 2.41 at 400 MHz in CDCl3 at 298K 
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Figure 5.250: 13C NMR of 2.41 at 101 MHz in CDCl3 at 298K 
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Figure 5.251: 1H NMR of 2.42 at 400 MHz in CDCl3 at 298K 
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Figure 5.252: 13C NMR of 2.42 at 101 MHz in CDCl3 at 298K 
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Figure 5.253: 1H NMR of 2.43 at 400 MHz in CDCl3 at 298K 
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Figure 5.254: 13C NMR of 2.43 at 101 MHz in CDCl3 at 298K 
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Figure 5.255: 1H NMR of 2.44 at 400 MHz in CDCl3 at 298K 
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Figure 5.256: 13C NMR of 2.44 at 101 MHz in CDCl3 at 298K 
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Figure 5.257: 1H NMR of 2.45 at 400 MHz in CDCl3 at 298K 
 
 
 410   
 
 
Figure 5.258: 13C NMR of 2.45 101 MHz in CDCl3 at 298K 
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Figure 5.259: 1H NMR of 2.46 at 400 MHz in CDCl3 at 298K 
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Figure 5.260: 13C NMR of 2.46 101 MHz in CDCl3 at 298K 
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Figure 5.261: 1H NMR of 2.47 at 400 MHz in CDCl3 at 298K 
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Figure 5.262: 13C NMR of 2.47 101 MHz in CDCl3 at 298K 
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Figure 5.263: 1H NMR of 2.48 at 400 MHz in CDCl3 at 298K 
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Figure 5.264: 13C NMR of 2.48 101 MHz in CDCl3 at 298K 
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Figure 5.265: 1H NMR of 2.49 at 400 MHz in CDCl3 at 298K 
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Figure 5.266: 13C NMR of 2.49 101 MHz in CDCl3 at 298K 
 
 419   
 
 
Figure 5.267: 1H NMR of 2.50 at 400 MHz in CDCl3 at 298K 
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Figure 5.268: 13C NMR of 2.50 101 MHz in CDCl3 at 298K 
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Figure 5.269: 1H NMR of 2.51 at 400 MHz in CDCl3 at 298K 
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Figure 5.270: 13C NMR of 2.51 101 MHz in CDCl3 at 298K 
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Figure 5.271: 1H NMR of 2.52 at 400 MHz in CDCl3 at 298K 
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Figure 5.272: 13C NMR of 2.52 101 MHz in CDCl3 at 298K 
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Figure 5.273: 1H NMR of 2.53 at 400 MHz in CDCl3 at 298K 
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Figure 5.274: 13C NMR of 2.53 at 101 MHz in CDCl3 at 298K
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Figure 5.275: 1H NMR of 2.54 at 400 MHz in CDCl3 at 298K 
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Figure 5.276: 13C NMR of 2.54 at 101 MHz in CDCl3 at 298K 
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